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To my Dad

Preface
« At school you are engaged not so much in acquiring knowledge as in making
mental eorts under criticism. A certain amount of knowledge you can indeed
with average faculties acquire so as to retain; nor need you regret the hours you
spent onmuch that is forgotten, for the shadow of lost knowledge at least protects
you frommany illusions. But you go to a great school not so much for knowledge
as for arts and habits; for the habit of attention, for the art of expression, for
the art of assuming at a moment’s notice a new intellectual position, for the art
of entering quickly into another person’s thoughts, for the habit of submitting to
censure and refutation, for the art of indicating assent or dissent in graduated
terms, for the habit of regardingminute points of accuracy, for the art of working
out what is possible in a given time, for taste, for discrimination, for mental
courage, and for mental soberness. » William Johnson – Cory
I must confess I don´t know anything else about the author of these lines,
but the spirit of these words transcends the person behind them and, in my
case, describes perfectly my experience during the PhD. I enjoyed so much
each step of my path, each diculty, each accomplishment, each moment
of lucidity, everything that pushed me to improve. e big moments and
the small ones, everything was worth it, every single struggle, every single
achievement. All was an immense sea of wisdom and learning. An epiphany
of mental soberness.
rough this path, there were so many people who helped me in their
own unique way.anks to the colleagues at Medisip to share with us not
only a space but nice moments.anks to my colleagues at bioMMeda, their
company, help and conversations were not only stimulating but also fresh air
when things became dicult.anks to Inge and Jurgen for their kind help
and support. To Saskia who was an incredible support in moments of need
with gentle words and a smile. To the friends I met at the lab and out, it was
always a pleasure to share with them and to nd their support.anks to
the people at MEDES and Verhaert, it was an amazing experience to work
with them all. anks to Prof. Van Bortel and his team, especially to Jelle
and Dr. De Backer, they were always so helpful and patient.anks for all
ix
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their advice and help.anks to Dr. Chirinos and his team, my experience
at UPenn was incredibly productive, it helped me so much to grow as a
professional learning from all the team and their experiences. anks to
Patrick for this amazing opportunity, for the advice, for his support and
patience, especially during dicult moments.anks for this opportunity
that changed my life so positively. I am also grateful for the people I found
in Gent, at the bank, at the oces, I always found a helpful advice from
someone, and this made my adventure in Belgium even more special.
« José Arcadio Buendía soñó esa noche que en aquel lugar se levantaba una
ciudad ruidosa con casas de paredes de espejo. Preguntó qué cuidad era aquella,
y le contestaron con un nombre que nunca había oído, que no tenía signicado
alguno, pero que tuvo en el sueño una resonancia sobrenatural: Macondo. »
Cien años de Soledad. Gabriel García Márquez
“Macondo” is the imaginary place where I was born. And Ma-
condo has always the resonance of the word family. And my family
was a corner stone to culminate my experience. ey have always
been a great support in my life. ank you my family for everything.
anks to my mom and my dad. My dad, a spirit full of joy, full of wisdom,
full of light. You are my best friend. I will always miss you and I hope that
this achievement, which is your achievement as well, makes you proud.
anks mom for your courage, support and company. I love you so much
and I am so glad I can share this moment with you.
Finally, one great lesson during this experience, especially during these
last couple of years, was that, rarely, things in life go the way we want, expect
or plan. And Time inexorably passes and transforms everything. Facing the
construction of thismanuscript and the experiences I was having, I connected
deeply with an author that remarkably expressed these emotions, and I decide
to let his lucid words express my closure thoughts for this experience:
« Enn cette idée du Temps avait un dernier prix pour moi, elle était un
aiguillon, elle me disait qu’il était temps de commencer, si je voulais atteindre ce
que j’avais quelquefois senti au cours de ma vie, dans de brefs éclairs, du côté de
Guermantes, dans mes promenades en voiture avec Mme de Villeparisis, et qui
m’avait fait considérer la vie comme digne d’être vécue. Combien me le semblait-
elle davantage, maintenant qu’elle me semblait pouvoir être éclaircie, elle qu’on
vit dans les ténèbres, ramenée au vrai de ce qu’elle était, elle qu’on fausse sans
cesse, en somme réalisée dans un livre ! Que celui qui pourrai écrire un tel
livre serait heureux, pensais-je, quel labeur devant lui ! Pour en donner une
idée, c’est aux arts les plus élevés et les plus diérentes qu’il faudrait emprunter
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des comparaisons ; car cet écrivain, qui d’ailleurs pour chaque caractère en
ferait apparaître les faces opposés, pour montrer son volume, devrait préparer
son livre, minutieusement, avec de perpétuels regroupements de forces, comme
une oensive, le supporter comme une fatigue, l’accepter comme une règle, le
construire comme une église, le suivre comme un régime, le vaincre comme un
obstacle, le conquérir comme un amitié, le suralimenter comme un enfant, le
créer comme un monde sans laisser de côté ces mystères qui n’ont probablement
leur explication que dans d’autres mondes et dont le pressentiment est ce qui
nous émeut le plus dans la vie et dans l’art. Et dans ces grands livres-là, il y a
des parties qui n’ont eu le temps que d’être esquissés, et qui ne seront sans doute
jamais nies, à cause de l’ampleur même du plan de l’architecte. Combien de
grandes cathédrales restent inachevées ! On le nourrit, on fortie ses parties
faibles, on le préserve, mais ensuite c’est lui qui grandit, qui désigne notre tombe,
la protège contre les rumeurs et quelque temps contre l’oubli. Mais pour en
revenir à moi-même, je pensais plus modestement à mon livre, et ce serait
même inexact que de dire en pensant à ceux qui liraient, à mes lecteurs. »
Le Temps retrouvé. À la recherche du temps perdu VII. Marcel Proust
A book to end and to start.
Francisco J. Londono Hoyos
La Judea (Santa Rosa de Osos), 7 de enero de 2020
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e following list summarizes the most commonly used abbreviations and
symbols in this thesis.
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Samenvatting
Inleiding
Hart- en vaatziekten (CVD’s) vormen wereldwijd een belangrijke doodsoor-
zaak, waarbij in het bijzonder hartfalen (HF) een sterke opmars kent in
de verouderende bevolking. HF verschilt enigszins van andere belangrijke
CVD’s en omvat een globaal en complex ziekteproces, eerder dan een precies
denieerbare ziekte die met één enkele behandeling kan worden behandeld.
De wereldwijd toenemende incidentie en prevalentie van HF is oorzaak
van toename van morbiditeit en mortaliteit, verminderde levenskwaliteit en
toenemende zorgkosten. Ongeveer de hel van de patiënten met symptomen
van HF hebben een bewaarde linker ventrikel (LV) ejectiefractie (HFpEF),
en het zijn in het bijzonder deze patiënten die moeilijk te behandelen zijn, en
voor wie er momenteel geen bewezen eectieve farmacologische therapieën
zijn. Om deze therapieën te kunnen ondersteunen en ontwikkelen is er nood
aan een beter inzicht in de pathofysiologie van deze ziekte en bijgevolg aan
een verbeterde diagnostiek. We denken hierbij in de eerste plaats aan niet-
invasieve en adequaat gevalideerde methodieken en technieken voor het
nauwkeurig kwanticeren van cardiovasculaire functie en hemodynamica,
en meer speciek aan methoden voor het begroten van intra-ventriculaire
drukverschillen (IVPD’s) en gradiënten (IVPG’s), de ventriculo-vasculaire
interactie en energetische aspecten van de hart- en vaatfunctie. Dergelijke
hulpmiddelen zijn essentieel voor de ondersteuning van op wetenschappelijk
bewijs gestoelde (evidence-based) geneeskunde en de verwezenlijking van
richtlijnen voor de behandeling van patiënten met hartfalen (in het bijzonder
HFpEF).
De algemene doelstelling van dit doctoraatsproject is de ontwikkeling, val-
idatie en implementatie van niet-invasievemethoden voor de beoordeling van
de cardiovasculaire functie, waarbij we drie concrete doelstellingen hebben ge-
formuleerd: 1) Het ontwikkelen en valideren van een niet-invasieve methode
voor de schatting van IVPD’s, waarbij de techniek zal worden gebruikt voor
het karakteriseren van de intraventriculaire hemodynamiek in patiënten met
hartfalen met bewaarde en verminderde ejectiefractie (HFrEF); 2) Evaluatie
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van de dierentiële eecten van organische en anorganische nitraten in de
vasculaire functie van patiëntenmet HFpEF; 3) Ontwikkelen van aanvullende
methodieken voor het niet-invasief begroten van cardiovasculaire functie
voor een aantal verschillende toepassingen.
Om de realisatie van deze doelstellingen overzichtelijk en nader toe te
lichten, is het manuscript verdeeld in drie grote delen. Deel I - Fundamenten
verscha de lezer de nodige achtergrond in o.a. de anatomie en fysiologie
van hart- en bloedvaten, de pathofysiologie van hartfalen, diagnostiek en
beeldvorming en methodologische concepten die worden gehanteerd binnen
het cardiovasculair onderzoek en geneeskunde. Deel II - Nieuw Cardiovascu-
lair Onderzoek presenteert de resultaten van origineel onderzoek en studies
die gericht zijn op het onderzoeken van de haalbaarheid, accuraatheid en
de toegevoegde waarde van nieuwe analyses en indices die de hart- en vaat-
functie kwanticeren. In Deel III – Eindbeschouwing, wordt gestart met een
algemeen overzicht van de resultaten, de beperkingen en belangrijkste be-
sluiten van het voorgestelde cardiovasculair onderzoek. Hierop aansluitend
wordt een aantal suggesties geformuleerd voor een verdere verbetering van
de vooropgestelde diagnostische methoden. Tot slot wordt een persoonlijk
perspectief met betrekking van dit promotieproject geschetst.
Deel I - Fundamenten
Dit deel omvat de anatomische, (patho-) fysiologische en technische
basisprincipes ter inleiding en ondersteuning van het originele onderzoek
dat aan bod komt in Deel II - Nieuw cardiovasculair onderzoek.
Hoofdstuk 1 - Het cardiovasculaire systeem
Dit hoofdstuk gaat van startmet een beknopte beschrijving van de functionele
anatomie van het hart- en bloedvatenstelsel, om aansluitend de basisprincipes
van de cardiovasculaire fysiologie (hartcyclus en hartfunctie) te behandelen.
Hierbij wordt gefocust op het linker ventrikel (LV) waarbij de hartfunctie,
conform de benadering in de cardiologie, wordt opgesplitst in de systolische
(lediging) en diastolische (vulling) functie. Systolische functie wordt bes-
chreven in termen van de mechanica van contractie, met aandacht voor de
determinanten van de contractie van het linker ventrikel en het meten van
de systolische functie. Wat de vulling van het hart betre bekijken we de
hemodynamische fasen van diastole, de eigenschappen van het LV in diastole
en niet-invasieve methoden voor de evaluatie van de LV diastolische func-
tie. Aansluitend wordt de fysiologie van het perifere vaatstelsel behandeld,
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met een bijdrage omtrent de regulerende rol van het autonome zenuwstelsel
in cardiovasculaire functie. Het laatste deel van het hoofdstuk onderzoekt
de pathofysiologie van het cardiovasculaire systeem, met als voornaamste
ziektebeelden atherosclerose en hartfalen. Het gebruik van organische en an-
organische nitraten bij de behandeling van cardiovasculaire ziekte wordt kort
toegelicht. Ook de impact van veroudering op de cardiovasculaire gezond-
heid komt aan bod in dit laatste deel.
Hoofdstuk 2 - Niet-invasieve technieken voor het meten van
cardiovasculaire functie
Dit hoofdstuk introduceert de technische principes van de (voor deze doc-
toraatsthesis) meest relevante niet-invasieve beeldvormingsmodaliteiten en
methoden voor het meten van fysiologische signalen in cardiovasculair on-
derzoek.
Het hoofdstuk begint met de beschrijving van drukgolfmetingen voor de
beoordeling van de arteriële stijfheid en hemodynamica. Vervolgens worden
de principes van echocardiograe en magnetische resonantie beeldvorm-
ing (MRI), twee belangrijke cardiovasculaire beeldvormingsmodaliteiten, in
detail uitgelegd, samen met de belangrijkste cardiovasculaire toepassingen.
Hoofdstuk 3 - Toelichting bij gebruikte methoden voor modellering en
signaalverwerking
In een eerste deel (dat de lezer voorbereidt op hoofdstuk 4) wordt aandacht
besteed aan basisprincipes van de vloeistofdynamica, intra-ventriculaire
stroming en de schatting van IVPG’s en IVPD’s uit echocardiograe of car-
diale MRI. Het computermodel van bloedstroming in het linker ventrikel,
dat verderop wordt gebruikt voor de validatie van ontwikkelde methoden,
wordt in dit deel wat meer in detail toegelicht.
Het tweede deel van het hoofdstuk (ter ondersteuning van hoofdstuk
5) introduceert methoden voor de beoordeling van vasculaire functie door
bepalen van de impedantie en hemodynamische analyse (met splitsing van
drukgolven in hun voorwaartse en gereecteerde componenten) en behan-
delt het concept van “wave power” en het hydraulisch vermogen. Er wordt
toegelicht hoe de Womersley theorie wordt toegepast voor een verbeterde
benadering van de debietgolf in de halsslagader.
Het laatste deel van het hoofdstuk behandelt het theoretische enmethodo-
logische kader van hoofdstuk 6, waarin speciek ontwikkelde hulpmiddelen
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voor de beoordeling van arteriële gezondheid in niet-routinematige om-
standigheden worden voorgesteld. Deze initiatieven omvatten verschillende
signaal- en beeldverwerkingsmethoden, zoals het tracken van de verplaatsing
van de arteriële wand op basis van RF-ultrasone gegevens, signaaluitlijning
op basis van correlatie-technieken en methoden voor het bepalen van de
golfsnelheid en inschatten van de sterkte van golfreecties.
Deel II - Nieuw cardiovasculair onderzoek
In dit deel worden de resultaten van eigen origineel onderzoek toegelicht.
Deze resultaten zijn gepubliceerd in peer-reviewde wetenschappelijke tijds-
chrien.
Hoofdstuk 4 - Hartfunctie
Dit hoofdstuk herneemt kort het theoretische vloeistof-dynamische kader
dat aan de grondslag ligt van de analyse van de intra-ventriculaire stroming
en de afgeleide drukschattingen (IVPD’s) uit echocardiograe en MRI. De
ontwikkelde methoden worden eerst gevalideerd op basis van een vloeistof-
dynamisch computermodel van het linker ventrikel, waarbij gesimuleerde
snelheidsdata worden gebruikt als pseudo-MRI/ultrageluid data waarna de
nauwkeurigheid van de schattingen van IVPD’s uit dergelijke snelheidsdata
kan worden ingeschat. De gunstige resultaten van de op MRI gebaseerde
methodemotiveerden verder onderzoek naar een grotere steekproef, inclusief
proefpersonen zonder HF, en patiënten met HFrEF en HFpEF. De studie
leverde interessante resultaten op met betrekking tot de karakterisering van
HF-subtypen door het gebruik van IVPD-parameters, maar verder onderzoek
is noodzakelijk om de bevindingen te bevestigen en de toepassing van de
methode te verbeteren.
Hoofdstuk 5 - Vasculaire functie
Dit hoofdstuk focust op het inschatten van de eecten van organische en
anorganische nitraten, een vasodilaterend medicijn en gebruikt bij de far-
macologische behandeling van patiënten met hartfalen, op de vaatfunctie.
Er wordt gebruik gemaakt van data gemeten in een steekproefpopulatie van
patiënten met HFpEF. Er wordt in het bijzonder gefocust op eecten van
de medicatie op de hemodynamica in de halsslagader als toegang tot de
cerebrale circulatie.
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“Conventionele” hemodynamische analyse toont aan dat behandeling
met organische nitraten leidt tot een inconsistente vermindering van arteriële
golfreecties, cerebrovasculaire weerstand en impedantie van de halsslagader,
en dit in tegenstelling tot een behandelingmet anorganische nitraten. Verdere
analyse van de door de hemodynamische golven gegenereerde energie en
vermogen gee aan dat organische nitraten de penetratie van hydraulisch
vermogen vanuit de aorta naar de halsslagader verhogen, terwijl anorganische
nitraten geen signicante veranderingen in deze parameters veroorzaakten.
Deze analyses vormen een mechanistische basis voor een aantal bekende
en gedocumenteerde bijwerkingen van organische nitraten zoals hoofdpijn,
duizeligheid en hypotensie bij patiënten met HFpEF. Bovendien bieden de in
dit hoofdstuk besproken resultaten aanvullend bewijs ter ondersteuning van
een eectieve behandeling van patiënten met HFpEF op basis van anorganis-
che nitraten.
Hoofdstuk 6 - Speciek ontwikkelde hulpmiddelen
Dit hoofdstuk bundelt drie aanvullende toepassingen van cardiovasculair
onderzoek die in de loop van het doctoraatsonderzoek in meer of mindere
mate zijn bestudeerd geweest.
In een eerste studie werden niet-invasieve technieken geëvalueerd voor
de studie van de interactie tussen hemodynamica en cardiovasculaire func-
tiemodulatie door het autonoom zenuwstelsel. Hiertoe werden stresstests
uitgevoerd bij (vermoedelijk) gezonde vrijwilligers, waarbij bloeddruk- en
echocardiograsche metingen werden verkregen. Resultaten onthullen de
specieke fysiologische respons van het autonome cardiovasculaire systeem
om elke stressstimulus adequaat te regelen.
In een tweede deel wordt een webgebaseerde applicatie voorgesteld met
als doel de standaardisatie van parameters voor arteriële stijfheid (gekwanti-
ceerd als de voortplantingssnelheid van de intra-arteriële drukgolf) te be-
vorderen. Ondanks het feit dat het algemeen aanvaard is dat arteriële stijfheid
een sterk voorspellende waarde hee bij de beoordeling van cardiovasculair
risico, wordt een wijdverspreid gebruik van deze parameter gehinderd door
de afwezigheid vanmethodologische standaardisatie om afgeleide parameters
te bepalen. De ontwikkelde toepassing maakt een gemakkelijke beoordeling
mogelijk van een gegeven gemeten waarde van arteriële stijfheid, waarbij een
percentielscore wordt meegegeven voor die specieke parameter die wordt
begroot op basis van bestaande referentie databanken.
Een derde project werd uitgevoerd in een samenwerking met het
bedrijf Verhaert, binnen een project genancierd door de Europese
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ruimte-organisatie ESA. Deze hee een bijzondere interesse in de aanpassing
van het cardiovasculaire systeem in extreme ruimte-omstandigheden.
Momenteel zijn de beschikbare apparaten om de cardiovasculaire toestand
van astronauten te evalueren relatief beperkt. Doelstelling van ESA was om
nieuwe methoden te exploreren die potentieel kunnen worden ingezet voor
een meer nauwkeurige opvolging van de adaptatie van het cardiovasculair
systeem bij langer verblijf in de ruimte. Wij ontwikkelden een systeem
dat tonometrie en ultrasone metingen integreert, en onderzochten
de functie van het systeem bij gezonde personen onder verschillende
omstandigheden, waarbij proefpersonen werden gekanteld, werden
blootgesteld aan onderdruk van het onderlichaam of terwijl proefpersonen
werden onderworpen aan centrifugaal krachten tijdens testen in de korte
arm centrifuge. Over het algemeen werden bemoedigende resultaten
bekomen met het ontwikkelde systeem.
Deel III - Eindbeschouwing
Hoofdstuk 7 - Conclusies
In dit hoofdstuk wordt gestart met een overzicht van de behaalde resultaten,
een bespreking van de beperkingen, en formulering van een aantal con-
clusies. Vervolgens wordt wat dieper ingegaan op een aantal suggesties voor
vervolgonderzoek voor een verdere verbetering van de vooropgestelde meth-
odieken. Hierbij denken we vooral aan actuele relevante technieken zoals
machinaal en diep leren. Het werk wordt afgesloten met een persoonlijk
perspectief op het voorliggende promotieproject.
xxviii
Summary
Introduction
Cardiovascular diseases (CVDs) are a leading cause of death globally with
heart failure (HF) showing a critical progress among the population and
diering from other major CVDs since it is considered a disease process
rather than a precise illness that can be treated with a single form of ther-
apy.e increasing incidence and prevalence of HF worldwide is responsi-
ble for a large burden of morbidity and mortality, poor quality of life, and
healthcare costs. Although approximately half of patients with HF have a
preserved le ventricular (LV) ejection fraction (HFpEF), there are currently
no proven eective pharmacological therapies to improve patient outcomes.
Consequently, evidence-based and sustainable strategies to gain a better un-
derstanding of the pathophysiological process, to enhance diagnostic tools
and, ultimately, to nd an eective treatment should be encouraged, con-
sidering that non-invasive diagnostic procedures constitute a desirable (and
feasible) advantage.erefore, the validation of diagnostic strategies based on
non-invasive data analysis for cardiovascular assessment is essential to dene
evidence-based medicine and to accomplish helpful guidelines. Indeed, non-
invasive assessment of cardiovascular function using non-invasive data is
feasible through dierent approaches, such as the estimation of intraventricu-
lar pressure gradients (IVPGs) and dierences (IVPDs), the calculation of
haemodynamic parameters, the application of wave power analysis, among
others.
Hence, the general aim of this PhD project is to develop non-invasive
methodologies for the assessment of cardiovascular function. is aim is
break down into three concrete goals: 1) To develop and to validate a non-
invasive processing tool for the estimation of IVPDs in order to characterise
patients without HF, and with HF and reduced ejection fraction (HFrEF)
or HFpEF; 2) To evaluate the dierential eects of organic and inorganic
nitrates in the vascular function of HFpEF patients; 3) To propose and to de-
velop additional strategies for improving cardiovascular medicine in dierent
applications.
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To elaborate on these goals, the manuscript is divided in three major
parts. Part I - Fundamentals establishes essential concepts of cardiovascu-
lar research and medicine, providing the basis for novel research proposals.
Part II - Novel Cardiovascular Research presents results of studies aiming
to explore the value of novel analyses and indices quantifying cardiac and
vascular function in various settings. Part III - Closureoughts develops
the nal remarks regarding the manuscript, starting with a general overview
of the results, limitations and conclusions of the proposed cardiovascular re-
search, followed by suggestions concerning potential future work to improve
these diagnostic methodologies. Finally, a personal perspective outlines the
general conclusions of this PhD project.
Part I - Fundamentals
is part sets the basic anatomical, physiological and technical principles to
support the novel cardiovascular research proposed in Part II.
Chapter 1 -e Cardiovascular System
is chapter contains a general description of the basic anatomy, physiology
and pathophysiological processes and adaptations of the cardiovascular sys-
tem.
First, the chapter presents a concise description of the functional car-
diovascular anatomy.e second portion of the chapter presents the basic
principles of cardiovascular physiology, such as cardiac cycle and heart func-
tion. Heart function is considered as systolic and diastolic function. e
former is discussed in terms of mechanics of contraction, determinants of LV
contraction and physiologic measurements of LV systolic function.e later
deals with haemodynamic phases of diastole, LV diastolic properties and
non-invasive evaluation of LV diastolic function. Following, the physiology
of the peripheral vascular system is addressed. Lastly, the regulation role of
the autonomic nervous system (ANS) in cardiac function is shortly revised.
e last portion of the chapter examines the pathophysiology of the cardio-
vascular system, focusing on HF and atherosclerosis. Finally, the chapter
addresses the impact of aging on cardiovascular health.
Chapter 2 - Non-invasive techniques for cardiovascular assessment
is chapter introduces the technical principles of relevant non-invasive
signalling and imaging methodologies in cardiovascular medicine.
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e chapter begins with the description of pressure wave measurements
to support the assessment of arterial stiness. Following, the chapter in-
troduces the main principles and concepts common to all cardiovascular
imagingmethodologies, and then, echocardiography andmagnetic resonance
imaging (MRI), two major cardiovascular imaging modalities, are explained
in detail. Both sections concerning echocardiography and MRI dene basic
principles of each technique, major cardiovascular applications and addi-
tional considerations.
Chapter 3 - Modelling and Processing Methodologies
is chapter revises concepts related to cardiovascular function and completes
the fundamental theory to support Part II.
e rst section of the chapter formulates basic principles of cardiac func-
tion assessment further developed in Chapter 4, comprising uid dynamics
of intraventricular ow and the estimation of IVPGs and IVPDs through
imaging methodologies, such as echocardiography or cardiac MRI. Addi-
tionally, a validation strategy consisting in a computational uid dynamics
model of the LV is introduced.
e second section of the chapter, associatedwithChapter 5, encompasses
vascular function assessment through haemodynamic and wave power ana-
lysis.is section develops relevant concepts on the Womersley ow prole,
the calculation of forward and backward components of pressure, the deter-
mination of hydraulic power, and other suitable approaches.
e last section of the chapter deals with the theoretical framework of
Chapter 6, in which dedicated tools for the assessment of arterial health
in non-routine conditions are presented.ese initiatives involve dierent
signal/image processing methods, such as arterial wall tracking based on RF
ultrasound data, signal alignment through correlation, wave speed determi-
nation, wave separation and the calculation of the reection magnitude.
Part II - Novel Cardiovascular Research
is part of the manuscript presents the novel cardiovascular research pro-
posed.
Chapter 4 - Cardiac Function
e chapter presents the theoretical framework of uid dynamic principles ap-
plied to the analysis of intraventricular ow and derived pressure estimations.
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Considered approaches calculate parameters using non-invasive ow data
from standard imaging techniques, such as echocardiography and MRI. Fur-
thermore, the relevance of IVPGs and IVPDs for a proper cardiac function
is established, thereby supporting the selection of IVPDs related parameters
to assess cardiac function in HF patients and, potentially, to support the
characterisation of HF subtypes.
Several methods have been proposed for non-invasive IVPDs estimation,
but comparison has been hampered by technical diculties. erefore, a
CFD model is proposed to perform the evaluation of echocardiographic and
MRI based approaches. e favourable results of the MRI-based method
motivated further research on a larger sample, including subjects without HF,
and patients with HFrEF and HFpEF.e study provided interesting results
regarding the characterisation of HF subtypes by the use of IVPD parameters
but further research is warranted to conrm the ndings and improve the
application of the method.
Chapter 5 - Vascular Function
roughout the chapter, dierent approaches are proposed to assess the
impact of treatment based on nitrates in vascular function, particularly in a
sample population with HFpEF.
Traditional haemodynamic analysis show that the treatment with or-
ganic nitrates produces an inconsistent reduction in arterial wave reections,
cerebrovascular resistance and carotid characteristic impedance, in contrast
to inorganic nitrates treatment. Furthermore, a novel analysis based on wave
power transmission is also implemented, indicating that organic nitrates
increase power penetration from the aorta into the carotid whereas inorganic
nitrates did not produce signicant changes in wave power parameters.
Such analyses may relate the changes in cerebrovascular circulation in-
duced by organic nitrates to their (documented) poorly tolerance and side
eects like headache, dizziness and hypotension in patients with HFpEF.
Moreover, results discussed in this chapter provide additional evidence to
support further research for an eective HFpEF treatment using inorganic
nitrates.
Chapter 6 - Dedicated tools
e chapter introduces three supplementary applications of cardiovascular
research in precise elds of interest, each contributing to the understanding of
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cardiovascular function.e rst study focuses on the haemodynamic assess-
ment of the cardiovascular function modulation by the ANS. To achieve this
goal, stress testing is performed in (presumably) healthy volunteers and blood
pressure and echocardiographic measurements are obtained. Results reveal
specic physiological response of the autonomous cardiovascular system to
regulate adequately each stress stimulus.
e second proposal presents the implementation of a web-based ap-
plication to promote the standardization of arterial stiness parameters.
Undoubtedly, arterial stiness has been identied as a crucial parameter for
the assessment of cardiovascular risk although a wider implementation has
been hampered by the lack of established reference values and the absence of
methodological standardization to determine derived parameters.us, the
proposed application allows the easy assessment of a given measured value
of arterial stiness, providing the percentile reference associated with that
specic value.
A third project was carried out in collaboration with the company Ver-
haert, within a project funded by the European SpaceAgency (ESA), to analise
cardiovascular adaptation in extreme conditions. Currently, the devices avail-
able to evaluate the cardiovascular status of astronauts are relatively limited.
e objective of ESA was to explore new methods that could potentially be
used for a more accurate follow-up of the adaptation of the cardiovascular
system during a longer stay in space. We developed a system that integrates
tonometry and ultrasonic measurements, and investigated the function of the
system in healthy individuals under dierent conditions, where test subjects
were tilted, exposed to lower body pressure or subjected to centrifugal forces
at the short arm human centrifuge. In general, encouraging results were
obtained with the developed system.
ese applications evidence that dierent elds of research can contribute
to gain insights into cardiovascular function from dissimilar and comple-
mentary perspectives.is chapter concludes Part II, describing innovative
contributions in biomedical engineering to cardiovascular research.
Part III - Closure Thoughts
Chapter 7 - Conclusions
is chapter elaborates the nal remarks of the PhD project. First, a gen-
eral overview of the results, limitations and conclusions of the proposed
cardiovascular research is stated. Next, the chapter develops on suggestions
concerning potential future work to improve these diagnostic methodolo-
gies, including current relevant subjects such as machine and deep learning.
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Finally, a personal perspective outlines the general conclusions of this PhD
project.
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Rationale
e global burden of cardiovascular diseases (CVDs) has reached pandemic
proportions and continues to rise. Not only do CVDs lack geographic, gender,
or socioeconomic boundaries, but their major contributory causes show an
increasing trend, among which stand out the aging of the world popula-
tion, lifestyle changes due to urbanization, progressive industrialization and
burgeoning globalization. Indeed, CVDs are the leading cause of death world-
wide and proper strategies must be proposed to face eectively this epidemic
and the entailed parallel augmentation in health care and social costs, consid-
ering specic factors, such as the demographic, economic, social, nutritional
and epidemiological context.
Particularly, heart failure (HF) shows a critical progress among the popu-
lation and diers from other major CVDs since it is considered the common
nal path of various disease processes, rather than a distinct illness that can
be treated with a single form of therapy. In fact, HF involves the develop-
ment of several pathological adaptations and complex interactions, aecting
both cardiac and vascular function. Moreover, HF has a wide spectrum of
dysfunction, in which two major subtypes have been identied, based on
whether or not the ventricle maintains its ability to eject a suciently large
proportion of its end-diastolic volume with each heart beat: HF with reduced
ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF).
Even if systolic and diastolic dysfunction manifest in both subtypes in dif-
ferent degrees, HFrEF is generally related to systolic dysfunction whereas
HFpEF is associated with diastolic dysfunction. In contrast to HFrEF, an ef-
fective treatment for HFpEF is still elusive while its incidence and prevalence
continue to rise, largely due to an increasingly aging population and to the
obesity epidemic.
With this perspective, specic strategies to tackle HFpEF should be en-
couraged, rst searching for a deeper understanding of the pathological
adaptations involved, then identifying proper parameters and tools to sup-
port diagnosis and, nally, nding an eective treatment. Nonetheless, any
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suggested strategy must be supported by evidence to produce and consol-
idate useful clinical practice guidelines for the improvement of patient care
and decision-making, considering the context and the sustainability of the
proposal in terms of costs. Additionally, practicality and cost/eectiveness
are two essential conditions for the successful application of any approach
in the clinical setting. Consequently, non-invasive diagnostic procedures
constitute not only a desirable advantage but also a feasible one because of
the current availability of advanced signalling and imaging technologies.
Non-invasive diagnostic methodologies for cardiovascular
research
e validation of diagnostic strategies based on non-invasive data analysis
for cardiovascular assessment remains a fundamental research necessity and
a crucial step to dene evidence-based medicine and to accomplish helpful
guidelines.erefore, the strategies developed through this document for
non-invasive assessment of cardiovascular function encompass an explicit
or an implicit validation scheme to support the results, the discussion and,
particularly, the conclusions extracted from each project. Concretely, valida-
tion was accomplished by using in silicomodels, contrasting results between
dierent sample populations or, implicitly, by applying methods that are
extensively validated.
Furthermore, non-invasive data were obtained using established sig-
nalling and imaging techniques, such as applanation tonometry in combina-
tion with sphygmomanometry to measure blood pressure, ultrasound (or
echocardiography) and MRI to measure blood ow and image structures,
the latter two being well-established imaging techniques in clinical cardiovas-
cular medicine. Non-invasive assessment of cardiac and vascular function
using these data is feasible through dierent approaches, which include the
estimation of intraventricular pressure gradients (IVPGs) and dierences
(IVPDs), the calculation of haemodynamic parameters, the application of
wave power analysis, among others. Moreover, these approaches employ
data already obtained from common clinical procedures in cardiovascular
medicine or from slightly modied protocols, improving practicality and
avoiding excessively long or additional protocols.
However, non-invasive approaches are facing also new challenges. For
instance, in terms of feasibility of the approaches, digitalization is a milestone
of cardiovascular medicine and a pivotal attribute of cardiovascular imaging,
although the increasing amount of available data is oen exceeding the pro-
cessing capacity, which is generally manual, thus leading to errors. It is clear,
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then, that better processing tools must be developed to address these chal-
lenges and to improve cardiovascular medicine supporting evidence-based
guidelines and clinical decision making.
Cardiovascular research
e major focus of the research studies presented throughout this manuscript
is related to the non-invasive assessment of cardiac and vascular functions
in CVD states, particularly in patients with HF.ese chapters elucidated
the need not only to improve the comprehension of underlying mechanics
of an adequate cardiovascular function and pathophysiological process and
adaptations, including age related changes, and the involvement of other
systems for proposing eective treatment, but also the urgency to develop
better diagnostic tools for identifying subjects at risk and implementing
prevention strategies towards the general population. Hence, this manuscript
includes also research proposals in this regard, aiming to tackle the CVD
epidemic at dierent levels and stages.
Research objectives
Briey, the general aim of this PhD project is the development of non-invasive
methodologies for the assessment of cardiovascular function, which can be
broken down into three concrete goals:
Goal 1 - To develop and to validate a non-invasive processing tool for
the estimation of IVPDs in order to characterise patients without HF,
and with HFrEF or HFpEF.
Goal 2 - To evaluate the dierential eects of organic and inorganic
nitrates in the vascular function of HFpEF patients.
Goal 3 - To propose and to develop additional strategies for improving
cardiovascular medicine in dierent applications.
e technical development of non-invasive algorithms for signal and
image processing is supported on and aligned with investigation conducted
at the bioMMeda research group of Ghent University, including biomed-
ical ultrasound research, cardiovascular mechanics and other research tools
(https://www.biommeda.ugent.be/research). Moreover, the med-
ical component of the research is carried out in partnership with the arterial
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haemodynamics and cardiovascular core lab of theUniversity of Pennsylvania
(https://www.med.upenn.edu/accl/).
Specic studies to achieve the listed goals are additionally supported by
other institutions or work teams involved in cardiovascular research projects,
which include the Asklepios Study, Reference Values for Arterial Stiness’
Collaboration, the company Verhaert, the Institute for Space Medicine and
Physiology (MEDES), the European Space Agency (ESA), among others.
Structure
e manuscript is divided in three major parts.
Part I - Fundamentals establishes essential concepts of cardiovascular
research andmedicine, providing the basis for novel research proposals. First,
Chapter 1 provides an overview of the cardiovascular system anatomy, a brief
discussion of the principles of cardiovascular physiology and a concise review
of relevant pathophysiological conditions, current clinical treatment and the
impact of the aging process on cardiovascular structure and function.en,
Chapter 2 introduces non-invasive techniques to measure and image the
cardiovascular system, focusing on two major cardiovascular imaging modal-
ities: ultrasound (or echocardiography) and MRI. Finally, Chapter 3 expands
and revises concepts related to cardiovascular function and its assessment,
such as intracardiac uid dynamics, in silico simulations, haemodynamic
analysis and signal/image processing algorithms.
Part II - Novel Cardiovascular Research presents results of studies aiming
to explore the value of novel analyses and indices quantifying cardiac and
vascular function in various settings.is part is divided in three chapters,
each addressing one of the formulated goals for this PhD project. Chapter 4
focuses on the assessment of cardiac function through non-invasive ow data
to calculate IVPGs and IVPDs.e chapter starts providing a review on the
non-invasive assessment of IVPGs and IVPDs, and their potential role in the
characterisation of patients with HF.en, the chapter deals with the assess-
ment of methodologies to estimate IVPDs, in which an echocardiographic
and an MRI approach are evaluated with the use of a computational uid
dynamics (CFD) model of the le ventricle (LV).ese results supported
the implementation and feasibility assessment of an MRI-based processing
algorithm to estimate IVPDs noninvasively in subjects without HF, with
HFrEF or with HFpEF. Chapter 5 entails the assessment of vascular function
implementing conventional and novel haemodynamic analyses to compare
the eects of organic and inorganic nitrates in a HFpEF population. e
rst section of the chapter introduces the evaluation of vascular function
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through classical haemodynamic assessment in time and frequency domains,
and the second section describes the implementation of a novel analysis to
evaluate wave power transmission into the cerebrovascular circulation. In
Chapter 6, further dedicated tools to assess the cardiovascular system are
explored.is chapter starts with the discussion of a study concerning the
inuence of the autonomic nervous system (ANS) in adjustments of the
cardiovascular function under stress conditions. Next, the second section
introduces a web-based application to support the standardization of vascular
stiness parameters and to promote their widespread use in common clinical
practice. Finally, the third section is an exploratory feasibility study of a con-
tinuous physiological and medical monitoring system, based on tonometry
and ultrasound measurements, with potential applications in space science.
Part III - Closureoughts presents the nal remarks regarding the
manuscript, starting with a general overview of the results, limitations and
conclusions of the proposed cardiovascular research, followed by suggestions
concerning potential future work to improve these diagnostic methodologies.
Finally, a personal perspective outlines the general conclusions of this PhD
project.
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The Cardiovascular System
is chapter presents an overview of the cardiovascular system, starting with
a succinct description of basic anatomy followed by a brief discussion of
physiological principles to nish with a concise review of relevant patho-
physiologic conditions, current clinical treatment and the impact of the aging
process on cardiovascular structure and function.
It is important to highlight that this chapter is based, extracted, adapted
and/or edited from dierent textbooks with themost relevant sources: Hurst’s
the heart book of Fuster [16],Mayo Clinic Cardiology: Concise Textbook of
Murphy [17], Textbook of cardiovascular medicine of Topol and Cali [18],
Braunwald’s heart disease: a textbook of cardiovascular medicine of Libby [19],
Vascular surgery book of Rutherford [20], Grossman & Baim’s cardiac catheter-
ization, angiography, and intervention book of Moscucci [21], Introduction to
vascular ultrasonography book of Zwiebel and Pellerito [22], Heart failure in
children and young adults: frommolecular mechanisms to medical and surgical
strategies book of Chang and Towbin [23], Cirugía vascular book of Martínez
[24], ande heart as a muscle-pump system and the concept of heart failure
article of Weber and Janicki [25].
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1. The Cardiovascular System
1.1 Functional cardiovascular anatomy
1.1.1 Cardiac anatomy
e heart lies within a resilient sac, the pericardium, composed of two layers:
brous and serous.e former, a collagenous and inelastic tissue, encases the
heart and extends onto the great vessels wall.e latter, a delicate mesothelial
layer, lines the inner surface of the brous (parietal) pericardiumand the outer
lining of the heart and intrapericardial great vessels (visceral pericardium
or epicardium). e pericardium houses the pericardial cavity, which is
lled by a serous uid (the pericardial uid) secreted by the serous layer.
e ascending aorta, pulmonary artery, portions of both venae cavae and all
pulmonary veins are intrapericardial [16].
Figure 1.1: Illustration of the heart position within the thorax. Adapted
from https://commons.wikimedia.org/wiki/File:Blausen_0458_
Heart_ThoracicCavity.png and https://commons.wikimedia.org/
wiki/File:Blausen_0467_HeartLocation.png. By Blausen.com sta
(2014). "Medical gallery of Blausen Medical 2014". WikiJournal of Medi-
cine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436. [CC BY 3.0
(https://creativecommons.org/licenses/by/3.0)], from Wikime-
dia Commons.
e heart itself is a hollowmuscular structure with a pyramidal geometry
(a base, three surfaces and an apex). It lies within the rib cage (or thoracic cav-
ity) in themiddle of its central compartment, the mediastinum (see gure 1.1).
e three surfaces of the heart are the anterior or sternocostal, the inferior or
diaphragmatic and the posterior (base).e heart has an internal division
in two halves, right and le, by a longitudinal and obliquus septum (see
gure 1.2); each half has an (upper) atrium that receives blood and a (lower)
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ventricle that ejects blood into the corresponding circulation system. e
ventricles constitute the apex of the heart whereas the atria, lying opposite to
the ventricles, form the base and receive the venae cavae and the pulmonary
veins [16].
Figure 1.2: Illustration of the (anterior) heart anatomy. Adapted from https://
commons.wikimedia.org/w/index.php?curid=26986391 and https://
commons.wikimedia.org/w/index.php?curid=26986380. By BlausenMed-
ical Communications, Inc. - Donated via OTRS, see ticket for details, CC BY 3.0.
e venous return from the venae cavae and coronary sinus ows into
the right atrium (RA) (see gure 1.2) and passes to the right ventricle (RV)
crossing the tricuspid valve. en, blood streams through the pulmonary
valve to the pulmonary arterial circulation, where it is distributed to the
lungs. Next, the oxygenated blood arrives to the le atrium (LA) through the
pulmonary veins, it passes to the le ventricle (LV) throughout the mitral
valve and, nally, during ejection, the aortic valve opens to let the blood ows
into the aorta and the systemic circulation [16].
e atria and the ventricles are separated by the atrioventricular (AV)
groove, which is well dened posteriorly but interrupted in the anterior
portion by the aorta and the pulmonary trunk; the AV groove encases the
coronary sinus, the right coronary artery and the le coronary artery termi-
nation (see gure 1.2).
1.1.2 Vascular anatomy
Veins are elastic vessels that transport blood from tissues to the heart. Most
veins present valves with cusps directed toward the heart and covered by
endothelium.ese valves have muscular bundles at their base that actively
participate in their opening and closure (see gure 1.3).e venous return
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system is a complex network of venules and small and great veins, subdivided
in two parts: 1) the systemic venous return that transports deoxygenated
blood from tissues and organs to the RA; and 2) the pulmonary venous system
that transports oxygenated blood from the pulmonary circulation to the LA.
e systemic venous return presents two central structures: the venae cavae.
e superior and the inferior vena cava drain blood into the RA from the
upper and the lower half of the body, respectively [16].
Figure 1.3: Illustration of the major components of the vascular sys-
tem. Adapted from https://commons.wikimedia.org/wiki/File:Blood_
vessels_(retouched)_-en.svg. By Kelvinsongderivative work: Begoon [CC
BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0)].
Arteries are membranous conducts, with divergent ramications, in
charge of the distribution of the blood expelled in each cardiac systole to
all body tissues. To accomplish their tasks, arteries are designed to tolerate
pressure. ey have thick walls consisting in: 1) an intima layer, provided
with very active endothelial cells that respond to dierent constrict or dilat-
ory stimuli; 2) a medial layer formed by smooth muscle cells and elastin;
and 3) an adventitia layer composed of brocellular connective tissue [19],
[20]. Closer to the heart, arteries are more elastic than muscular while the
proportion of smooth muscle is higher in median calibre arteries. A graph-
ical overview of these components is presented in gure 1.3. e arterial
system is an intricate network of high-pressure, thick walled vessels (arteries,
arterioles and capillaries). Arteries are more than simple passive conduits for
transporting blood to tissues, arteries are biomechanical structures adapted
to execute their functions, both metabolic and mechanic, under dierent
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stress conditions, either in the short or long term, for ensuring continuous
optimal blood ow [20]. While the great vessels of the arterial system move
away from the origin, they branch to proportionate adequate irrigation to
all organic territories.e arterial system is subdivided in two circulation
systems: systemic and pulmonary. At the heart, two voluminous trunks arise
from each ventricle: the aorta (le) and the pulmonary arteries (right) [16].
e aorta, which is the major arterial structure in the human body, is in
charge of the distribution of oxygenated blood through the systemic circula-
tion.e aorta begins at the aortic valve annulus and has fourmajor segments:
ascending aorta, aortic arch, descending aorta, and abdominal aorta. e
three leaets of the aortic valve are connected to a sinus (of Valsalva), of
which the right and le sinuses give rise to the right and le coronary arteries,
respectively [16], [18]. From the aortic arch, the innominate (or brachioceph-
alic), le common carotid, and le subclavian arteries emerge (in that order).
From the innominate artery, the right subclavian artery arises. Both sub-
clavian arteries (le and right) originate both axillary arteries, which provide
the upper limbs with oxygenate blood, and continue as brachial arteries at
the (upper) arm. Later, brachial arteries bifurcate to form the radial and ulnar
arteries which run down the forearm [16], [20]. e descending thoracic
aorta borders the LA, oesophagus, and vertebral column. e abdominal
aorta is the nal portion of the artery before it ends at the aortic bifurcation,
from which the le and right common iliac arteries arise and, posteriorly,
branch into dierent structures, being the femoral artery (at each side) of
high importance for the lower limbs circulation [16], [19], [20].
e pulmonary trunk (or main pulmonary artery) is a major vessel of
the human heart that emanates from the RV. Its function is to transport
deoxygenated blood to the pulmonary circulation. e pulmonary artery
branches into le and right pulmonary arteries before arriving to the lungs
[16], [20].
1.2 Principles of cardiovascular physiology
e cardiovascular system is composed of two separate circulations to ac-
complish its main functions (see gure 1.4). e (low resistance and high
capacitance) pulmonary circulation performs bidirectional gas exchange
with the environment.e (relatively high resistance) systemic circulation
supplies essential molecules, such as oxygen and nutrients, to the tissues and
extracts CO2 and waste products for transporting them to organs in charge
of their removal (lungs, kidneys, liver).e heart pumps blood through both
circulations by the action of its chambers at each side: the thin-walled atrium
7
1. The Cardiovascular System
Figure 1.4: Diagram of the cardiovascular system.e diagram presents the heart
at the centre of the cardiovascular system and depicts the separation of the pulmon-
ary and systemic circulations. Adapted from https://commons.wikimedia.
org/wiki/File:Blausen_0168_CardiovascularSystem.png. By Blausen
Medical Communications, Inc. [CC BY 3.0 (https://creativecommons.org/
licenses/by/3.0)], via Wikimedia Commons.
receives blood and has a booster pump function, and the thicker-walled
ventricle pumps the blood to its respective circulation [16].
e cardiovascular system must adjust to function under dierent de-
mands. During exercise, extreme conditions, and even during respiration,
adaptation mechanisms should be in place to guarantee a proper cardiac
function.us, this section reviews the general mechanisms to accomplish
these tasks [16].
1.2.1 Cardiac physiology
1.2.1.1 Cardiac cycle
e cardiac cycle (i.e., the temporal sequence of events taking place during a
single heartbeat) starts with an electrical signal transmitted by specialised
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conduction tissue.ese conduction cells provide an adequate sequence of
activation for maximizing lling and contraction eciency. Furthermore,
the conduction tissue regulates the heart rate (HR) in response to various
inuences, particularly from the autonomic nervous and neuroendocrine
systems.e electrocardiogram (ECG) represents the electrical activity of
the specialised conduction tissue and the spread of the electric impulse [16].
Located in the RA, a group of conduction cells, known as the sinus node
or sinoatrial node (SAN), operates as the natural pacemaker of the heart.
ereupon, the electric signal begins at the SAN and then travels throughout
both atria, generating an atrial contraction (P wave). Next, the electrical
signal courses the junctional region between interatrial and interventricular
septa, rst passing through the AV node and then through the His bundle.
Conduction is slow at the AVnode and, consequently, there is a delay between
atrial contraction and ventricular depolarisation (PR interval) that facilitates
the synchronization between atria and ventricles, enhancing their function.
Instead, the conduction velocity increases aer the His bundle, from which
the electrical signal propagates through bundle branches and Purkinje bres
with several ventricular ramications favouring preferential current ow.
Accordingly, this stage of the cardiac cycle presents a fast-ventricular depolar-
isation (QRS complex) followed by the subsequent ventricular repolarisation
(T wave). In brief, the electrical activation of the heart follows a specic
(ecient) path of coordinated events, which results in the ejection of blood
by the ventricles into the systemic and pulmonary circulations [16]. is
process is summarised graphically in gure 1.5.
By convention, ventricular end diastole establishes the onset of the me-
chanical cycle. At that moment, there is an abrupt and quick intraventricular
pressure increment until ventricular pressure exceeds atrial pressure and
forces the closure of the AV valves. During this phase, ventricular volume
is xed (isovolumic contraction) and ventricular pressures continue to rise
rapidly. When aortic and pulmonary arterial pressures are exceeded, both
semilunar valves open and the phase of rapid ejection begins. In addition to
pressure gradients across semilunar valves, arterial elastic properties inu-
ence the rate of ejection, which is pivotal on the le side of the heart since the
systemic circulation is submitted to higher pressure and systolic expansion.
roughout ejection, ventricular and aortic/pulmonary arterial pressures rise
to a peak and then fall together with the rate of ejection of blood (phase of
reduced ejection) [16]. A reduced blood ow is maintained by blood inertia
and arterial recoil (the windkessel model eect [26]) until the pressure in the
outow tracts surpasses the falling pressure in the ventricle and, soon aer,
semilunar valves close and ejection ends, an event signalled by the dicrotic
notch of the respective arterial pressure waveforms.
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Figure 1.5: Diagram of the cardiac cycle and its phases. 1) Aer ventricular
contraction, a period of relaxation starts in which no electrical signal is gen-
erated by cardiac tissue. 2) e cardiac electric signal begins at the sinoatrial
node and then travels throughout both atria (P wave), 3) generating an atrial
contraction. 4) en, the signal passes through the atrioventricular node and
from there to the His bundle, from which the electrical signal propagates through
bundle branches and Purkinje bres with several ventricular ramications fa-
vouring preferential current ow (QRS complex). 5) A fast-ventricular depol-
arisation is triggered 6) and followed by the subsequent ventricular repolarisa-
tion (T wave), aer which ventricular relaxation begins, marking a new cardiac
cycle. Adapted from https://commons.wikimedia.org/wiki/File:2023_
ECG_Tracing_with_Heart_ContractionN.jpg. By OpenStax College [CC
BY 3.0 (https://creativecommons.org/licenses/by/3.0)].
e following phase, the isovolumic (constant volume) relaxation, is an
active energy-dependent process.is phase starts with the closure of the
semilunar valves and extends until intraventricular pressure drops below
atrial pressure and the AV valves open. With this opening, early diastolic
lling of the ventricles begins, accounting for most of the ventricular lling
(∼ 75 − 80%), and then pressures in the atrium and ventricle equalize and
lling slows or even stops. is period is named diastasis and is followed
by atrial contraction, which re-establishes the AV gradient and additional
blood is pumped into the ventricle without an excessive increase in atrial
pressure. Concretely, the LV lling pattern is the result of the transmitral
pressure produced by elastic recoil (suction), the rate ofmyocardial relaxation,
chamber compliance, LA pressure, and HR [16]. AWiggers diagram showing
temporal relationships between relevant parameters at the LV is presented in
gure 1.6.
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Figure 1.6: Wiggers diagram. Temporal relationships between: aortic (orange line),
LV (blue line) and LA (yellow line) pressures; LV volume (magenta line); ECG
(green line); and phonocardiogram (grey line). e diagram marks the systolic
and diastolic periods (bottom) and the phases of the cardiac cycle (top). Addi-
tionally, opening and closure of mitral and aortic valves are shown together with
characteristic features of atrial pressure curves, in which wave "a" reects atrial
contraction, wave "c" corresponds to an increase in atrial pressure aer mitral clos-
ure, and wave "v" evidences the atrial early lling. e ECG tracing shows three
main components: the P wave (atrial contraction), the QRS complex (ventricular
depolarisation) and the T wave (ventricular repolarisation). Moreover, heart sounds
are indicated as 1st and 2nd due to the reverberation of blood from the sudden closure
of the mitral and aortic valves, respectively, and 3rd rarely heard in young or athletic
people, but may also be a sign of serious cardiac problems. Adapted from https://
commons.wikimedia.org/wiki/File:Wiggers_Diagram_2.svg. By adh30
revised work by DanielChangMDwho revised original work of DestinyQx; Redrawn
as SVG by xavax [CC BY-SA 4.0 (https://creativecommons.org/licenses/
by-sa/4.0)], via Wikimedia Commons.
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Even if volume variations and pressure waveforms during lling are
comparable in both sides of the heart, the thick-walled LV generates a much
higher lling pressure (up to 7 − 8mmHg) than the RV, which is a reection
of the high-resistance systemic vascular bed, while mean LA pressure is also
(normally) higher than RA pressure. Comparatively, pressure and lling
patterns exhibit concrete dierences at both sides of the heart due to intrinsic
properties of the cardiac chambers and their associated circulation, whether
systemic or pulmonary [16].
1.2.1.2 Function of the heart
Ventricular pump performance, or the proper blood supply to the tissues at
adequate lling pressures, can be evaluated through function curves relating
lling pressure to mechanical output estimations, such as stroke volume (SV,
the volume ejected per beat), cardiac output (CO, the volume ejected per
minute), stroke work (the product of mean ejection pressure and SV), among
others. Such curves demonstrate the Frank-Starling mechanism of the heart,
which states that the SV of the heart proportionally relates to the end-diastolic
volume (EDV) [16]. EDV (preload) or surrogated quantities of volume, such
as pulmonary capillary wedge and LV end-diastolic pressure (EDP) are used
to generate the curves for describing the Frank-Starling mechanism (see
gure 1.7). Shis of the function curves are related to changes in intrinsic
contractile performance, but eects caused by altered diastolic compliance
cannot be dierentiated from those caused by altered contractile performance
[16], [17]. Contractile function is the intrinsic property of the cardiac muscle
to contract independently of changes in loading conditions (preload, which
is the load present at the end of diastole before the beginning of systolic
contraction, or aerload, which is the systolic load on the LV aer systolic
contraction starts). Contractile function relates the rate of contraction with
the peak force of the cardiac muscle and, oen, with the rate of relaxation
(the lusitropic eect) [16], [17].
Although both aspects of heart performance, systolic (myocardial con-
traction) and diastolic (relaxation and lling) function, overlap and interact,
in practice, it is convenient to analyse them separately [16].
Systolic function
Myocardial contraction or systole can be dened as the period between
the isovolumic contraction and the end of the ejection phase. e SV is
the volume of blood pumped from the heart during ejection and the CO is
calculated by multiplying SV and HR [16].
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According to the Frank-Starling mechanism or Starling’s law of the heart,
the initial muscle bre length regulates the contraction force (at any given
tension). Based on this premise, experiments introduced the concepts of
preload, aerload and contractility as mechanical determinants of cardiac
function [17].
Preload can be dened as ventricular end-diastolic wall stress, which is re-
lated to muscle sarcomere length and venous lling pressure. Corresponding
to Starling’s law, SV and wall shortening extent and velocity are proportional
to preload, while systolic wall stress and SV present an inverse relation at a
constant preload. Alterations in preload are a crucial factor of ventricular
performance and length-function curves. Indeed, the capacity to increase
preload in stress situations is a functional reserve to maintain LV systolic
performance in many disease states [16], [17].
Aerload, amajor determinant of SV, is characterised as the tension (force
or wall stress) on the LV bres aer shortening starts, which is basically the
arterial pressure. With a constant preload, a rise in LV ejection impedance
induces a bre shortening and an LV SV decline. In a healthy heart, SV can
be preserved by augmenting LV EDV and EDP, i.e., an aerload increase is
met by a preload increase. In contrast, the diseased heart (such as in heart
Figure 1.7: Frank-Starling curves.e Frank-Starling law characterises the correla-
tion between the contraction force and the initial length of muscle cells.e failing
heart curve shows a decreased slope indicating that higher cardiac preload is required
to maintain adequate stroke volume, i.e., contractile force. Adapted from the refer-
ence: Optimal perioperative uid management: What is the strategy? - Scientic
Figure on ResearchGate. Available from: https://www.researchgate.net/gure/Frank-
Starling-curves-of-ventricular-contractility_g2_306088064 [accessed 20 Oct, 2019]
via license: Creative Commons Attribution 4.0 International [27].
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failure) or the intact heart during acute conditions (such as hypovolemia) has
limited preload reserve and, thus, cannot increase suciently to maintain
the SV [16], [17].
Contractility is the generic term to express the intrinsic strength of
myocardial contraction, and thus it has been related to the inotropic state,
although it has not a straightforward quantitative denition. With constant
preload and aerload (loading conditions), cardiac performance is related
to contractility, which in turn is aected by dierent factors as sympathetic
neural activity. Responses of the LV contraction to alterations in preload, af-
terload, and contractility are assessed through the analysis of the LV pressure-
volume relationship (functional curves) [16], [17].
Physiologic measurements of LV systolic function
LV ejection fraction (EF) is the most well-accepted expression of global
LV function, indicating how much EDV is ejected from the LV with each
contraction. Various imaging approaches are used to measure EF, being
echocardiography the standard (see Chapter 2). Accuracy depends on the
limitations of the method and, therefore, magnetic resonance imaging (MRI)
has been proposed as a quality alternative to improve EF estimation (see
Chapter 2) [17]. For the EF calculation, LV EDV and end-systolic volume
(ESV) are obtained, and the following equation is applied:
LVE jection Fraction (EF) = (LV EDV − LV ESV)
LV EDV
= SV
EDV
(1.1)
Maximal ventricular elastance is another common parameter to assess
systolic function. End-systolic pressure-volume intercepts form a straight
line on the pressure-volume curve for a given degree of contractility, and the
slope of this line is the maximal elastance (see gure 1.8), which is directly
proportional to contractility. is approach involves the development of
pressure-volume curves and the control of either preload or aerload [17].
Diastolic function
Diastolic function is the lling capacity of the heart to reach an adequate
EDV at appropriate blood pressures.
Determinants of LV diastolic performance vary in their importance and
interaction during the four diastolic phases, which are isovolumic relaxation,
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Figure 1.8: Estimation of themaximumelastance.ree dierently loaded cardiac
cycles. e end-systolic pressure–volume points all lie on a line termed the end-
systolic pressure–volume relationship (ESPVR).e slope of the ESPVR ismaximum
elastance (Emax). At any time during systolic contraction (e.g., 50ms time points are
shown as lled circles) a line can be drawn connecting pressure–volume points from
each of the dierently loaded contractions dening elastance (∆P/∆V ) at that time
point. Ventricular systolic contraction can therefore be regarded as a time-varying
elastance. Adapted from the reference: Le ventricular function: Time-varying elast-
ance and le ventricular aortic coupling - Scientic Figure on ResearchGate. Avail-
able from: https://www.researchgate.net/gure/ree-dierently-loaded-cardiac-
cycles-e-end-systolic-pressure-volume-points-all-lie_g1_307959220 [accessed
20 Oct, 2019] via license: Creative Commons Attribution 4.0 International [28].
early LV lling, diastasis, and lling at atrial contraction.is division is only
a convention to facilitate the description of LV diastolic properties since it
has been dicult to understand LV diastolic function due to: 1) the complex
interaction between factors through all phases (particularly in disease states),
2) the additional factors that inuence LV diastolic properties, such as systolic
function, pericardial restraint, among others, and 3) the overlap of the eects
of these factors on the dierent phases of diastole [16], [17].
LV diastolic properties
During systole, the compression of elastic cardiac components produces
elastic recoil, which in turn results in an LV suction eect by active relaxation
during the early lling phase. is eect increases the pressure gradient
between LA and LV, thus enhancing early diastolic lling and producing a
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normal LV lling pattern. Abnormalities in relaxation generate lower trans-
mitral gradients and an anomalous LV lling pattern with greater proportion
of lling at atrial contraction. Under stress conditions, such as exercising,
this pattern hampers the ability of the heart for an optimal lling [16], [17].
e −dP/dtmax curve and τ (the time constant of relaxation) are calculated
invasively as estimations of the rate of isovolumic relaxation.ese methods
present several limitations that restrict its application, hence other indices of
isovolumic relaxation has been proposed using echocardiography and tissue
Doppler measurements (see Chapter 2). Nonetheless, the best method to
assess LV relaxation is still under research [16], [17].
Myocyte/myocardial and LV chamber compliance are less energy-
dependent properties that govern the LV lling aer relaxation.e former
is determined by collagen bres and sarcomeric proteins while the latter
is determined by external elements, e.g., the pericardium and pulmonary
airway pressure. Stress-strain relationship curves are used to evaluate
myocardial compliance, yet in vivo measurements are impractical, so
pressure-volume loops are determined during diastasis to characterise the
combined eects of myocardial and chamber compliance and external forces,
such as LV relaxation and viscoelastic properties. Chamber compliance,
or its reciprocal (stiness), is assessed with the slope of a tangent to the
pressure-volume relationship, in which a steeper slope indicates a stier
LV (see gure 1.8). However, this approach has several restraints, and its
application has limited to experimental studies [17].
LV relaxation and chamber compliance are critical determinants of trans-
mitral pressure gradient and LV lling. During diastole, the transmitral
pressure gradient ensures competent LV lling whereas normal SV is pre-
served by an adequate LV EDP such that the myocardium volume is optimal
(Frank-Starling mechanism). Changes in ventricular stiness induce ad-
justments in LV EDPs to maintain lling. A slower LV relaxation causes a
reduction of early diastolic transmitral gradient and a greater proportion
of lling at atrial contraction. A compensatory increase of atrial pressure
might be present in either case. At young age, diastole shows an ecient early
lling whilst, in the aging heart, a slower LV relaxation produces a higher
lling at atrial contraction. During exercise, a healthy heart shows a faster
LV relaxation rate and a shorter PR interval, reducing diastolic lling time to
preserve both early and late lling without raising atrial pressure [16], [17].
Non-invasive evaluation of LV diastolic function
For practical reasons, non-invasivemethods for calculating LVlling patterns
have been developed to assess indirectly LV diastolic function.e current
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gold standard technique is echo-Doppler, and age-related values has been
established for transmitral ow velocities (Chapter 2).e assessment of dias-
tolic function is complemented with the calculation of additional parameters,
such as maximal LA volume, LV lling in response to preload reduction (the
Valsalva manoeuvre) and mitral annular motion assessed by tissue Doppler
imaging (TDI) (see Chapter 2).
1.2.2 Physiology of the vascular system
Vascular function modulates total and peripheral resistance to control blood
ow by regulating arterial vasculature tone and venous capacitance and
return. Fast adaptation of blood ow to dierent physiological conditions,
even daily routine activities as standing up or exercising, is crucial to an
appropriate distribution of blood ow along the circulation system to preserve
adequate pressures and metabolic tissue needs [18], [19]. Elastic arteries, such
as the aorta or the common carotid arteries, have a relevant task in the
distribution of CO since they act as a reserve of blood and energy to keep
ow during diastole, when the ejection ceases.is phenomenon is known
as the windkessel eect [26] and it helps to damp the pulsatility of pressure
in smaller vessels and capillaries (see gure 1.9).
1.2.2.1 Regulation of blood ow
Vascular tone is inversely proportional to arterial size, being highest in the
smaller, muscular arteries and arterioles, which are major determinants of
peripheral resistance and local blood ow. Several physiological mechanisms
inuence the level of vascular tone and, hence, lumen diameter and resistance.
All these mechanisms eventually focus on the modulation of vascular smooth
muscle responding to modications of the mechanical forces at the vascular
wall or the release of neurotransmitters or metabolites by surrounding tis-
sues. Particularly, myogenic tone is the intrinsic ability of vascular smooth
muscle to constrict in response to pressure or stretch. On the other hand,
the endothelium releases vasoactive factors that inuence vascular tone [16],
[20].
Although myogenic responses in arteries, arterioles and veins are re-
ported, the mechanisms behind this eect are still elusive. On the other
hand, endothelium inuences vascular tone by releasing vasoactivemolecules,
such as nitric oxide (NO), peptide endothelin and dilator and constrictor
prostaglandins (see gure 1.10), either through cholinergic, physical or chem-
ical stimulation. An important example of physical stimulation is shear stress
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Figure 1.9: Graphical depiction of blood pressure values and changes through-
out the vascular system. Blood pressure in the arterial tree is pulsatile due to the
pump function of the heart and arterial mechanical properties. At this portion
of the vascular system, systolic, diastolic, mean and pulse pressure are identied
(pulsatile red line). Blood pressure is reduced in arterioles (straight red line) and
capillaries (purple line) and pulsatility ceases. Blood pressure continues to decrease
through the venous return system (blue line) until blood reaches the right atrium
of the heart. Adapted from https://commons.wikimedia.org/wiki/File:
2109_Systemic_Blood_Pressure.jpg. By OpenStax College [CC BY 3.0
(https://creativecommons.org/licenses/by/3.0)].
that acts on the vascular endothelium as a stimulant for vascular tone regula-
tion in the short term and arterial remodelling in the long term, according
to tissue blood ow demand [16], [20].
Regarding the control of peripheral blood ow and resistance, another
important factor to consider is autonomic regulation. Arterial pressure is
partly controlled by direct sympathetic innervation. Sympathetic eerent
activity is dictated by sophisticated interactions from dierent portions of
the nervous system and feedback signals from cardiovascular mechano- and
chemoreceptors localised in the heart, the aortic arch and the carotid sinuses.
During sympathetic activation (i.e., the “ght or ight reaction”), blood
pressure (BP) rockets, venous return raises and, thus, CO is redistributed.
In contrast, parasympathetic activity typically generates opposite responses:
vascular relaxation and reduced cardiac rate and output. However, the role of
the parasympathetic system is considered secondary in peripheral vascular
regulation [16], [17], [19].
Moreover, sympathetic vasoconstrictor and vasodilator bres respond to
emotional stress and/or to postural changes and are involved in the regulation
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Figure 1.10: Postulated pathways of vasodilation. ere are three relevant
vasodilation pathways: e endothelin pathway involving peptides known as
endothelins that constrict blood vessels and promote platelet aggregation;e nitric
oxide (NO) pathway in which NO is produced in endothelial cells from the amino
acid L-arginine modulating vasodilation and adhesion of both platelets and mono-
cytes to the vascular wall;e prostacyclin pathway, which involves the synthesis of
a prostaglandin (derived from the arachidonic acid) that is an eective vasodilator
and inhibits blood platelet activation. cAMP: cyclic adenosine monophosphate;
cGMP: cyclic guanosine monophosphate. Adapted from the reference: Reprinted
from Humbert M, Sitbon O, Simonneau G. 2004. Treatment of pulmonary arterial
hypertension. N Engl J Med, 351:1425-36. Copyright © 2004 with permission from
Massachusetts Medical Society. Adapted from the reference: A review of pulmonary
arterial hypertension: Role of ambrisentan - Scientic Figure on ResearchGate.
Available from: https://www.researchgate.net/gure/Postulated-pathways-in-the-
pathobiology-of-pulmonary-arterial-hypertension-PAH-and-drug_g1_6254474
[accessed 20Oct, 2019] via license: Creative Commons Attribution-NonCommercial
4.0 International [29].
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of body temperature. Notably, local metabolites produced during exercise or
ischemia have a powerful vasodilator eect in vessels within skeletal muscle.
Not only these metabolites stimulate the release of endothelial factors (NO
and prostacyclin) but their incremental eect in ow operates as a (shear
stress) stimulus for the further release of endothelial vasoactive substances.
However, metabolic regulation is only one of several mechanisms, including
neural, myogenic and humoral/endothelial, for peripheral blood ow con-
trol, since it concerns a complex interaction determined partly by ambient
conditions [17], [19], [20].
e ability of most vascular beds to maintain a constant blood ow over
a range of systemic arterial pressures is known as autoregulation, and it is
determined by the capability of the resistance vessels to constrict in response
to a pressure increase and to dilate due to a pressure fall. Autoregulation is
especially well developed in cerebral, coronary, and renal circulations [19],
[20].
Pressure-Flow waveforms
Figure 1.11: Graphical description of pressure (red) and ow (blue) waves align-
ment to perform Fourier analysis. At the aorta (le) and carotid (right) arteries.
Adapted from F. Londono-Hoyos, P. Zamani, M. Beraun, I. Vasim, P. Segers and J.
A. Chirinos, ‘Eect of organic and inorganic nitrates on cerebrovascular pulsatile
power transmission in patients with heart failure and preserved ejection fraction’,
Physiological measurement, vol. 39, no. 4, p. 044001, 2018 [3].
Peripheral resistance also impacts arterial ow and pressure waves. Dur-
ing systole, the compliant aorta stores a portion of the SV that is pushed
forward by elastic recoil during diastole. When the blood arrives to the high
resistance arterioles, a part is transmitted while other part is reected to the
arterial tree. In terms of ow, the reected wave subtracts from the forward
wave, producing a short period of reversal ow in early diastole unless peri-
pheral resistance is low [20]. Instead, the pressure reected wave adds to
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the forward wave, producing an upward deection on the downslope of the
pressure pulse.is eect accounts for the systolic pressure amplication,
diastolic pressure reduction and pulse pressure widening observed as blood
ows from the aorta to the peripheral arteries. Even if wave reections occur
through all the arterial tree at vessel branches, bifurcations and narrowing,
high-resistance vessels are a pivotal factor [20]. Moreover, waveform modi-
cations due to reections are more evident in peripheral arteries [20]. Fourier
analysis of pressure and ow waveforms delivers supplementary information
about the peripheral cardiovascular system (see gure 1.11 and Chapters 3
and 5).
1.2.3 Autonomic nervous system in cardiac function
e sympathetic and parasympathetic components of the autonomic nervous
system inuence the cardiovascular function, and their interactionmodulates
cardiac function through direct eects on heart’s contractility and/or vascular
tone in response to a variety of conditions.e parasympathetic system re-
duces BP through a fall in HR and, in a lower degree, contractility. In contrast,
sympathetic activation increases BP by elevating total peripheral resistance
and CO through a rise in cardiac contractility, HR, venoconstriction, and
arterial vasoconstriction [16]–[18]. In normal physiological conditions, para-
sympathetic activity dominates via active sensors known as baroreceptors,
which are stretch-dependent mechanoreceptors that sense pressure changes
and transmit via aerents to the nucleus tractus solitarius and, ultimately,
to the vasomotor centre of the brain. A sudden raise in BP stretches the
baroreceptors and results in an increased ring of the frequency action po-
tentials, producing an inhibition of the sympathetic drive and a stimulation
of (parasympathetic) vagal tone. By contrast, a drop in pressure generates
lower wall tension and, thus, lower ring of impulses, causing a disinhibition
of sympathetic activity and a reduction of vagal tone.is inverse coupling
of sympathetic and parasympathetic systems boosts the control of BP levels
[16]–[18].
e baroreex is a fast response mechanism to maintain BP and includes
a collection of reexes such as arterial baroreceptors (high pressure receptors)
and cardiopulmonary receptors (low pressure receptors). e most sensi-
tive sensors are the arterial baroreceptors, which are located in the carotid
sinuses, aortic arch, and at the origin of the right subclavian artery.ese
baroreceptors present a set point above which they are activated. is set
point depends largely on endogenous factors and disease states although
in normal physiological conditions, baroreceptors are activated at a mean
arterial pressure (MAP) above 70mmHg, whereas below this threshold they
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become “silent”. Aer nearly one day, hypertension or hypotension resets the
baroreceptors to the new blood pressures levels [16], [18], [19].
Arterial baroreceptors placed at the carotid sinuses react to both increases
or decreases in arterial pressure, whilst baroreceptors at the aortic arch are
sensitive only to increments in arterial pressure. Cardiopulmonary receptors
are located in the heart and large veins, such as venae cavae. Unlike arte-
rial baroreceptors, low pressure receptors respond primarily to changes in
volume and/or chemical stimuli, contributing to BP modulation through
the regulation of body uid volume. Finally, chemoreceptors are chemical
sensors that regulates sympathetic activation.ey are divided in two compo-
nents: central, which are found in the brainstem and respond to abnormally
elevated carbon dioxide (CO2) levels in the blood (hypercapnia), and peri-
pheral, which are placed in the carotid bodies and respond to abnormally
low levels of oxygen (O2) in the blood (hypoxemia).us, hypercapnia and
hypoxemia activate the sympathetic system [17]–[19].
1.3 Pathophysiology of the cardiovascular system
1.3.1 Heart failure
Heart failure (HF) has become one of the major causes of death worldwide
with increasing prevalence and incidence as the population ages. Despite
this, there is not a unifying hypothesis to describe the clinical HF syndrome.
In fact, current treatment delays the progression of signs and symptoms
but do not stop or cure HF. Any form of heart disease can lead to HF, thus
there is not a single causative mechanism and research on this regard is
a current active eld. A hypothesis considers HF as a progressive model
in which several alterations, including adaptation processes, contribute to
aect multiple organs, tissues and reex control mechanisms under diverse
conditions and at dierent timing, adding to the complexity of the syndrome
[16].
Due to this complexity, the sequence of events leading to HF, the precise
mechanisms involved, and the quantication of the contribution of each
individual component remains elusive. Nonetheless, enough information is
available to construct a working hypothesis. Fundamentally, a trigger event
(clinically “invisible” caused by an unusual stress to the system) causes a
loss of myocardium or excessive overload followed by physiological changes,
forcing the cardiovascular system to adapt to the “hostile” new environment.
In order to sustain an elevated load, rst the LV chamber increases in size
and, aer, the heart dilates.is ensures an increase in EDV to maintain SV
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despite a reduced EF, providing a short-term benet. Indeed, lack of dilation
may precede shock and early death [16]. Furthermore, compensatory mech-
anisms activate the “neurohormonal” systems, including the sympathetic
nervous system, and further myocardial remodelling takes place. Ultimately,
it becomes obvious that all these physiologic adaptations contribute to the
pathologic progression of HF. Nevertheless, specic questions remain to be
answered in this apparently coherent but oversimplied hypothesis [16].
Figure 1.12: Illustration of the anatomical dierences between a normal heart
and a heartwith systolic or diastolic dysfunction. In systolic dysfunction (le), the
heart is dilated and cardiacmuscle is weakened thus hampering the pump function of
the heart and reducing the quantity of ejected blood. In diastolic dysfunction (right),
the heart is stier (thicker LV wall) impeding proper relaxation and lling. HFrEF:
Heart failure with reduced ejection fraction. HFpEF: Heart failure with preserved
ejection fraction. Adapted from https://commons.wikimedia.org/wiki/
File:Major_categories_of_cardiomyopathy.png. By Npatchett [CC BY-
SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0)].
HF is a pathophysiological state with variable signs and symptoms, such
as shortness of breath (dyspnoea), fatigue and weakness, swelling (oedema)
in legs, ankles and feet, and others, in which metabolic tissue demands
are not meet as a result of a diminished pump function of the heart (see
gure 1.12). HF has a poor prognosis and a vast etiologic basis, even if, in
most patients, cardiac function and cardiac pump are maintained at rest
in early stages by compensatory mechanisms, whereas systemic vascular
resistance (SVR) is increased and fails to adapt to variations of metabolic
needs [16]. Concretely, systolic dysfunction is characterised by progressive LV
dilatative remodelling and the ensuing loss of myocardial contractile strength.
Further cardiac remodelling occurs as ventricular dysfunction aggravates,
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partially cause by sympathetic activation, deteriorating the emptying capacity
of the ventricles, i.e., a reduced EF, with a parallel compensatory increment in
diastolic volume. Instead, diastolic dysfunction exhibits an intact emptying
capacity but impaired ventricle lling that results in increased lling pressures
and, ultimately, in pulmonary oedema (uid accumulation in the tissue and
air spaces of the lungs) [16].
1.3.1.1 Heart failure classication and stages
Dierent classication and staging schemes have been proposed.e New
York Heart Association (NYHA) functional classication is the most widely
used. It presents four HF stages as table 1.1 shows.
Nonetheless, the NYHA classication is considered imprecise and, there-
fore, preference is being given to the use of a staging scheme of HF asso-
ciated with increasing morbidity and mortality, and more closely linked
with prevention and therapy. In this scheme (2001 American college of car-
diology/American heart association (ACC/AHA) Guidelines) [30], HF is
considered a continuum that encompasses four interrelated stages described
in table 1.1.
Table 1.1: Heart failure (HF) classication schemes. Adapted from [16].
Classication Scheme Class/Stage Description
NYHA
I Patients without symptoms or limitations of physical activity
II Patients with mild symptoms and slight limitation of physical activity
III Patients with marked symptoms and pronounced limitation of physical activity
IV Patients with severe symptoms and serious limitations of physical activity even at rest
2001 ACC/AHA Guidelines
A Patients with risk factors of HF but without structural heart disease or HF symptoms
B Patients with structural heart abnormalities but no HF symptoms
C Patients with structural heart disease and HF symptoms
D Patients with marked HF symptoms and severe disability
1.3.1.2 Mechanisms of heart failure
To achieve a global understanding of the pathophysiology of HF and its pro-
gression, a thorough analysis should be performed, including measurements
of mechanical/haemodynamic features, cardiac impaired performance and
maladaptive responses.
e basis of the Frank-Starling law is the relation between contractile
force (contractility) and sarcomere lengthening. According to this law, if
LV volume raises then contractility raises too, together with systolic blood
pressure, and hence aerload (see gure 1.7). While EDV is considered a
subrogated measure of preload, aerload is dened as the wall tension during
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LV ejection [16], [17]. Within a cylinder, the Laplace equation relates wall
tension to pressure, radius and wall thickness, as:
Wal l tension = (pressure ∗ radius)
2 ∗wal l thickness (1.2)
is oversimplied equation emphasizes that an increase in wall tension
is produced by dilation of the ventricles (i.e., a greater radius) or, at a given
radius, an increase in LV pressure. Moreover, an increase in wall thickness
caused by hypertrophy balances the increased pressure, reducing the tension
on any individualmuscle bre during the phase of compensatory hypertrophy
[16].
e dilated heart becomes more sensitive to aerload (and less to pre-
load) and, while cardiac eciency decreases, both wall tension and aerload
increase due to the inability of the heart to reduce its radius during con-
traction. ese initially advantageous ventricular dilatation to sustain SV
becomes a substantial disadvantage and diminishes further the myocardial
performance. Moreover, dilatation leads to functional regurgitation of AV
valves, and apoptosis can be induced by stretched myocardial cells thereby
contributing to further disease progression. It is worth to mention that addi-
tionally to systolic pump function, LV performance depends also on active
relaxation, diastolic elastic recoil, passive diastolic properties, and vascular
loading conditions [16].
In early stages of HF, CO is normal at rest but is not maintained during
stress. In contrast, a more advanced HF stage may show an elevated EDP and
CO even at rest with the correspondent augmentation in EDV and ESV, which
in turn reduces ventricular elastic recoil during relaxation, and therefore,
rapid early lling diminishes. e rise in diastolic pressure also impacts
negatively the pulmonary circulation. Clearly, before reaching an advanced
HF stage, the body has activated many adaptative mechanisms that have
failed progressively to maintain an adequate CO [16].
Although systolic and diastolic dysfunction oen coexist and inuence
each other in HF patients, structural alterations of the ventricles are distinct-
ive (see gure 1.12). In systolic dysfunction, the ventricle is large and dilated
(eccentrically hypertrophied) and presents a deteriorated ejection and limited
output.is subtype of HF is therefore also called HF with reduced ejection
fraction, or abbreviated as HFrEF. In diastolic dysfunction, the ventricle is
a small thick-walled and stiened chamber (concentrically hypertrophied)
that is not only unable to distend properly at normal lling pressures but
also exhibits limited lling, alterations in relaxation, incoordinate wall mo-
tion during isovolumic relaxation, and altered ventricular inow velocity.
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Nonetheless, it is typical that EF is preserved in this patients, leading to
the terminology HF with preserved ejection fraction (HFpEF). Additionally,
patients have a limitation of exercise tolerance since the SV cannot be aug-
mented at fast HRs. Hence, this condition leads to an increase in ventricular
lling pressures and congestive symptoms even if systolic function is (nearly)
intact [16], [17].
In contrast to the well-established systolic dysfunction orHFrEF, diastolic
dysfunction or HFpEF has been recognized only in past decades as a major
and growing epidemiological problem [31]–[33]. Commonly, LV diastolic
alterations develop earlier than systolic dysfunction as relaxation is more
energy dependent than contraction. Diastolic dysfunction is a multifactorial
problem conditioned by age, hypertension, myocardial brosis, hypertrophy,
ischemia, increased aerload, inter alia. Consequently, the contribution of
diastolic dysfunction to HF is dicult to establish considering that diastolic
and systolic dysfunction symptoms are clinically indistinguishable. In fact,
the recognition, evaluation, and treatment of diastolic dysfunction remain a
challenge [16], [17].
Nevertheless, detection of patients with diastolic dysfunction is equally
essential as they have a prognosis nearly as poor as patients with systolic
dysfunction. Even for systolic dysfunction patients, the degree of diastolic
dysfunction is a powerful predictor of mortality [17]. Reliable (non-invasive)
diagnostic tools and potential therapies for LV diastolic function remain an
active eld.
1.3.1.3 Heart failure treatment
Prevention should be the primary goal with patients at risk. Hypertension,
diabetes, obesity and/or coronary artery disease, particularly in the elderly,
must be eectively treated to control the development of HF [17].
Table 1.2: Commonmedications used to treat heart failure [17].
Medication Action Possible side eects Examples
Beta-blockers (BB) ↓HR ↓ BP Fluid retention, low BP, low pulse, Carvedilol - metoprolol - bisoprilol
Limits/reverses heart damage in HFrEF general fatigue, lightheadedness
Angiotensin-converting Vasodilation Dry cough, low BP, Lisinopril - captopril
enzyme (ACE) inhibitors ↓ BP ↓ workload on the heart worsening kidney function, Enalapril- fosinopril - perindopril
Improve blood ow electrolyte imbalances
Angiotensin II receptor Alternative to ACE inhibitors Dizziness, changes in kidney function, Candesartan - Losartan - Valsartan
blockers (ARB) increased potassium levels
Hydralazine and nitrates Vasodilators Dizziness, headache, Hydralazine and isosorbide dinitrate
Improve cardiac function swelling of the hands, arms, feet, or legs Nitroglycerine
Diuretics Avoid uid retention Dehydration, Furosemide - bumetanide
Improve signs of pulmonary oedema electrolyte abnormalities, low BP torsemide - metolazone
Aldosterone antagonists Diuretic eect Changes in kidney function, Spironolactone - eplerenone
Improve symptoms in HFrEF swelling or tenderness in the breasts
Digoxin (digitalis) ↑ contractility ↓HR Nausea, vomiting, heart rhythm disturbances, Lanoxin
Improve symptoms in HFrEF kidney dysfunction
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To reduce both morbidity and mortality, all patients with HFrEF should
undergo aggressive treatment of the prime cardiovascular disease, in particu-
lar coronary artery disease, valvular heart disease or hypertension. Eective
therapies include angiotensin-converting enzyme (ACE) inhibitors or an-
giotensin II receptor blockers (ARB) and beta-blockers (BB) (see table 1.2).
Particularly, ACE inhibitors and BB slow progressive dilation of the heart.
Digoxin or diuretics therapies control symptoms but have not been proven
to reduce mortality. Nonetheless, improvement of quality of life is crucial
and all measures in this regard should be taken [17].
In contrast, an optimal therapy approach for HFpEF is still unknown and
few studies have been published on this regard. Following the principles of
HFrEF treatment, the underlying cause of HFpEF should be addressed while
cardiac loading conditions, HR or cardiac rhythm and ecient depolarisation
should be improved. Diuretics and hypertension control could benetHFpEF
patients with pulmonary oedema or dyspnoea. Patients without evidence of
increased lling at rest may not benet from diuretics. Exercise tolerance
could be enhanced with ACE inhibitors. LV relaxation therapy slows HR
and allows the ventricle to better relax and ll before atrial contraction [17].
In the long term, hypertension control and regression of LV hypertrophy
frequently improve HF symptoms. In brief, treatment should be patient
specic. ACC/AHA practice guidelines [34]–[36] present a useful foundation
to dierent approaches in the treatment of HF patients.
Nitrate therapies
e major eect of nitrates/nitrites in the cardiovascular system is the re-
laxation of smooth muscle in veins, larger arterioles and arteries through
an endothelial pathway (see gure 1.10), which results in a reduction of BP
and aerload due to the shi of central blood volume to the venous system
[17]. Two classes of nitrates/nitrites available for treatment, organic and in-
organic, mediate their principal eects (see table 1.3) via the NO pathway
(see gure 1.10). Nevertheless, there are signicant dierences between these
two classes related to their chemical structure and origin that determine
distinctive pharmacokinetic and pharmacodynamic properties [37].
Synthetically produced, organic nitrates are small non-polar hydrocarbon
chains attached to a nitrooxy-radical (–ONO2), which imparts its biological
eects. Glyceryl trinitrate (GTN) or nitroglycerine (NTG) (see gure 1.13) is
themost commonly usedmedicinal organic nitrate, although other employed
organic nitrates include pentaerithrityl tetranitrate, isosorbide dinitrate and
isosorbide mononitrate (see table 1.3).
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Table 1.3: A comparison of the therapeutic eects of organic and inorganic ni-
trates/nitrites in humans. Adapted from [37].
Organic nitrates/nitrites Inorganic nitrates/nitrites
Endothelial dysfunction Have a negative impact on endothelial function Have a positive impact on endothelial function
through the production of reactive oxygen species regardless of duration of supplementation acutely
Blood pressure Leads to a fall in systemic BP Leads to a fall in systemic BP
Rapid in onset (around 15–30 min) Nitrate – slow in onset (around 3 h)
Limited by the development of tolerance Eects more sustained with no evidence of tolerance
which ameliorates its BP lowering eects Dose dependent
Pulmonary hypertension Leads to a reduction in pulmonary Leads to a reduction in pulmonary arterial
arterial pressure when inhaled pressure when inhaled
Platelet function Inhibits platelet aggregation with no evidence Inhibits platelet aggregation
of attenuation of this eect with chronic administration Eects are likely to be mediated by nitrite–NO
Other therapeutics Treatment of acute pulmonary oedema Antimicrobial eects in dierent parts of the gastrointestinal tract
Treatment of angina Enhancement of gastric blood ow and mucosal healing
Treatment of anal ssures Improve exercise capacity
Examples Nitroglycerine, pentaerithrityl tetranitrate Sodium nitroprusside,
and sources isosorbide dinitrate, isosorbide mononitrate green leafy vegetables and beetroot
Figure 1.13: Chemical structure of nitroglycerine (organic nitrate) and so-
dium nitrite (inorganic nitrite). Adapted from National Center for Biotechno-
logy Information. PubChem Database. Nitroglycerin, CID=4510, https://
pubchem.ncbi.nlm.nih.gov/compound/Nitroglycerin (accessed on Oct.
31, 2019) and National Center for Biotechnology Information. PubChem Data-
base. Sodium nitrite, CID=23668193, https://pubchem.ncbi.nlm.nih.gov/
compound/Sodium-nitrite (accessed on Feb. 13, 2020).
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Inorganic nitrates/nitrites are simpler molecules (salts of nitric acid and
nitrous acid respectively, see gure 1.13) produced endogenously and present
in the diet with more subtle and prolonged eects dependent on certain
conditions [37]. Inorganic nitrates are taken up by plants, especially green
leafy vegetables and beetroot, through water and soil, and then ingested by
humans, resulting in their reduction to nitrites largely via the entero-salivary
circulation (see gure 1.14).
Figure 1.14:e entero-salivary circulation of dietary nitrate. Ingestion of nitrate
(NO3-) (a) from dietary sources is swallowed and rapidly absorbed across the upper
gastrointestinal tract (1) into the systemic circulation (2), where it mixes with endo-
genous nitrate. Approximately 70% of ingested nitrate is excreted by the kidneys (3)
whereas 25% is actively concentrated in the salivary glands (c). Nitrate-rich saliva is
secreted into the oral cavity (4) where facultative anaerobic bacteria reduce nitrate
to nitrite (NO2-) (d) via the action of nitrate reductase enzymes. Nitrite-rich saliva
is then swallowed (5) and further metabolized to nitric oxide (NO) nonenzymat-
ically in the acidic stomach (e). NO exerts various biological eects in the body
(6-f). Some nitrite escapes acidic reduction in the stomach and enters the systemic
circulation (6) where it gets reduced to NO in the blood and in other tissues that
then exerts biological eects (f). Adapted from [38].
In practice, the use of organic nitrates is prevalent for treatment of cardio-
vascular diseases to relief symptoms and support BP control. Furthermore,
in patients with acute infarction and decreased LV function, organic nitrates
limit infarct size and impact positively ventricular remodelling [17]. None-
theless, benecial eects of organic nitrates are lost aer drug treatment is
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discontinued and they show a limited impact in the mortality rate of these
patients. Another major limitation of organic nitrates use is tolerance, that
is a loss of haemodynamic eects with sustained use. e mechanism of
this phenomenon remains unknown, but tolerance can be temporally over-
come with escalation of dose [17]. Even though the use of organic nitrates
dominates cardiovascular treatment, this may change with the increasing
recognition of their limitations, and ongoing discovery of benecial eects
and specic advantages of inorganic nitrate/nitrite [37].
In Chapter 5, we propose a thorough haemodynamic analysis in HFpEF
patients comparing the eects of organic and inorganic nitrates/nitrites in
cardiovascular function to support the search for a proper treatment.
1.3.2 Atherosclerosis
Figure 1.15: Illustration of the anatomical dierences between a normal vessel
and an atherosclerotic vessel. Adapted from https://commons.wikimedia.
org/wiki/File:Blausen_0053_Artery_NormalvsDiseasedVessel.png.
By Blausen.com sta (2014). &quot;Medical gallery of Blausen Medical 2014&quot;.
WikiJournal of Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436. [CC
BY 3.0 (https://creativecommons.org/licenses/by/3.0)].
Atherosclerosis is a major pathological process in large arteries and the
most common cause of clinical complications related to arterial wall degen-
eration. In fact, atherosclerosis is a degenerative disease characterised by the
accumulation of cells, matrix bres, lipids, and tissue debris in the intima
(see gure 1.15). Altered biomechanical and haemodynamic conditions trig-
ger adaptive responses in arterial wall thickness, lumen diameter or both
to preserve the structural and functional integrity of the arterial tree but
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pathological conditions may lead to lumen stenosis, aneurysm formation, or
obstructive intimal hyperplasia [20].
Smoking, elevated serum lipid levels, hypertension, obesity, diabetes
mellitus, physical inactivity, emotional stress or genetic predisposition are
correlated factors associated with atherosclerosis development in certain
arterial beds more than in others. Haemodynamics and wall properties,
associated with variations in the distribution of shear and tensile stresses,
also inuence plaque formation. For instance, sites prone to plaque formation
are the coronary arteries, carotid bifurcation, infrarenal abdominal aorta,
and iliofemoral arteries whilst the thoracic aorta and the common carotid,
distal internal carotid, renal, mesenteric, and upper extremity arteries are, in
general, spared [20].
1.3.3 Aging
Life expectancy had a tremendous increase in the past century, and never
before a society has had as many elderlies as nowadays. Considering the high
incidence and prevalence of cardiovascular disease among the elderly, the
need to understand age-related changes in the cardiovascular system and
how they trigger pathological processes becomes obvious. Older patients are
more prone to systolic hypertension, HFpEF and to coronary artery disease
involving multiple vessels. To lower the elevated morbidity and mortality of
cardiovascular diseases among the elderly, eective prevention and treatment
must be implemented. However, randomized controlled trials do not specify
appropriate treatment adaptation to populations diering from those studied,
and these trials rarely enroll elderly patients, despite the greater burden of
cardiovascular diseases in this population [18]–[20].
Evidently, more studies should provide evidence-based medicine
across age, including specic information on drug ecacy, safety and
functional/health status outcomes, especially for patients who account for
the greater health care expenditures. Accordingly, a careful consideration of
therapeutic benets across patient age and heterogeneity of aging should
guide treatment selection. In summary, a broader perspective, including
patient priorities, which are quality of life and functional independence
rather than longevity for many older persons, should become pivotal to
ensure the best cardiovascular care [18]–[20].
Cardiovascular changes related to aging
Aging is a natural process of adaptation decline that brings several changes
in all the body, including the cardiovascular system. Notwithstanding, aging
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is a remarkably heterogenous process without a universal denition or an
accurate biomarker. In eect, there is not a precise age or progression estab-
lishing the onset or development of physiological changes related with aging
in all individuals, even though a global pattern exists (see table 1.4).
Table 1.4: Relationship of cardiovascular human aging in health to cardiovascu-
lar diseases. Adapted from [16].
Age-associated changes Plausible mechanisms Possible relation to human disease
Cardiovascular structural remodelling↑Migration of and ↑matrix production↑ Vascular intimal thickness by vascular smooth muscle cell Promotes development of atherosclerosis
Possible derivation of intimal cells from
other sources
Elastin fragmentation Systolic hypertension↑ Elastase activity LV wall thickening↑ Vascular stiness ↑ Collagen production by vascular
smooth muscle cell and ↑ cross-linking of collagen Stroke
Decline in cognitive function
Altered growth factor regulation/tissue Atherosclerosis
repair mechanisms Possible LV hypertrophy↑ LV myocyte size with altered Ca2+ handling Retarded early diastolic cardiac lling↓Myocyte number (necrotic and apoptotic death) ↑ Cardiac lling pressure↑ LV wall thickness Altered growth-factor regulation Lower threshold for dyspnoea
Focal matrix collagen deposition ↑ Likelihood of HF with relatively normal
systolic function
Possible LV hypertrophy↑ Le atrial size ↑ Le atrial pressure/volume ↑ Prevalence of atrial brillation and
other atrial arrhythmias
Cardiovascular functional changes
Altered regulation of vascular tone ↓ NO production/eects Vascular stiening; hypertension
Early atherosclerosis
Changes in gene expression of proteins that Lower threshold for atrial and ventricular
Reduced threshold for cell Ca2+ overload regulate Ca2+ handling; increased arrhythmia
polyunsaturated fatty acids ratio in cardiac Increased myocyte death, increased brosis
membranes Reduced diastolic and systolic function↑ Vascular load↓ Intrinsic myocardial contractility
Ventricular-vascular load mismatch during stress↓ Cardiovascular reserve ↑ Plasma levels of catecholamines Lower threshold for HF and increased
severity of HF↓ β-adrenergic modulation of HR, myocardial
contractility and vascular tone due to
postsynaptic signalling decits
Reduced physical activity
Exaggerated age changes in some aspects
of cardiovascular structure and function,
e.g., arterial stiness
Learned lifestyle
Negative impact on atherosclerotic
vascular disease, hypertension, and HF
A hallmark of cardiovascular aging is the weight increase of the heart
due to myocyte hypertrophy and connective tissue deposition. Furthermore,
increased septal thickness and decreased base-to-apex dimensions result in
ventricular size reduction and shapemodication. In spite structural changes,
greater vascular stiness and early reected pulse waves, systolic function
remains basically normal at rest, partly due to a benecial adaptation that
enables the continued ejection of blood during late systole. In contrast, the
enhanced stiness impairs compliance and requires greater lling pressure
to adapt via the Frank-Starling mechanism producing diastolic dysfunction
[18].is causes a prolonged (impaired) relaxation and slower early diastolic
lling. Parallel structural changes, such as mitral or aortic valvular disease,
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hypertension, atrial arrhythmias, or senile amyloidosis (accumulation of a
protein in the heart causing increased wall thickness), promote additional
alterations of haemodynamic conditions aggravating diastolic dysfunction
[18].
Alterations in the cardiac conduction system of the aging heart arise from
apoptosis and the deposition of collagenous and fatty tissue, concretely at the
SAN, and calcication of the AV node and le and right bundle branches.
As a result, PR and QT intervals in the ECG frequently show moderate
increases together with a longer QRS complex, a lower T wave amplitude
and bundle branch blocks. Moreover, episodes of atrial brillation become
more common among aged individuals. Consistent alterations of autonomic
regulation lead to an impaired baroreex response to physiological stressors
and increased central nervous system eects. In consequence, HR and heart
rate variability (HRV) are reduced, vasoreactivity is diminished, and cardiac
contractile responses are blunted [18].
e aging arterial system shows representative changes in elasticity, dis-
tensibility and dilation induced by collagen deposition and a weakened vas-
cular elastin. Particularly, endothelial impairment caused by alterations, such
as apoptosis and progressive irregularity in endothelial cell size and shape, is
dicult to separate from coexisting hypertension, hypercholesterolemia, and
atherosclerosis.e intima develops a more complex content originating a
diuse intimal thickening, which characterises most adult human arteries,
even in the absence of atherosclerosis. is process may not parallel lipid
accumulation and may occur in individuals without substantial burden of
atheroma. Smooth muscle growth and lipid and calcium deposition aect the
elastic lamina of the media layer contributing to arterial stiening and, hence,
to a reduction in arterial distensibility and compliance, and the following aug-
mentation of the travel speed of the pulse along an arterial segment, known
as pulse wave velocity (PWV). A higher PWV results in a faster propagation
speed of waves, hereby leading to faster return of wave reections boosting
further systolic pressure. Moreover, vascular remodelling due to elastance
changes and congenital, degenerative, mechanical and haemodynamic factors
leads to dilatation and elongation of the aorta and major arteries, setting the
stage for dissection or rupture [18]–[20].
Regarding cardiovascular performance, normal aging involves reduction
of aerobic capacity due to an impaired O2 extraction from the circulating
blood volume, which in turn is related to a decline in muscle mass and an
increase of body fat. To counterbalance aging eects to some extent, suc-
cessful physical training can enhance exercise tolerance, aortic elasticity,
muscle mass, ventricular performance, and even achieve the same peak CO
as younger cohorts, albeit by dierent mechanisms. It is therefore clear that
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lifestyle inuences the pace of aging and quality of life in later years. Other
(risk) factors impacting the aging process include hypertension, hypercho-
lesterolemia, coronary artery disease, diabetes mellitus, smoking and LV
hypertrophy [18], [20].
Overall, aging has substantial eects in cardiac structure and function in
terms of physiological responses to exertion and clinical responses to disease.
Notably, risk factors play a decisive role in pathophysiological progression
and can aggravate and accelerate the aging process.
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Non-invasive techniques for
cardiovascular assessment
is chapter builds up on the foundations established in Chapter 1, intro-
ducing non-invasive techniques to measure and image the cardiovascular
system. In fact, accurate imaging is crucial to evaluate cardiac anatomy,
function and metabolism.is chapter focuses on two major cardiovascular
imagingmodalities that use soundwaves (ultrasound) and themagnetic prop-
erties of the hydrogen nucleus (magnetic resonance imaging) to characterise
the heart and vessels.
e rst part of the chapter deals with measuring techniques to obtain
arterial pressure waveforms, which are essential to assess arterial stiness and
potential cardiovascular risk factors of a subject. Next, common concepts for
imaging techniques are presented, and then imaging modalities are reviewed,
discussing basic physical principles, cardiovascular applications and clinical
implications. Finally, advantages, limitations and additional considerations
regarding each modality are discussed.
is chapter is based, extracted, adapted and/or edited from several bibli-
ographic resources. For writing the rst section, regarding the pressure wave
measurement, the main sources were the articles: Expert consensus document
on arterial stiness: methodological issues and clinical applications [39] of
Laurent et al., and Assessment of arterial pressure wave reection: methodolo-
gical considerations [40] of Swillens and Segers, and the Doctoral dissertation
Development and validation of non-invasive diagnostic tools for the assessment
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of arterial stiness and wave reections with application in Sub-Saharan Africa
of Kips [41].e principal sources employed to develop the following sections
of the chapter concerning imaging modalities were Biomedical Signal and
Image Processing book of Najarian and Splinter [42], Biosignal and medical
image processing book of Semmlow [43], Hurst’s the heart book of Fuster
[16],Mayo Clinic Cardiology: Concise Textbook of Murphy [17], Textbook of
cardiovascular medicine of Topol and Cali [18], Braunwald’s heart disease: a
textbook of cardiovascular medicine of Libby [19], Vascular surgery book of
Rutherford [20], Introduction to vascular ultrasonography book of Zwiebel
and Pellerito [22], Heart failure in children and young adults: from molecular
mechanisms to medical and surgical strategies book of Chang and Towbin [23],
Feigenbaum’s Echocardiography digital edition of Feigenbaum, Armstrong
and Ryan [44] and the heart as a muscle-pump system and the concept of heart
failure article of Weber and Janicki [25].
2.1 Non-invasive arterial pressure wave measurement
Arterial pressure waveforms have always been essential for the assessment
of the cardiovascular system.e two most commonly used techniques to
measure non-invasively the pressure waveform in the vascular periphery are
photoplethysmography and applanation tonometry [39].
Based in a technique described by Penaz [45], photoplethysmography
uses the changes in light absorption to estimate volume variations of an organ
or a structure [39]. Concretely, nger artery size is continuously measured
using a nger cu equipped with a light source and a detector. An external
pressure is applied constantly to the artery through an inatable bladder
to counterbalance the internal pressure [46]. Changes in pressure are re-
gistered and displayed as pressure waveforms. A disadvantage of the method
is that nger pressure waveforms only correspond well with radial pressure
waveforms in young, healthy subjects whereas this is not the general case,
particularly in pathological states.
Applanation tonometry employs high-delity strain micromanometers
directly applied on the skin at a constant pressure to record arterial pressure
waveforms.is technique relies on the existence of a hard structure against
which it is possible to applanate a supercial artery, such as radial, carotid,
femoral and brachial locations, even if accurate measurements are dicult to
obtain in the brachial artery [39], [41]. Since calibration is a necessary step
for tonometric waveforms, dierent approaches have been proposed. At the
brachial artery, calibration is rather easy using systolic and diastolic pressures
from sphygmomanometry measurements. At other arterial locations, calib-
ration is more complex. One approach suggests the use of brachial diastolic
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Figure 2.1: Pressure waveforms obtained with applanation tonometry to es-
timate the carotid-femoral pulse wave velocity. Examples of pressure wave-
forms of the carotid (thick line) and the femoral (thin line) arteries obtained
with applanation tonometry. e foot-to-foot method uses these waveforms
for calculating the carotid-femoral pulse wave velocity (cf-PWV) by multiply-
ing the carotid-femoral distance (∆L) by 0.8 and dividing the result by the time
interval (∆t) between the foot of the carotid and the femoral waveform (see
Chapters 3 and 6). Adapted from https://commons.wikimedia.org/wiki/
File:Method-of-pulse-wave-analisys.png. By Omboni S, Posokhov IN
[CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0)].
blood (DBP) and mean arterial (MAP) pressures to calibrate tonometric
waveforms at any location [39], [41].is method is based on the observation
that the dierence between DBP and MAP remains constant throughout the
large arteries [39], [41]. Brachial tonometry is required to calculate MAP
from the arithmetic average of a calibrated (brachial) pressure waveform. A
simpler approach proposes to estimate MAP as the sum of DBP and 40%
of the pulse pressure (PP) [41]. Although the aorta is the most relevant lo-
cation of the arterial system, aortic pressure waveforms cannot be obtained
noninvasively.us, transfer functions have been built to synthetised aortic
pressure waves from radial pressure curves even if the generalised nature of
the method is a limitation, especially in pathophysiological applications. An
alternative procedure is to measure the pressure wave at a site closer to the
heart, such as the carotid (see gure 2.1) or the subclavian arteries, in spite of
a more challenging acquisition [39].
High-delity applanation tonometry is also a well-accepted method to
estimate pulse wave velocity (PWV) of the carotid-femoral segment (see
gure 2.1). In this case, waveforms are recorded sequentially at each site, using
a simultaneously recorded electrocardiogram (ECG) signal as time reference
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for calculating the transit time of the pressure wave between both locations.
Nevertheless, applanation tonometry is a highly user-dependent method so
operators must have enough training to perform adequate measurements
[39].
2.2 Cardiovascular imaging
2.2.1 Principles of imaging
Unlike other organs, the heart has a ne structure and complex motion that
requires imaging modalities with high temporal and spatial resolution. Two
major modalities comply with these requirements: ultrasound and magnetic
resonance imaging (MRI) [18].
Imaging displays the interaction of energy with matter to discern struc-
ture and function. For example, ultrasound shows the dierential reection
of acoustic waves from the border of two tissues with distinct acoustic im-
pedances and MRI denes the dierential distribution of weak magnetic
characteristics within the body. Regardless the dierences between both
modalities, there are common basic concepts that are relevant to consider
[18].
2.2.1.1 Basic concepts
Spatial resolution is dened as the smallest separation at which two objects
are dierentiated. Each imaging modality and each device has a specic
spatial resolution, but some generalities can be derived [18]. For instance,
spatial resolution for ultrasound is higher in the near eld than in the far
eld and better in the axial direction (along a scanline) than in the lateral
direction (across scan lines).ree-dimensional (3D) MRI typically has also
greater resolution in the imaged plane than in the axis along which slices of
the object are being selected [18].ere is an important dierence between
physical resolution of the imaging modality, which was described above,
resolution display and functional spatial resolution. Resolution display is
the spacing of the picture elements (pixels) on the screen and can be greater
or lesser than the physical resolution [18].e functional spatial resolution
is the lesser of the physical and screen resolutions. Temporal resolution is
described as the shortest time a device needs to generate an image (frames
per second). In general, there is a trade-o between temporal and spatial
resolution. Velocity resolution refers to the smallest dierence in velocity
that can be distinguished [18].
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Digital acquisition, storage and visualisation is the preferred option for
cardiac imaging due to several advantages over analogue techniques, such
as a more ecient review of examinations and comparison with previous
stored examinations, facilitated access, long-termed archiving without loss
of quality, lower costs, etc. To accomplish this goal, a standard format has
been implemented together with the improvement of network systems [18].
e digital imaging and communications in medicine (DICOM) image
format standard is a set of rules for exchanging images, specifying informa-
tion about the patient, the purpose and the technique of the examination, and
the pixel data themselves. In this format, each imaging modality has specic
data elements and storage structures for communication and exchanging in-
formation [18]. In practice, echocardiography (ultrasound) has diverse needs,
requiring grayscale, colour, and spectral Doppler storage, and images may
be stored either uncompressed or with lossless or lossy JPEG compression
[18]. Instead, nuclear standard, which includes MRI, encompasses the many
complex studies of nuclear cardiology without any compression because the
small size of the data [18]. Data reduction in cardiac imaging is fundamental
with limited disk storage and network bandwidth. Lossless or lossy digital
compression is available in DICOM standard. Lossless algorithms enable
the recovery of the original image, but these algorithms have relatively poor
compression ratios. Lossy algorithms have higher compression ratios but
distort slightly the recovered image. Hence, there is a compromise between
quality and storage space [18].
2.2.2 Echocardiographic imaging
Echocardiography is the most used cardiac imaging method to assess struc-
tural, functional, or haemodynamic abnormalities of the heart or great vessels
[18], [19]. Indeed, the echocardiographic technology is non-invasive, rather
inexpensive, portable and harmless to biological tissues, and produces rela-
tively high-resolution images in real time. Furthermore, echocardiographic
modalities allow to acquire diverse information, such as anatomical struc-
tures from multiple tomographic planes with two-dimensional (2D) imaging
and cardiac haemodynamics and blood ow magnitude and direction with
Doppler and colour ow imaging [18], [19]. Moreover, ow data provide
indirect information on tissue metabolism and functionality.erefore, echo-
cardiography plays a central role in diagnosis and quantication of the nature
and severity of specic cardiovascular pathologies [18], [19].
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2.2.2.1 Principles
Ultrasonic waves are acoustic waves with frequencies above the upper audible
limit of human hearing (> 20kHz). In practice, the most common method
to produce medical ultrasound is by mechanical vibrations of a specialised
material when an external alternating electric eld is applied across it, i.e.,
the piezoelectric eect. Acoustic waves are generated with devices known
as transducers or probes, in which piezoelectric crystals are the core [18].
Placed between two electrodes that apply a voltage, these crystals are induced
to expand and contract in a sinusoidal manner. By doing so, appropriate
sound waves for diagnostic use are produced. When travelling through
matter, a fraction of these waves is reected or scattered upon nding an
impedance mismatched in the boundary of two media while the remaining
fraction is transmitted [18]. When acoustic backscatter waves strike the
crystal, the piezoelectric eect is opposite, converting the induced vibrations
in an electrical signal whose amplitude is proportional to the mechanical
pressure [18].e electric signal is detected by the electrodes attached to the
crystal and converted to a digital signal to be further processed for imaging
and characterising the medium [18], [19].
Mechanical waves are characterised by: 1) period (T), that is the time
between two consecutive repetitions of an identical pattern; 2) frequency ( f ),
the reciprocal of T , dened as number of times a pattern repeats itself per
second; and 3) wavelength (λ), which describes the spatial repetition of the
pattern sequence [42], [43].ese concepts are related as:
λ = cT = c
f
(2.1)
where c is the local speed of sound.
e relationship between speed of sound propagation (c), elasticmodulus
(K) and local density of a material (ρ) is described as:
c = √K
ρ
(2.2)
is equation shows that the speed of sound is limited by the features of
the material, indicating a time delay between the emitted and the detected
acoustic waves, known as time of ight (TOF).ese time delays provide
practical information about physical properties of the tissues under study
[42], [43].
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Inwave propagation, amore general term for the factor limiting the speed
of sound is acoustic impedance (ZA) and depends directly on the density of
the material [42], [43]:
ZA = ρc (2.3)
Regarding the interaction of ultrasound waves with matter, the most
relevant concepts to consider are attenuation, reection, refraction and scat-
tering.
Indeed, attenuation is an essential physical phenomenon in medical
ultrasound. Body tissue converts acoustic waves into motion as a result
of friction, which translates into heat energy. is absorption reduces the
intensity of sound waves that are reected and, ultimately, detected by the
transducer.us, the process of detection is more dicult in a deep region of
interest as the attenuation is higher [42], [43].e attenuation in the pressure
signal, dP, is described as:
dP = αPdz (2.4)
Where P is the incident pressure; dz is the distance over which the
absorption takes place; and α is the attenuation factor of the medium [42],
[43]. Solving this equation for P in the case of a plane wave:
P(z) = P0e−αz (2.5)
Where P0 is the pressure at z = 0. is equation is known as the
Beer–Lambert–Bouguer law of attenuation and shows the exponential de-
crease in amplitude of ultrasound as it passes through homogeneous tissue
[42], [43].
Attenuation varies with tissue type (see table 2.1) and is stronger at higher
frequencies, particularly at deeper locations, producing a low-pass ltering
eect and limiting the frequency that can be used clinically in echocardio-
graphy [42], [43].
Attenuation is oen dened as the intensity ratio of a measured signal
(P1) to the source signal (P0) expressed in logarithmic form:
dB = 10log10 ( P1P0) (2.6)
Due to the high attenuation coecient of air, usually a gel with a low
attenuation coecient is used as an interface between the transducer and
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Table 2.1: Values of ultrasonic parameters for dierent biological tissues.
Adapted from [18].
Tissue Speed of Attenuation Acoustic impedance
propagation [m/s] coecient [cm−1] [104kg/m2s]
Blood 1540 0.0198 1.6
Bone 2240 3.01 3.8-7.4
Fat 1450 0.1 1.4
Muscle 1540 0.193 1.7
Lung 0.26
Plasma 0.0069 1.5
Water 1480
the skin during ultrasound measurements to avoid air gaps. Additionally,
ultrasound is unable to image the lungs, since they contain air, or any struc-
ture behind. Bone also has a high attenuation coecient, making dicult
to perform ultrasound measurements of tissues covered by them [42], [43].
Eectively, it is necessary to have a eld of vision of the tissue without bones
or lungs in the way. For instance, certain windows must be used to image the
heart and avoid the lungs [42], [43].
Aer the transducer emitted acoustic waves, they propagate across the
body tissue, nding acoustically dierent media. At these interfaces, the
energy is partially reected, and the remainder is transmitted into the second
tissue, generating secondary waves [42], [43]. By denition, the angle of
incidence (θ i) is equal to the angle of reection (θr) (see gure 2.2). In
practice, the angle of incidence should be limited below 3○ to avoid reected
waves to miss the transducer [42], [43].
Figure 2.2: Graphical description of the Snell law. At the interface of two dierent
media, the passing through of an incident (i) pressure wave generates a reected (r)
and a transmitted (t) pressure wave-front.
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Reection occurs at a smooth boundary of two media. How much of the
incident wave is reected can be calculated as the ratio of the reected wave
to the incident wave, i.e., the pressure reection coecient (r) [42], [43]:
r = Pr
Pi
= ZA2cosθ i − ZA1cosθ t
ZA2cosθ i + ZA1cosθ t (2.7)
Where θ i and θ t are the incident and transmitted angles, respectively;
ZA1 and ZA2 are the acoustic impedances of bothmedia; and Pi is the incident
pressure and Pr is the reected pressure.is equation shows that the pressure
reection coecient is dependent on the acoustic impedance of both media
[42], [43].
In turn, the ratio of the transmitted to reected wave pressures, or the
pressure transmission coecient (t) is dened as:
t = Pt
Pi
= 2ZA2cosθ i
ZA2cosθ i + ZA1cosθ t (2.8)
Where transmitted pressure is Pt .
ese equations establish that modest variations of acoustic impedance
between twomedia generate noticeable alterations in the intensity of reected
and transmitted signals. In fact, biological tissues have comparable acoustic
impedances, allowingmost of the soundwaves to be transmitted (see table 2.1).
us, ultrasound can penetrate the body to provide information on deep
structures, but it can also “bounce” between interfaces, acting as a source of
noise [42], [43].
Another source of noise associated with reection is induced by the small
size of the cells. Reection at a microscopic scale (structures smaller than
the wavelength of sound) undergoes scattering, which is dened as diuse
reection, meaning the acoustic waves are sent in all directions [42], [43].
Scattering occurs at tissue inhomogeneities that induce the reected waves
to interfere with each other, producing a complex ultrasound pattern known
as speckle. Because speckle is relatively constant over time, it is possible to
track its motion to detect tissue deformation and strain. In sum, scattering is
a form of attenuation and a complex source of noise in ultrasound imaging
[42], [43].
Resolution is another relevant parameter of ultrasound imaging.ere
are two scanning directions, and thus two distinctive resolutions: axial and
lateral [18]. Axial resolution is the capacity to distinguish two subsequent
layers in the direction of the wave propagation and is a direct function of the
emitted signal wavelength, whereas lateral resolution refers to the ability to
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discern between two points perpendicular to the wave propagation and is
determined by the ultrasound beam width and, hence, by the dimension of
the transducer [42], [43].
2.2.2.2 Echocardiography
e transducer sends short pulses of ultrasound to biological tissue, but only
a part of the energy is reected from deep structures to the transducer [18].
e depth (d) of the reector is calculated with the time delay (∆t) between
the emitted and the received signal:
d = c∆t
2
(2.9)
Where velocity of sound (c) is assumed to be constant in so tissue
(1540m/s) and the factor of 2 accounts for the time to and from the object.
When a reected echo strikes the transducer, the piezoelectric crystal
produces aminuscule voltage in response to the vibrations from the returning
ultrasound. To adjust for the signicantly weaker echoes from deep struc-
tures, logarithmic compression and time-gain compensation apply greater
amplication to echoes returning aer longer intervals [18]. Amplitude and
phase information is obtained from the amplied signal to localise and display
structures [18]. Echoes can be displayed as M-mode, which is a time-distance
sweep showing motion of structures along a single scan line (gure 2.3A),
B-mode (gure 2.3B) or a surface rendering of a 3D echo.
Intracardiac blood ow velocity measurements are obtained by Doppler
echocardiography to derive haemodynamic parameters (see gure 2.4). An
ultrasound beam with a known frequency ( f0) is transmitted to the heart or
the vessels, and red blood cells reect the ultrasound waves at a frequency ( fr)
that depends on the direction of the cells with respect to the receiver (trans-
ducer): toward means a higher frequency, away means a lower frequency
[19].e Doppler shi is detected by the transducer and calculated as [19]:
∆ f = fr − f0 = 2 f0 υ ⋅ cosθc (2.10)
Where c is the speed of sound in blood (1540m/s), υ is the velocity of
the moving target and θ is the angle between the ultrasound beam and the
direction of the moving target [19].
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Figure 2.3: Examples of ultrasound images. A) M-mode scan through a
le ventricle of a heart with diastolic dysfunction. B) B-mode scan of a ca-
rotid artery. A) Adapted from https://commons.wikimedia.org/wiki/
File:HCM,_diastolic_dysfunction_E00544_(CardioNetworks_
ECHOpedia).jpg. By CardioNetworks: Secretariat [CC BY-SA 3.0
(https://creativecommons.org/licenses/by-sa/3.0)]; B)
Adapted from https://commons.wikimedia.org/wiki/File:
CCA_Ultrasound_110318140725_1409520.jpg. By © Nevit Dilmen
[CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0)].
e Doppler shi (∆ f ) is then translated into a blood ow velocity:
υ = ∆ f ⋅ c
2 f0 ⋅ cosθ (2.11)
e angle θ increases when the ultrasound beam is not parallel with
the blood ow direction, resulting in the underestimation of ∆ f and peak
velocity by the factor cosθ [19].
SpectralDoppler imaging shows the instantaneous velocity over time, and
the time velocity integral (TVI) can be obtained from this curve.e most
common spectral Doppler modalities are continuous-wave (CW) Doppler
and pulsed-wave (PW) Doppler. A third common modality, Doppler ow
mapping (colour Doppler), is a computer-enhanced version of PW Doppler
[18].
In CWDoppler, the transducer has two components: an emitter and a
receiver, both running continuously. CW Doppler quanties high-velocity
ow (jets and gradients) along the scan line and is not limited by aliasing
but does not provide information about the localisation of the source. CW
Doppler images show an envelope (the maximal measured velocity) lled
with signals [18]. In contrast, in PW Doppler the transducer is composed by
a single crystal that transmits brief bursts of ultrasound at a pulse repetition
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Figure 2.4: Spectral Doppler scan of a common carotid artery. Adapted
from https://commons.wikimedia.org/wiki/File:SpectralDopplerA.
jpg. By Drickey at en.wikipedia [CC BY-SA 2.5 (https://creativecommons.
org/licenses/by-sa/2.5)].
frequency, yet the receiver activates only aer a programmed time delay. PW
Doppler allows the measurement of blood velocities at a specic location
determined by a sample volume. Graphically, the number of scatters (red
blood cells or tissue reectors) determine the signal intensity (amplitude)
whereas the variation in velocity denes the width.e brightest line is the
most frequently measured velocity within the sample volume [18]. Aliasing
can occur if the Doppler shi frequency is more than one-half the pulse
repetition frequency (Nyquist limit), limiting the maximal velocity that can
be measured [19]. Lastly, Doppler ow mapping uses PW Doppler infor-
mation to superimpose colour on 2D imaging to display velocity, direction
or turbulence of blood ow, as the upper part of gure 2.4 demonstrates.
ereby, blood ow information is colour coded: red depicts a ow towards
the transducer and blue away from it. Practical applications are valvular
regurgitation, stenosis, and various shunt lesions. Colour Doppler has also a
Nyquist limit and a restriction in frame rate and velocity resolution due to the
need to scan multiple lines simultaneously, restriction that can be overcome
to some extent by parallel processing [18].
Tissue Doppler imaging (TDI) is a modication of PWDoppler to record
the motion of solid tissue (usually from the myocardium) with lower veloci-
ties or frequency shis but larger amplitudes than those of blood ow. For
example, TDI can register the motion of the mitral annulus.is is accom-
plished by the implementation of lters to remove high-velocity/low-intensity
signals from blood and to preserve the low-velocity/high-intensity signals
from tissue. TDI results are displayed as a spectral Doppler (velocity over
time) but can also integrate colour to complement the displayed information.
TDI recordings may over or underestimate the active component of the tissue
because of translational motion or tethering, respectively [18], [19].
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To overcome this limitation, a derivedmodality is proposed: deformation
imaging, strain (ε) or strain rate imaging.is modality measures the actual
extent of stretching or contraction.
2.2.2.3 Applications of echocardiography
Cardiac assessment
2D and M-mode are the most common echocardiographic modes for quanti-
cation of heart and chamber dimensions and provide structural and func-
tional information on cardiac disease.ese measurements are usually ob-
tained at end diastole and end systole with the transducer on the le para-
sternal region. Nonetheless, position and plane are dependent on the mea-
surement to be performed.ere are three orthogonal planes suggested for
cardiac imaging: long-axis (aortic root-apex), short-axis (perpendicular to
the long axis), and four-chamber (traversing both ventricles and atria through
the mitral and tricuspid valves). Recommended transducer positions for
obtaining these planes are parasternal, apical, subcostal, and suprasternal
[17] (see gure 2.5).
Doppler echocardiography has been established as a fundamental routine
measurement in cardiovascular medicine for haemodynamic assessment, re-
placing cardiac catheterization. Doppler echocardiography and 2D imaging
are not only performed using the same transducer but they delivered comple-
mentary information [17], [19]. For instance, 2D imaging operates as visual
guidance to identify the region of interest during Doppler echocardiography,
and superimposed colour by Doppler echocardiography enhances structural
information. For Doppler echocardiography measurements, the same planes
as for 2D imaging can be used yet the same transducer position frequently
is not favourable for both Doppler echocardiography and anatomical ima-
ging. Additionally, the signal to noise ratio in Doppler echocardiography
recordings is higher than for 2D modes [17], [19].
e following section presents a short description of the most impor-
tant echocardiographic parameters measured in routine clinical practice.
Guidelines for cardiovascular assessment have been published by the Amer-
ican Society of Echocardiography (ASE), the European Association of Cardio-
vascular Imaging (EACVI) [47], [48] and the American College of Cardiology
and the American Heart Association (ACC/AHA) [49], [50].
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Functional assessment of the cardiac structure
In general, M-mode and B-mode (or 2D imaging) are the appropriate modes
to perform structural measurements of the heart. Parameters include cham-
ber dimensions, such as: 1) right atrial (RA) size; 2) le atrial (LA) size
and volume; 3) right ventricular (RV) size, wall thickness and RV outow
tract (RVOT); 4) le ventricular (LV) end-diastolic diameter (EDD), end-
systolic diameter (ESD), septal wall thickness (SWT), posterior wall thickness
(PWT), LV outow tract (LVOT), mass and volume [17], [19] (see gure 2.5).
Moreover, valve areas are also routinely estimated. ese parameters are
determined through dierent standardized methods explained in detail in
expert guidelines, including general recommendations on the most accurate
method according to the location, the echocardiographic mode and view,
and complementary measurements.
Ultimately, estimation of echocardiographic parameters provides support
to diagnosis. For example, LV enlargement is an import nding, especially
in patients with valvular regurgitant lesions, hypertension, cardiomyopathy,
and LV remodelling aer myocardial infarction. RA size and RV size and wall
thickness are particularly important in patients with pulmonary hypertension,
pulmonary diseases, and tricuspid or pulmonary valvular lesions. ese
abnormalities may also reect the severity of le heart disease [17], [19].
Haemodynamic assessment of cardiac function
Doppler echocardiography measures blood ow velocity parameters. In car-
diac assessment, relevant quantities are stroke volume (SV), cardiac output
(CO) and volumetric ow. Diastolic lling variables are also measured with
Doppler echocardiography and includemitral inow, pulmonary venous ow
velocities, TDI, colour M-mode (CMM) of mitral inow, and derived pres-
sure parameters such as transvalvular gradients and intracardiac pressures.
Haemodynamic assessment allows the detection of abnormalities that impact
an adequate cardiac function.ese irregularities comprise valvular diseases
as valve stenosis (mitral, tricuspid, pulmonary or aortic), valve regurgitation,
valve prolapse, anomalies in cardiac elastic properties and lling, among
others [17], [19].
Systolic function assessment
Systolic function of the heart can be evaluated with several echocardiographic
techniques. At regional level, LV function is assessed using regional wall
motion analysis to determine the contractility of 16 LVwall segments: 6 at the
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Figure 2.5: Illustration of common transthoracic views in echocardio-
graphy and extracted anatomical parameters. Top) Apical 4 (le) and
2 (right) chambers view. Extracted parameters: right atrial (RA) size; le
atrial (LA) size; right ventricular (RV) size; Bottom) Le parasternal long
axis view (le) and LV short axis view (right). Extracted parameters: RV
outow tract (RVOT); LV outow tract (LVOT); septal wall thickness (SWT).
Adapted from https://commons.wikimedia.org/wiki/File:Apical_
4_chamber_view.png, https://commons.wikimedia.org/wiki/File:
Apical2Chamber.png, https://commons.wikimedia.org/wiki/File:
LeftParasternalLongAxis.gif and https://commons.wikimedia.org/
wiki/File:LeftVentricleShortAxis.gif. By Patrick J. Lynch and C. Carl
Jae [CC BY 2.5 (https://creativecommons.org/licenses/by/2.5)].
base, 6 at the mid-ventricle and 4 at the apex. To evaluate LV global systolic
function, relevant parameters include SV, CO, cardiac index, LV ejection
fraction (EF), strain and systolic tissue velocity of the mitral annulus and
myocardium [17].
e general expression to calculate haemodynamic parameters such as
ow or SV by Doppler echocardiography is:
Flow rate = CSA ∗ f low velocity (2.12)
Where CSA is the cross-sectional area of the orice [19].
In the cardiovascular system, pulsatile ow varies throughout the cardiac
cycle and, therefore, individual velocities of the Doppler spectrum are inte-
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grated to measure the total volume of ow (see gure 2.6) [19].is quantity
is called the time velocity integral (TVI) and determines SV as:
SV = CSA ∗ TVI (2.13)
Figure 2.6: Pulsed-wave Doppler of the abdominal aorta owwith reversal ow
during diastole. Adapted from https://commons.wikimedia.org/wiki/
File:Endocarditis_of_aortic_valve_E00258_(CardioNetworks_
ECHOpedia).jpg. By CardioNetworks: Secretariat [CC BY-SA 3.0
(https://creativecommons.org/licenses/by-sa/3.0)].
is equation can be applied to calculate ow across any cardiac orice,
even if the most common application is to determine SV at the LVOT. All
CSAs are assumed to be circle shaped; thus, circle diameter is also measured.
To calculate CO, SV is multiplied by heart rate (HR) and, to estimate cardiac
index, CO is divided by body surface area (BSA) [19].
Other method to calculate SV is to determine the dierence between LV
end-diastolic volume (EDV) and LV end-systolic volume (ESV) if there is
no valvular regurgitation. Otherwise, the regurgitant volume needs to be
subtracted to obtain SV across the orice [19].
Systolic velocity of myocardial tissue or mitral annulus
e peak systolic tissue Doppler velocity at the annular level (S’), measured by
TDI, reects overall longitudinal LV contraction, correlates well with LV EF
and it has been shown to be a good predictor of clinical outcome in various
cardiovascular disorders. Peak systolic annular velocities detect subtle deteri-
oration of myocardial function even with preserved EF, providing objective
evidence of myocardial contraction impairment. Moreover, this parameter
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reects a progressive evolution of pathophysiologic states together with the
impairment of other measurements of systolic and diastolic function, hence
demonstrating that systolic and diastolic function are integrated aspects of
myocardial function [19].
Diastolic function assessment
Assessment of (the heterogenous) diastolic function is an integral part of car-
diac function examination, comprising active (relaxation), passive (chamber
stiness) and other characteristics of the heart. In fact, the LV lling pattern
is the result of the transmitral pressure gradient determined by factors such
as elastic recoil (suction), myocardial relaxation and compliance, cardiac
rhythm, LA pressure and pericardial compliance [18]. Adequate lling of the
ventricles during rest and stress conditions should be guaranteed without
an abnormal increase in diastolic pressure or pulmonary venous congestion
[18].
Figure 2.7: Doppler imaging to assess diastolic function. Top) Pulsed-wave Dop-
pler of mitral inow. Bottom) Tissue Doppler imaging of the mitral annulus. Le
images show a healthy subject with normal diastolic function: high peak mitral
ow velocity of the early rapid lling wave (E) and longitudinal motion of the
mitral annulus during early diastole (e’), and normal E/e’ ratio. Middle echocardi-
ographic images of a subject with diastolic dysfunction without increased lling
pressure are displayed.ese images presented a low E and e’, and normal E/e’ ratio.
Right images of a subject with diastolic dysfunction and increased lling pressure
evinced high E, low e’ and high E/e’ ratio. Systolic mitral annulus velocity (S’) is
also reduced in proportion to e’.e A peak is the late diastolic lling wave due to
atrial contraction and the a’ peak is the longitudinal motion of the mitral annulus
during late diastole. Adapted from https://en.wikipedia.org/wiki/File:
Diastolic_function.png#file. By Unknow.is work is licensed under the
Creative Commons Attribution-ShareAlike 3.0 License.
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e standard technique to evaluate diastolic function and estimate lling
parameters is non-invasive echocardiography, being M-, B- and Doppler
echocardiography the most common used modes, the latter incorporating
TDI (see gure 2.7), pulmonary vein Doppler, hepatic vein Doppler, and
CMM for determining the propagation velocity of mitral inow (Vp, see
gure 2.8). Signicant diastolic parameters are myocardial relaxation, iso-
volumetric relaxation time (IVRT), mitral inow, pulmonary venous ow,
amond other derived measurements [17], [18].
Figure 2.8: ColourDopplerM-mode scan of themitral inow. Ventricular lling
of a healthy subject showing mitral ow velocity of the early rapid lling wave (E)
and ow velocity of the late lling wave caused by atrial contraction (A).
e rate of myocardial relaxation (τ) correlates with the longitudinal
motion of the mitral annulus during early diastole (e’) and during atrial
contraction (a’), which can be obtained by TDI. IVRT (the time between
the aortic valve closes and mitral valve opens) depends on τ, aortic end-
systolic pressure (ESP) and LA early diastolic pressure, thus a change in these
parameters is reected on IVRT. For instance, IVRT is longer for slowed
relaxation and acute ischemia while it is shorter when LA pressure is elevated
[18], [19].
Mitral inow analysis is fundamental for the assessment of diastolic func-
tion. Performed measurements to determine the LV lling pattern consist of
the peak mitral ow velocity of the early rapid lling wave (E), the peak veloc-
ity of the late lling wave caused by atrial contraction (A), the E/A ratio, and
the deceleration time (DT), which is the time interval for the peak E velocity
to reach zero baseline (see gure 2.7). In general, three abnormal patterns
are recognized (see table 2.2): impaired relaxation (grade 1), pseudonormal
lling (grade 2), and restrictive lling (grade 3 and 4). Mitral patterns depend
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on load conditions so additional assessments are necessary to perform a
comprehensive evaluation, especially to distinguish a pseudonormal lling
from normal. To conrm the pseudonormal lling pattern, additional data,
such as increased maximal LA volume, LV lling changes in response to
preload reduction (the Valsalva maneuver), and the mitral annular motion,
are necessary to reveal relaxation abnormalities. e ratio of E/e’ is also
a meaningful parameter since it is directly related to LA pressure and LV
end-diastolic pressure (EDP) (see gure 2.7). Indeed, e’ is one of the most
sensitive parameters for detecting overall myocardial dysfunction [17]–[19].
Moreover, abnormal LV lling patterns and their derived parameters are
associated with distinct LV lling pressures although considerations about
age, valvular regurgitation, LV EF, and HR need to be done for estimating
these pressure patterns. Further studies are necessary to determine the appli-
cability of thesemethods to all types of cardiac diseases, including prospective
studies to compare the prognostic signicance of LV systolic and diastolic
indices in heart failure (HF) patients (see Chapter 4) [17]–[19].
Additional measurements of diastolic function include Vp into the LV
during diastole, which is less preload dependent than the E velocity [18]. Vp
is measured as the slope of an apical CMM through the mitral valve during
diastole (see gure 2.8). However, the low reproducibility of Vp has hampered
its implementation.
Diastolic lling patterns in disease states
Abnormalities of LV lling patterns are associated with changes in LV dias-
tolic properties, lling pressures and prognosis. It is clear then that several
parameters determine the grading of diastolic lling patterns (see gure 2.7
and table 2.2). e rst sign of diastolic dysfunction in almost all cardiac
diseases is impaired relaxation, followed by a compensatory mild decrease in
LV compliance and an increment in LA pressure (pseudonormalized lling).
In this case, LV suction is diminished and blood is partially forced into the LV
in early diastole due to the elevated LA pressure. Progression of the disease
leads to a further (and marked) decrease in LV compliance and an increase
in LA pressure resulting in rapid ventricular lling in early diastole and min-
imal lling at atrial contraction.is pattern is termed restrictive and can
be reversible with treatment or irreversible, i.e., the end stage of diastolic
dysfunction [19]. An example of these lling patterns is shown in gure 2.7.
is progression of lling impairment is observed in diverse disorders and
in normal aging (see Chapter 1).
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Table 2.2: Diastolic dysfunction grading based on diastolic lling patterns.
Adapted from [19].
Grading Description Parameters during
rest conditions
Normal diastolic Normal elastic recoil, myocardial E/A ≥ 1.5;
lling pattern relaxation and lling pressure DT = 160 − 240ms;
e’ ≥ 10cm/s;
E/e’ < 8;
Vp ≥ 50cm/s
Grade 1 Impaired relaxation with E/A < 1;
(mild dysfunction) normal lling pressure Prolonged DT;
e’ < 7cm/s;
E/e’ ≤ 8;
Vp < 50cm/s
Grade 2 Pseudonormalized mitral E/A = 1 − 1.5;
(moderate dysfunction) inow pattern DT = 160 − 240ms;
e’ < 7cm/s;
Vp < 45cm/s
Grade 3 Reversible restrictive E/A > 2;
(severe reversible dysfunction) (high lling pressure) DT < 160ms;
Grade 4 Irreversible restrictive e’ < 7cm/s;
(severe irreversible dysfunction) (high lling pressure) E/e’ > 15;
A: late diastolic velocity; DT: deceleration time; E: early diastolic velocity; e’: early diastolic
mitral annular velocity; Vp: propagation velocity .
Vascular assessment
Transthoracic echocardiography is oen used to visualise the aortic root
and arch, but it has constraints to imaging the whole aorta satisfactorily.
Instead, transoesophageal echocardiography (TEE) allows to visualise the
entire thoracic aorta in most patients with added advantages over other
techniques, such as portability, simultaneous assessment of cardiac function
and associated conditions, and no need for contrast agents. Several aortic
conditions can be readily evaluated with TEE, for instance aortic aneurysms,
rupture, aortic dissection, ulcer, debris, abscess, and coarctation [17].
In elderly patients, atherosclerotic plaques and debris are common nd-
ings during routine echocardiographic examinations. Irregularly shaped and
mobile aortic plaques are associated with age, smoking, and high systolic
blood pressure (SBP), whereas debris is common in patients who suered an
embolic event. In patients with aortic atherosclerosis, plaque can penetrate
the internal elastic lamina into the media, producing an ulcer that may result
in an intramural hematoma, an aortic dissection, or an aortic rupture [19].
A thorough examination of the carotid region encompasses real-time
B-mode imaging, and Doppler analysis of the carotid bifurcation, proximal,
medial, and distal internal carotid artery, the proximal external carotid artery,
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and the vertebral artery. e incorporation of colour Doppler facilitates
the identication of stenosis and shortens the examination time [19]. An
additional index of increased risk of major cardiovascular events and car-
diovascular mortality is the carotid intima-media thickness (IMT). IMT is
measured using B-mode imaging of the carotid artery to identify the “double-
line density” of the intima-media complex and the adventitia of the artery.
PWV can be also calculated using Doppler imaging. For the estimation of
PWV, transit time is calculated from two ow pulses recorded simultaneously
or sequentially with ECG gating [39].
Additionally, local arterial stiness can be determined by echocardio-
graphy in supercial arteries, such as the common carotid, common femoral,
and brachial arteries. Notably, carotid stiness is particularly relevant due to
the high impact of atherosclerosis at this location [19]. Although common
echocardiographic modalities are able to measure changes in diameter and
stroke at dierent locations, precision is limited by the spatial resolution of
pixel analysis.erefore, echo tracking systems were introduced to obtain
higher precisions using the radio frequency (RF) signal.ese systems allow
the non-invasive measurement of local arterial stiness, local PWV, IMT and
arterial distensibility, the later used to estimate the Young’s elastic modulus
(see [39] Chapters 3 and 6). However, a high degree of technical expertise and
longer times are necessary to perform echo tracking measurements, hence
its use is concretely indicated for mechanistic analyses in pathophysiology,
pharmacology, and therapeutics, rather than for epidemiological studies [39].
2.2.2.4 Additional considerations of echocardiographic imaging
Some more recent echocardiographic modes begin to be available in clinical
practice introducing new tools for cardiovascular assessment. Harmonic
real-time 3D imaging can deliver a highly accurate and reliable echocardio-
graphic measurement of LV volume and mass [19]. A novel method is vector
ow imaging (VFI), which performs a quantitatively estimation of ow ve-
locity at any location into a vessel and displays a more intuitive depiction
of the ow movements [51]. Echocardiographic particle image velocimetry
(echo-PIV) is a technique for obtaining quantitative velocity maps from con-
trast ultrasound images [52]. Shear wave elastography is a technique that
characterises the mechanical properties of a medium by applying a focused
ultrasonic high-energy beam with a conventional ultrasound transducer to
analyse the propagation of the internal mechanical perturbation (or shear
wave propagation) [53].
Anatomical and functional cardiovascular indexes are extracted from
echocardiographic images applying dierent techniques, such as edge de-
tection, segmentation, among others (see Part II - Novel Cardiovascular
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Research). In the frequency domain, imaging analysis may deliver further
useful information and improve contrast and resolution. For example, noise
has a certain degree of omnipresence with undetermined frequency content
even if the high frequency content could be oen attributed to noise. Hence,
lters can be designed to eliminate this type of high-frequency noise. An
interesting approach is the use of wavelet-based lters to reach an optimal
trade-o between good signal averaging over homogeneous regions and
minimal resolution degradation of image details (see Chapter 7) [42].
Artefacts are a limitation to take into consideration. In echocardiographic
images, many artefacts are the result of reective properties of the tissues.
Examples of artefacts are the “comet tail” eect in the image when two re-
ective surfaces are close to each other and the sound wave bounces between
them or the apparent structures that do not exist behind any highly reective
interface that only transmits a small amount of ultrasound [42].
Finally, potential bioeects of ultrasonic imaging have been addressed,
and comprise thermal eects, mechanical and cavitational eects, cellular
and subcellular eects, biochemical eects, and the eects of ultrasound on
organs and systems. However, no epidemiological data can support any seri-
ously harmful side eect due to ultrasound exposure, especially for imaging
purposes as in echocardiography.is is one of the reasons why ultrasound
is among the most used diagnostic techniques in hospitals [42].
2.2.3 Cardiovascular magnetic resonance imaging
Cardiovascular magnetic resonance imaging (MRI) is an appropriate tech-
nique for the assessment of morphological and physiological anomalies of
the heart, pericardium, and great vessels of the thorax. With a considerable
growth in the last decades, MRI emerged as a desirable imaging techno-
logy due to its speed, reliability, ease of use, harmlessness, reproducibility,
high image quality and eld of view (FOV). Capitalising these technical ad-
vantages, MRI allows near-real-time imaging, tissue tagging-tracking, and
four-dimensional (4D) acquisition and display. Concretely, the technique
is able to obtain high-detail anatomical images, histologic characterisation,
intracardiac or intravascular blood ow, cardiac chamber contraction and
lling measurements, parameters of regional myocardial mechanics, and
tissue perfusion imaging. Hence, MRI has been established as an essential
diagnostic modality in cardiovascular medicine.
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2.2.3.1 Basic principles of MRI
Since a complete description of the underlying physics of MRI is complex
and requires quantum mechanics, the approach followed in this section
to describe the basic principles of MRI uses approximations of classical
mechanics.
e principal mechanism of nuclear magnetic resonance is based on the
spinning of nuclei with an odd number of nucleons (protons and/or neutrons)
in the presence of an external magnetic eld. Protons rotate around the axis
of the applied magnetic eld like spinning tops.e angle and the annular
velocity of the rotation (ω) are intrinsic properties of each particle as well as
the magnetic eld (m) produced by the particle [42], [43]. At a macroscopic
level, the interaction between the external and intrinsic magnetic elds is
the basis for imaging. Nuclei with these characteristics possess a magnetic
dipole and group together to form an ensemble. e sum of all magnetic
moments is termed the nuclear magnetization and is zero when there is not
an external magnetic eld [42], [43]. For imaging, a strong constant magnetic
eld (H0, 0.2 − 4T) is generated in a selected direction (the z-direction in
this description) to produce a nuclear magnetization (M) of the ensemble of
nuclei, which is oriented in the direction of the external eld, either parallel
or in the exact opposite direction (antiparallel) [42], [43]. When particles
are submitted to the external magnetic eld, they spiral down to align with
the forced direction, as represented in gure 2.9. is process is named
precession and takes place with a specic frequency to each element dened
by:
ω0 = γH (2.14)
Where ω0 is the Larmor frequency, H is the magnitude of the magnetic
eld and γ is the gyromagnetic constant that is primarily determined by
the type of nucleus.e hydrogen proton is abundant in tissue, water and
many biological molecules, thus this proton is used for clinical imaging and
its Larmor frequency and gyromagnetic constant (42.58MHz/Tesla) play a
central role [42], [43].
If these rotating particles (or spins) are exposed to electromagnetic energy
at the Larmor frequency, they rotate further and further from the equilibrium
position near the z-axis as gure 2.10A shows [42], [43]. Since the Larmor
frequency is within the RF range for protons, an RF pulse at the proper
frequency in the xy-plane tips the spins away from the z-axis an amount
established by:
θ = γHTp (2.15)
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Figure 2.9: Illustration of the principle of eld application and alignment. A) A
single proton has a magnetic moment which rotates in the presence of an applied
magnetic eld (Bz). B) A group of upward dipoles create a net moment in the same
direction as the magnetic eld, but any horizontal moments (x or y) tend to cancel.
Adapted from [43].
Where θ is the tip angle and Tp pulse time. Common values for θ are
90○ or 180○.
At the end of the RF pulse, the magnetization alignment emits its own
RF signal at the Larmor frequency, which is referred to as the free induction
decay (FID) signal and is dened by:
S(t) = ρ sinθ cos(ω0t) (2.16)
Where ρ is the density of spins, θ the tip angle and ω0 is the Larmor
frequency. From this expression, a 90○ tip angle produces the strongest
possible signal whereas a 180○ tip angle modies the sign of the moment and
originates an echo signal [42], [43]. Magnetic features of the tissue can be
identied from this RF pulse.
Eventually, spins relax towards the equilibrium position (see gure 2.10B)
in an exponential manner and two crucial relaxation times describe the
process: T1 and T2. T1 is known as longitudinal or spin-lattice relaxation
time and concerns the realignment rate of the longitudinal moment (Mz) and,
partially, the decrease of the xy-moment (Mxy). T2 is termed the transverse
or spin–spin relaxation time and is related to a further decrease ofMxy by a
loss of synchronization of the collective spins, which makes T2 shorter than
T1. Moreover, theMxy decline can be accelerated by local inhomogeneities
in the applied magnetic eld. In this case, the time constant, which includes
T2 inuences, is named T2* [42], [43].
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Figure 2.10: Illustration of the application of an RF pulse and the subsequent
relaxation. A) Aer an RF pulse tips the spins 90○, the net magnetic moment
approximates a vector rotating in the xy-plane (Mx y) and the net vector in the z
direction is zero. B) Aer the RF energy is removed, all spins begin to relax back to
their equilibrium position, increasing the z component (Mz), and decreasing the
xy-component (Mx y).e xy-component also decreases as the spins desynchronize.
Adapted from [43].
Considering these relaxation processes, FID signals are dened by the
following expression:
S(t) = ρ cos(ω0t)e−t/T∗2 e−t/T1 (2.17)
Table 2.3: Magnetic resonance imaging parameters. Adapted from [18].
Tissue 1H density T1 T2
(% H2O) [ms] [ms]
Muscle 100 600 40
Liver 91 270 50
Renal cortex 95 360 70
Renal medulla 95 680 140
Spleen 92 480 80
Fat 98 180 90
White matter 100 390 90
Gray matter 94 520 100
Blood 90 800 180
Cerebrospinal uid 96 2000 300
Water 100 2500 2500
Equation (2.17) is used to accomplish image contrast. Proton density (ρ)
is proportional to the FID signal amplitude but variation within the body
is not sucient to obtain good contrast. Magnetic properties (see table 2.3)
such as local relaxation times (T1 and T2 or T2*) can enhance contrast [42],
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[43]. In general, MRI contrast improves with increasing hydrogen density,
shortening of T1, and lengthening of T2.e estimation of relaxation times is
done by the manipulation of the RF pulse and local magnetic eld gradients.
A pulse sequence is dened as a combination of RF and magnetic pulses and
delays, and a data acquisition period. A practical pulse sequence eliminates
the T2* decay by sampling a realigned echo: aer the spins start to spread
out, an RF pulse with a phase-reversing of 180○ is applied so the direction
of the spins is reversed, and they come together aer a known delay: T2*
[42], [43]. As a result, this echo approach removes only theMxy decline due
to magnetic inhomogeneities but not the variations due to the sample itself
produced by the T2 relaxation, which are of interest. Ultimately, contrast
between dierent tissues relies on excitation and signal readout delay (TE,
echo time) and the time between repetitive RF excitations (TR, repeat time).
To highlight either T1 or T2 dierences between tissues, signal reception is
delayed for a certain period aer the generation of the RF pulse [42], [43].
T1 and T2 relaxation times provide the means to identify normal tissue and
characterise disease processes. Examples of T1 and T2 weighted MRI scans
are shown in gure 2.11.
Figure 2.11: Examples of cardiac MRI scans. Heart of a patient with sar-
coma in the le atrium. a) T1-weigthed. b) T2-weigthed. Adapted from
the reference: A Rare Cause of Dyspnea: Undierentiated Pleomorphic
Sarcoma in the Le Atrium - Scientic Figure on ResearchGate. Avail-
able from: https://www.researchgate.net/gure/Cardiac-MRI-Both-tumors-are-
isointense-in-T1-weighted-black-blood-imaging-a-e_g4_320679672 [accessed
20 Oct, 2019] via license: Creative Commons Attribution-NonCommercial 4.0
International [54].
Equation (2.14) (Larmor equation) is used to resolve localisation. Local-
isations can be tagged by resonant frequencies of each position in the sample
when the strength of the (locally) applied magnetic eld is dierent. e
signal of a specic zone can be determined using an RF pulse with only one
frequency component that excites only the spins in one region whose mag-
netic eld correlates with the RF frequency (Larmor frequency). A second
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approach is to excite a broader area and modify the magnetic eld strength,
so each area has a dierent resonant frequency [42], [43]. Electromagnets
(or gradient coils) generate gradient elds in the three dimensions to modify
(linearly) the magnetic eld strength over a limited area. Specic 2D slices of
the studied tissue can be isolated using the gradient eld in the remaining
direction, e.g., an xy-slice is isolated using the gradient eld in the z direction
(Gz) [42], [43]. In practice, the applied RF pulse has a range of frequencies (a
nite bandwidth) that together with the steepness of the gradient determine
the thickness of the slice:
∆z ∝ γGzZ(∆ω) (2.18)
A narrow bandwidth (∆ω) and a steep gradient eld (Gz) are necessary
to obtain a thin slice (∆z).
e general aspect of the image depends on dierent physical parameters,
some related to tissue properties, others to the MRI sequences. An advantage
of MRI is the control that the operator has on the generation and use of the
data. Size pixel is determined by the number of pixels in the reconstructed
image and the actual size of the imaged area, or the FOV [42], [43]. Resolution
is limited by the signal-to-noise ratio but can be improved using special
receiver coils or averaging, but there is an increase in cost or scan time,
respectively. In general, MRI is used to create anatomical images, but it can
generate also images of metabolic activities, which is known as functional
magnetic resonance imaging (fMRI) [42], [43].
MRI is a phase-sensitive modality in which blood ow velocity and
phase changes (linearly proportional to velocity changes) can be encoded
and displayed as velocity maps [18], [55]. Signal intensity varies according to
the blood ow direction, increasing toward brightness or darkness. Phase-
contrast MRI delivers information about instantaneous peak velocity and
(spatial) average velocity at time points of the cardiac cycle. Hence, volumetric
ow can be estimated by multiplication of (spatial) average velocity with the
corresponding vascular CSA. Additionally, time-velocity and volume of ow
curves can be derived to determine SV [18]. Furthermore, improvement of
MRI devices currently allow the acquisition of 4Dphase-contrast cardiacMRI
sequences for measurements of velocity vectors in three spatial dimensions,
with unrestricted image orientation for estimating pressure gradients in vivo
[13] (see Chapter 4).
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2.2.3.2 Applications of MRI
Cardiac assessment
MRI is the gold standard method to quantify ventricular volumes and mass
due to its 3D nature that does not rely on geometric assumptions [19]. Ac-
curacy and reproducibility of MRI measurements of global LV anatomy are
well established for basic parameters and considerably superior to that of 2D
echocardiography [19].ese parameters comprise LV and RV SVs, aortic
ow, LV and RV mass measurements, among others. Furthermore, MRI
is useful for the evaluation of regional contractile function performed by
visual inspection of cine loops in standard imaging planes.e use of conven-
tional techniques for the quantication of wall motion and thickening can
be performed for both the LV and RV, but myocardial tagging, a technique
that allows the assessment of myocardial strain and other deformations as
a measure of contractility, is preferred [18]. MRI tagging can be applied for
full 3D myocardial analysis by collective modelling of the numerous small
individual myocardial elements with high spatial and temporal resolution
and simplied post processing [18], [19].
Furthermore, MRI techniques are also the gold standard for estimating
LV EF and volumes [18].ese measurements and derived parameters are
calculated from end-diastolic and end-systolic images of the LV. Improvement
of the approach is possible using multilevel-cine MRI, which shows heart
and blood motion over dierent phases of the cardiac cycle. To account for
cardiac motion, a small number of phase-encoding steps is used in each
breath-hold, resulting in a complete cine examination over a breath-hold
period of 10-20 heart beats [18], [19]. In gure 2.12, two frames from distinct
cardiac sequences show a 4 chambers view.
Vascular assessment
Arterial wall assessment is essential to study the development of atheroscle-
rosis, which is a systemic process that can commonly result in aneurysms or
branch vessel stenosis. MRI enables the acquisition of information related to
atherosclerosis formation, which is collected mainly at the aorta or carotid
and brachial branches. MRI measures compliance in the ascending aorta
and PWV around the aortic arch as both parameters have an age-dependent
normal range, are abnormal in early atherosclerosis, and have been shown
to be predictive of cardiac events [19]. Moreover, plaque burden, plaque
vulnerability, cholesterol pools and overlying brous plaque can be evaluated
using MRI images. Plaque characterisation has been further achieved by the
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Figure 2.12: Example frames and comparison of cardiac MRI sequences of
the 4 chambers view. A) Healthy subject. B) Subject with a chronic
infarction, akinetic apex and transmural scar. Additionally, mitral regur-
gitation is observed. Adapted from https://commons.wikimedia.org/
wiki/File:4-CH_cine_normal.gif and https://commons.wikimedia.
org/wiki/File:4CH_cine_infarct.gif. By Doregan [CC BY-SA 4.0
(https://creativecommons.org/licenses/by-sa/4.0)].
employment of contrast agents, showing inammation, neo-vasculature, and
brous plaque. Indeed, magnetic resonance angiography using gadolinium-
based contrast agents is fast and routinely used for large and small vessels
[18], [19].
2.2.3.3 Additional considerations of MRI
Feature extraction, both geometrical and texture, fromMRI images are eect-
ive to identify most malignant and benign tumours, and several processing
techniques can be applied to analyse MRI images, although results are de-
pendent on resolution.e resolution along the slicing axis (the z-direction
in the section introducing the basic principles of MRI) is usually less than
the planar resolution so interpolation is performed between two slices to
improve overall resolution [42]. Another potential limitation of MRI is noise
that could be caused by subject motion, physiological activity, low frequency
dri, spontaneous neural and vascular uctuations, shear and strain noise,
thermal noise and artefacts arising from rapid imaging methods [42]. Filter-
ing and adjustment of contrast agents are common strategies to deal with
noise but the mainmethod for denoisingMRI images is the use of the wavelet
transform and coecients (see Chapter 7).
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Although MRI is fundamentally safe, some concerns must be considered.
In patients with metallic implants or implanted electronic devices, compat-
ibility could be an issue [42]. Even though most metallic implants are MRI
compatible, including prosthetic cardiac valves, vascular stents, and ortho-
paedic implants, there are still problems with some neurological devices,
such as vascular clips used for cerebral aneurysm surgery due to the potential
risk of dislodgement from the vessel [42]. Electronic implants like cardiac
pacemakers, cardiac debrillators, and neurologic stimulators represent a
contraindication due to the risks of interference with the programming of the
device. Haemostatic clips, metallic sternal suture wires, and retained surgical
epicardial pacing wires are not known to lead to complications fromMRI,
aside from local imaging artefacts [42].
Additional safety steps should be considered for patients with dierent
conditions. For example, for critically ill patients that need life-support sys-
tems, claustrophobic subjects or allergic reactions to contrast agents, adequate
procedures must be implemented to perform safe MRI evaluations [42].
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Methodologies
Previously, Chapter 1 established fundamental anatomical and physiological
concepts of the healthy and pathologic cardiovascular system. Furthermore,
evidence of a global epidemic of cardiovascular diseases was discussed, em-
phasizing the rise in heart failure (HF) cases in an aging population. Sub-
sequently, Chapter 2 introduced non-invasive techniques to assess cardiovas-
cular function, their advantages and pitfalls.
ese chapters elucidated the need not only to improve the compre-
hension of underlying mechanics of an adequate cardiac function and the
deviation of pathophysiologic patterns to propose eective treatment but also
the urgency to develop better diagnostic tools for identifying subjects at risk.
Hence, this chapter expands and revises concepts related to cardiovascular
function and its assessment, such as intracardiac uid dynamics, in silico
simulations, haemodynamic analysis and signal/image processing algorithms.
Furthermore, developed tools for the processing, assessment and analysis of
data implemented in the context of this PhD project are introduced in this
chapter.
is completes Part I - Fundamentals, providing the basis for the follow-
ing chapters.
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3.1 Cardiac function
e proposed methods to assess cardiac function in Chapter 4 are based on
basic knowledge of intracardiac uid dynamics, including modelling of the
le ventricle (LV).ence, the following section presents a brief review to
support and expand some of these concepts
3.1.1 Fluid dynamics of intraventricular ow
Principles of uid dynamics have been applied to understand and evaluate
the pressure-velocity relationship of ow across an orice in various cardiac
situations [56]–[58]. With Doppler echocardiography, these principles allow
the calculation of pressure gradients noninvasively.e most basic applica-
tion of the simplied Bernoulli equation is to calculate transvalvular pressure
gradients in a stenotic orice using Doppler velocity proles:
∆P = ρυ2
2
[Pa] (3.1)
With the blood density ρ = 1060kg/m3, and velocity υ in m/s, this
expression can be further simplied:
∆P = 4υ2[mmHg] (3.2)
However, the simpliedBernoulli equation cannot account for the inertial
forces of pressure dierence across a non-stenotic orice or ow within the
cardiac chambers. In this case, a more complex mathematical description
must be implemented [56], [57].
e Navier-Stokes equations can be expressed as:
∇ ⋅ υ = 0
−∇P + B + µ∇2υ = ρ [∂υ
∂t
+ (υ ⋅ ∇)υ] (3.3)
Where υ is the three-component vector of local blood velocity; P is the
local pressure; B represents body forces (such as gravity) acting on the uid;
ρ (1060kg/m3) and µ (0.003 − 0.004Pa.s) are blood density and viscosity,
respectively; ∇ is ∂∂x i + ∂∂y j + ∂∂z k (i, j and k are unit vectors).ese expres-
sions associate pressure gradients to local and convective accelerations, to
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viscosity (or frictional) eects and to global body force terms. Nonetheless,
for the calculation of pressure gradients, the viscous term (µ∇2υ = 0) and
the gravitational force (B = 0) are both negligible in this context, thus the
Navier-Stokes equations reduce to:
−∇P = ρ [∂υ
∂t
+ (υ ⋅ ∇)υ] (3.4)
− ∂P
∂xi
= ρ ∂υi
∂t
+ ρ [υ1 ∂υi∂x1 + υ2 ∂υi∂x2 + υ3 ∂υi∂x3 ] (3.5)
Considering ow along a streamline, equation (3.4) becomes the Euler
equation:
∂P
∂s
= −ρ [∂υ
∂t
+ υ ∂υ
∂s
] (3.6)
To calculate noninvasively intraventricular pressure dierences (IVPDs),
equation (3.6) is integrated along an inow streamline between two selected
points (P1 and P2) inside the cardiac chambers:
∆P[t] = ∫ P2
P1
∂P
∂s
ds = 1
2
ρ(υ2P1[t] − υ2P2[t]) + ρ∫ SP2SP1 ∂υ[s, t]∂t ds (3.7)
It becomes clear that the instantaneous pressure dierence is the sum of a
convective (equation (3.8)) and an inertial (local acceleration, equation (3.9))
component:
∆PC[t] = 12ρ(υ2P1[t] − υ2P2[t]) (3.8)
∆PI[t] = ρ∫ SP2
SP1
∂υ[s, t]
∂t
ds (3.9)
A more complex analysis of the 3D nature of ow is possible resolving
equation (3.4). For the calculation of 3D pressure gradients, three orthogonal
contributions are dened, each with a single local acceleration component
and three separate convective components (x-, y-, and z-convective terms):
−∂P
∂x
= ρ ∂υx
∂t
+ ρ [υx ∂υx∂x + υy ∂υx∂y + υz ∂υx∂z ] (3.10)
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−∂P
∂y
= ρ ∂υy
∂t
+ ρ [υx ∂υy∂x + υy ∂υy∂y + υz ∂υy∂z ] (3.11)
−∂P
∂z
= ρ ∂υz
∂t
+ ρ [υx ∂υz∂x + υy ∂υz∂y + υz ∂υz∂z ] (3.12)
3.1.2 Intraventricular pressure dierence estimation
Pressure dierences are the force driving blood ow in several segments
of the cardiovascular system, including the cardiac chambers. Inside the
heart, small IVPDs are associated with an ecient lling of the ventricles
and with an ecient ejection of blood during systole.us, even if small in
magnitude, IVPDs are essential to the proper functioning of the cardiovascu-
lar system. Hence, a thorough evaluation of cardiac function should include
the estimation of IVPDs.
3.1.2.1 Colour M-Mode based estimation
Colour M-Mode (CMM) echocardiography is conventionally used to assess
LV diastolic dysfunction by estimating the propagation velocity of the inow
wave-front (Vp) (see Chapter 2). Additionally, CMM ow velocity data allow
to estimate noninvasively the IVPDs using the Euler equation (equation (3.6)).
An automatedMATLAB® (e Mathworks, Natick, Massachusetts) based
algorithm, proposed by Stewart et al. [59], was implemented by Vlachos
et al. [60] to examine CMM echocardiographic images. Aer selection of
the region of interest and the velocity colour scale, a point-by-point velocity
reconstruction is performed using de-aliasing and image processing tools.
First, the E-wave velocity eld is reduced to a series of 27 iso-velocity contours
evenly spaced between 45% and 55% of the peak E-wave transmitral velocity.
en, a smoothing spline is t to the series of iso-velocity contours, and a
statistical change-point analysis method is applied to objectively determine
the deceleration point.
From the reconstructed velocity eld, relative pressures within the region
of interest are estimated using the Euler equation (equation (3.6)). Peak
diastolic IVPDs from the le atrium (LA) to the LV apex are calculated
using equations (3.7) to (3.9). Furthermore, Vp is calculated as two segments
determined by the deceleration point since a single straight line is not an
accurate approximation for the Vp parameter. ese segments are then
termed initial and terminal propagation region.
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3.1.2.2 MRI based estimation
With the emergence and spread of magnetic resonance imaging (MRI), de-
rived sequences have provided a more complex set of ow data.us, two-
dimensional (2D) velocity vectors and equations (3.10) and (3.11) are used
to estimate pressure gradients in the imaging (xy) plane.us, calculation
of pressure dierences is performed by directly integrating only in-plane
pressure gradients over space [58]:
∆P = ∫
path
∂P
∂x
dx + ∫
path
∂P
∂y
dy (3.13)
Since the integration constant cannot be obtained from the estimated
pressure gradients, the selected path of integration is broken up into linear
segments and the total pressure drop, across all the segments, is calculated as
a sum using:
∆P =∑
i
⎡⎢⎢⎢⎢⎣(∂P∂x )i ∆xi + (∂P∂y )i ∆yi
⎤⎥⎥⎥⎥⎦ (3.14)
I implemented a MATLAB®-based application that employs an interac-
tively user-selected path for IVPD calculations, which is further described in
Chapter 4. Furthermore, available MRI data processed by this method allow
not only the analysis of diastolic but also of systolic IVPDs.e adaption of
the method to calculate 3D ow is also possible if either multi-slice or 3D ve-
locity data is available. Given the increasing accessibility and computational
power of MRI devices, a 3D implementation could add value to the approach
in the near future.
3.1.3 Computational uid dynamics model of the le ventricle
Knowledge of the full 3D intracardiac blood ow pattern may enhance cur-
rent visualisation tools and quantitative assessment of important cardiac
parameters, such as volumetric ows (cardiac output, pulmonary blood ow,
shunt ow, . . . ) or pressure gradients in healthy and disease subjects, which
might show signicantly altered intracardiac blood ow patterns. In the clin-
ical setting, echocardiography measurements are the gold standard approach
to assess cardiac function, but several methodological limitations may lead
to awed diagnoses.ese limitations include the neglection of the intrinsic
3D character of the haemodynamics by one-dimensional (1D) estimations
and aliasing problems. Hence, improved multidimensional ow estimators
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are necessary. One appealing approach to validate multidimensional ow
estimates is the use of a computational uid dynamics (CFD) model with a
full knowledge of the true haemodynamics. In Chapter 4, as part of the vali-
dation method to assess the the proposed methodologies to estimate IVPDs,
we made use of a CFD model of a contracting ventricle that was developed
by Van Cauwenberge et al. [61] and explained in detail in [2], [61], [62].
Figure 3.1: Computational uid dynamicsmodel of the le ventricle. emodel
is a prolate spheroid with a xed mitral inlet and aortic outlet, contracting and
expanding at a heart rate of 60bpm with an ejection fraction of 60%.
To assess the performance of proposed methods to calculate IVPDs, an
LV CFDmodel was built with ANSYS® DesignModeler™ as a prolate spheroid
with a xedmitral inlet and aortic outlet, contracting and expanding at a heart
rate (HR) of 60bpm with an ejection fraction (EF) of 60% (see Chapter 4).
Figure 3.1 shows themain features of the builtmodel.e computationalmesh
contained 180, 000 tetrahedral cells, and the 3DNavier-Stokes equations were
solved using a commercial CFD solver (ANSYS® Fluent®). During this CFD
simulation, the mesh was adapted mathematically according to a volumetric
boundary condition, with the intraventricular blood volume varying between
170ml at end-diastole and 69ml at end-systole [62].
To account for this volumetric change, each node of the computational
mesh needed to be displaced at each time step of the CFD-simulation (see
gure 3.2). An Arbitrary Lagrangian-Eulerian mesh motion dened on all
interior nodes ensured that the mesh quality was preserved, while avoiding
smoothing and remeshing. e systolic and diastolic periods were clearly
established by mitral and aortic ows: the mitral inow presented a specic
pattern with two characteristic peaks during diastole (E andAwaves), and the
aortic outow showed a unique peak during systole (S wave).e blood was
modelled as an incompressible Newtonian uid with a viscosity of 3.5mPa ⋅ s
and a density of 1060kg/m3. Further details are found in [61], [62].
70
3.2. Vascular function
Figure 3.2: Computational uid dynamics simulation. e model was adapted
mathematically according to a volumetric boundary condition, with the intra-
ventricular blood volume varying between 170ml at end-diastole (diastolic expan-
sion) and 69ml at end-systole (systolic contraction).
3.2 Vascular function
Vascular function assessment is a relevant complement to expand and support
the development of methods to evaluate overall cardiovascular function.
Hence, this section introduces basic denitions on non-invasive estimation
of arterial properties and the interaction between the cardiac pump and the
peripheral circulation, which are concepts further developed in Chapter 5.
3.2.1 Haemodynamic analysis
A custom-designed soware was built in MATLAB® (e Mathworks, Natick,
MA) [63], [64] to process o-line central arterial tonometry recordings and
Doppler ow velocity les. First, averaging is performed for both signals,
which is a more complex process for Doppler ow velocity les. Doppler
ow images are processed by selecting the onset and end of systolic ejection
for each cardiac cycle with two cursors. en, contours are automatically
traced using the transition in pixel intensity above a user-dened threshold
value, and the signal from each cardiac cycle is used to calculate an average
blood ow velocity waveform.ese operations are summarised in gure 3.3.
Next, volumetric ow is calculated by multiplying the previous estimated
instantaneous ow velocities and the LV outow tract cross-sectional area
(CSA). Visual time-alignment of pressure and ow curves is eectuated
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taking into consideration the concordance of the rapid systolic upstroke
of pressure and ow and the pressure dicrotic notch and cessation of ow
(gure 3.4A). Additionally, time alignment is accomplished by maximizing
the zero value of the phase angle of higher-frequency harmonics (7th to 10th)
of the input impedance, and the linearity of the early systolic pressure-ow
relationship [63], [64].
Figure 3.3: Segmentation of spectralDoppler images of bloodow velocity. Dop-
pler ow velocity les are processed by selecting the onset and end of systolic ejection
for each cardiac cycle with two cursors. en, contours are automatically traced
using the transition in pixel intensity above a user-dened threshold value. Next, the
signal from each cardiac cycle is used to calculate an average blood ow waveform.
Applying the Fourier transform, pressure and ow waveforms are broken
down into their harmonic components to perform the analysis in the fre-
quency domain. e ratio of the magnitude (amplitude) of pressure and
ow harmonics is known as input impedance (Zin) (gure 3.4B) whereas
the average modulus of the 3rd to 10th harmonics of Zin is denominated as
the characteristic impedance of the proximal aorta (Zc) [63]. For calculating
Zc, values 3 times the median value of Zin over that range of harmonics
were excluded following [63].e reection coecient (Γ), dened as the
amplitude of its rst harmonic (heart frequency), is calculated as:
Γ = Zin − Zc
Zin + Zc (3.15)
e analysis in the time domain is also performed. e characteristic
impedance of the proximal aorta (Zc − TD) is obtained in the time domain
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Figure 3.4: Haemodynamic analysis of the aorta and carotid arteries. A custom-
designed soware was built in MATLAB® (e Mathworks, Natick, MA) [63], [64]
to process o-line central arterial tonometry recordings and Doppler ow velocity
les. A) Visual time-alignment of pressure (dashed red line) and ow (dotted blue
line) curves is eectuated taking into consideration the concordance of the rapid
systolic upstroke of pressure and ow, and the pressure dicrotic notch and cessation
of ow. B) Modulus (red line) and phase (green line) of the input impedance (Zin)
obtained as the ratio of the magnitude of pressure and ow harmonics. C) Wave
separation analysis of the pressure curve. D) Pressure-ow loop calculation with the
(linear) early systole portion dened by green markers. E) Wave intensity analysis.
FCW corresponds to the forward compression wave and FEW corresponds to the
forward expansion wave.e red area is forward wave intensity and the green area
is backward wave intensity. Adapted from [4].
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since the frequency domain calculation may introduce a bias to lower values
of Zc. Zc − TD is dened as the ratio of early systolic pulsatile pressure/ow.
Systemic vascular resistance (SVR) corresponds to the modulus of Zin at
0Hz, and total arterial compliance is determined by two methods: pulse
pressure (CPPM) [65] and area (Carea) method [66].
Figure 3.5: Analysis of the central waveform. Central systolic (SBP) and diastolic
blood pressure (DBP) and pulse pressure (PP) are derived from a central pressure
waveform. e augmentation index (AIx) is computed as the ratio between the
augmentation pressure (AP = P2 - P1) and pulse pressure (PP), expressed as a
percentage. Adapted from https://commons.wikimedia.org/wiki/File:
Method-of-pulse-wave-analisys.png. By Omboni S, Posokhov IN [CC BY-
SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0)].
Wave separation analysis is computed separating the pressure waveform
into forward (Pf) and backward (Pb) traveling components (gure 3.4C),
and the ratio of the amplitudes of Pb/Pf is the reection magnitude.e rst
(P1) and the second (P2) systolic peaks are dened, and derived measure-
ments, such as augmented pressure (AP) and augmentation index (AIx), are
determined (gure 3.5):
Augmented pressure(AP) = (P2 − P1) (3.16)
AIx = [ AP
Pulse Pressure
] x100 (3.17)
P1 and P2 result from the incident and reected wave, respectively.us,
wave reections increase the AIx.
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Wave intensity analysis (WIA) is executed in the time domain and re-
quires pressure and ow to be measured at the exact same location and,
preferably, at the same time.e method states that any observed waveform
can be built up from a time-dependent succession of wave-fronts [67], which
can be interpreted as a disturbance to the ow that causes temporal changes
in pressure (dP) and ow velocity (dU) over one sampling interval.ese
elemental wave-fronts dP and dU propagate with a wave velocity c and can
be located in time and space, unlike the sinusoidal waveforms, which only
have a phase and frequency [40]. In the intact circulation, traveling wave-
fronts represent elemental units of energy transmitted within and between
blood vessels and the heart [67]. Innitesimal wave-fronts dP and dU can be
separated in a forward (subscript +) and a backward (subscript -) propagating
component:
dP± = 12(dP ± ρcdU) (3.18)
dU± = ± 12 (dU ± dPρc ) (3.19)
with ρ the density of blood.e wave speed c can be determined using
the water-hammer equation:
dP± = ±ρcdU± (3.20)
and follows from plotting pressure as a function of velocity (PU-loop,
gure 3.4D) for the whole cardiac cycle. Aer calculation of the innitesimal
wave-fronts dP and dU , wave intensity (dI) can be computed (gure 3.4E)
to analyse and represent the nature of waves:
dI = dPdU (3.21)
For each direction, there are two types of wave-fronts: compression
wave-fronts that increase pressure (generated by “blowing”) and expansion
wave-fronts that decrease pressure (generated by “sucking”). Any complex
wave can be synthesized from a succession of backward and/or forward
travelling compression and expansion wave-fronts [67].
In haemodynamic analysis, conversion of velocity (measured in a sample
volume) into a volumetric ow assumes a parabolic or at ow velocity
prole. However, the ow velocity prole of the carotid artery is neither, and
improvement of the conversion is achieved accounting for the Womersley
number for oscillatory ow [68].
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3.2.1.1 Carotid ow prole - implementing Womersley theory
Ponzini et al. [68] presented a Womersley number-based formula for es-
timating blood ow, proving its worth over traditional approaches without
requiring any dierent or new acquisition procedures.
e implemented method was based on the ow rate estimated by the
Womersley number-based formula:
QW = kWVM∑
pi
Api (3.22)
where kW depends on the Womersley number (W), which is dened as:
W = D√ f pi
2ν
(3.23)
where D is diameter, f is the frequency giving by the HR and ν is the
blood kinematic viscosity ((2.8 − 3.8) ⋅ 10−6m2/s). An expression linking the
maximum velocity and the ow rate at the peak instant has been proposed
[69]:
kW =
⎧⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎩
g1,W ≤ 2.7
pg1 + (1 − p)g2, 2.7 <W ≤ 3.1
g2, 3.1 <W ≤ 15 (3.24)
where
g1(W) = 0.5(1 + a1Wb1);
g2(W) = 0.5b2arctan(a2W); (3.25)
with
⎧⎪⎪⎨⎪⎪⎩a1 = 0.00417 b1 = 2.95272a2 = 1.00241 b2 = 0.94973 (3.26)
and
p = e(W−2.7)2/((W−2.7)2−(3.1−2.7)2) (3.27)
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3.2.2 Wave power analysis
Wave power analysis (WPA), a proposed method by Mynard et al. [70], links
a ow based alternative to wave intensity with a novel time domain analysis of
hydraulic power and the concept of wave potential. Furthermore, it provides
added value compared with previous methods in that it can be used to study
the distribution of wave power at junctions, is relatively insensitive to dia-
meter variations, and is quantitatively linked to transient changes in hydraulic
pressure power [70]. Indeed, an advantage of using wave power over wave
intensity is that it represents energy (W), a conserved quantity, rather than
wave intensity (W/m2) which is not conserved [70].ese advances enable
detailed time domain analysis of cardiovascular processes contributing to
hydraulic power and establishing the fundamental links between wave phe-
nomena and hydraulic power. Furthermore, these features of the method
support the analysis of transmitted energy into organs, which is particularly
relevant for the brain, and may help understanding specic pathophysiolo-
gical processes, the link between central haemodynamics and brain/cognitive
function, or be useful in the analysis of the eects of certain medication, as
will be shown in Chapter 5.
Mynard et al. [70] described in detail the WPA dening a quantity as
“wave power” (dpi) from the 1D equations governing pressure and ow. In
gure 3.6, a graphical depiction of WPA is outlined to illustrate its steps and
extracted parameters.
As with wave intensity, a linear separation can be performed by assuming
constant Zc, where Zc = ρc/A, with A the CSA, and dpi = dpi++dpi−, leading
to:
dpi± = ± 14Zc (dP + Zc dQ)2 (3.28)
Under these linear ow conditions, Zc dQ = ρcdU and wave power and
wave intensity are related via dpi = AdI.
In gure 3.6B, wave power curves are characterised by two major positive
peaks: a forward compression wave (FCWWP) and a forward expansion wave
(FEWWP).
3.2.2.1 Forward and backward components of pressure, ow, and hydraulic
power
e forward and backward components of pressure (P±) and ow (Q±) rep-
resent the pressure and ow that would exist if only forward or only backward
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Figure 3.6: Wave power analysis. A) Time-alignment of pressure (dashed red line)
and ow (dotted blue line) curves. B)Wave power curves characterised by twomajor
positive peaks: forward compression wave (FCWWP) and forward expansion wave
(FEWWP). C) Curves of pressure power (ΠP , black line) and forward (ΠP+, red line)
and backward (ΠP−, green line) components. D) Kinetic power curves (ΠQ , black
line) and forward (ΠQ+, red line) and backward (ΠQ−, green line) components, and
a nonlinear interaction component (ΠX , dashed blue line). E) Total hydraulic power
(Π).
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waves existed [71]. Hydraulic power can be also separated into such compo-
nents. In most settings, a linear separation could be used [70]:
P = P+ + P− + Pud (3.29)
Q = Q+ + Q− (3.30)
where the constant Pud is undisturbed pressure and represents the equi-
librium pressure that is attained when no wave potential or waves exist in
the vascular system, typically at a value of ∼ 10mmHg in human adults [71].
e linear separation makes use of the water-hammer equation that relates
incremental changes in (P±) and (Q±) via Zc as follows:
dP± = ±Zc dQ± (3.31)
Combining equations (3.29) to (3.31), and integrating, it can be shown
that [70], [71]:
P± = 12(P − Pud ± Zc dQ±) (3.32)
Q± = 12 [Q ± 1Zc (P − Pud)] (3.33)
Ignoring gravitational eects, hydraulic power (Π) at a given location is
equal to the sum of pressure (ΠP) and kinetic (ΠQ) components:
Π = ΠP +ΠQ = PQ + ρQ32A2 (3.34)
Pressure power represents the potential for hydraulic work per second,
while kinetic power represents the rate of energy transfer due to the owing
uid. Note that the sign of Π simply indicates the direction of power transfer.
From equations (3.29) and (3.30), pressure power can be expressed in
terms of P± and Q± as:
ΠP = (P+ + P− + Pud)(Q+ + Q−) (3.35)
From equations (3.32) and (3.33), an absolute form of the water-hammer
equation can be derived:
P± = ±Zc Q± (3.36)
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By making use of equation (3.36), equation (3.35) can then be expanded
and simplied to yield:
ΠP = (P+ + Pud)Q+ + (P− + Pud)Q− (3.37)
Forward and backward components of ΠP can now be dened as:
ΠP± = (P± + Pud)Q± = 14 [2PQ ± Zc Q2 ± 1Zc (P2 − P2ud)] (3.38)
where the right-hand side is obtained by substituting equations (3.32)
and (3.33). Importantly, the pressure power components are additive:
ΠP = ΠP+ +ΠP− (3.39)
Curves of pressure power (ΠP) and its forward (ΠP+) and backward
(ΠP−) components are shown in gure 3.6C.
Kinetic power may be expressed also in terms of forward and backward
ow components:
ΠQ = ρ2A2 (Q+ + Q−)3 (3.40)
Expanding,
ΠQ = ρ2A2 (Q3+ + 3Q−Q2+ + 3Q2−Q+ + Q3−) (3.41)
In the case where ΠQ±, the forward and backward components of kinetic
power are:
ΠQ± = ρ2A2Q3± (3.42)
However, the two middle terms in equation (3.41) show that the sum of
these components do not equal the net kinetic power. Rather:
ΠQ = ΠQ+ +ΠQ− +ΠX (3.43)
where ΠX = (3Q−Q2+ + 3Q2−Q+)ρ/2A2 describes a nonlinear interaction
[70].
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All three curves, kinetic power (ΠQ) and its forward (ΠQ+) and backward
(ΠQ−) components, are shown in gure 3.6D.
Total hydraulic power may be written as:
Π = (ΠP+ +ΠQ+) + (ΠP− +ΠQ−) +ΠX (3.44)
To remark, the impact of the kinetic power is generally very small com-
pared with pressure power [70]. Total hydraulic power (Π) is presented in
gure 3.6E.
3.3 Dedicated tools for the assessment of arterial health (in
non-routine conditions)
In the course of this PhDproject, additional dedicated tools for the processing
and analysis of data were developed, such as the use of radio frequency (RF)
data or supplementary haemodynamic analysis.ese are briey introduced
in this section and extended in Chapter 6.
3.3.1 Wall tracking algorithm based on RF ultrasound data
Ultrasound based tracking algorithms serve to measure the vessel diameter,
for instance, by a displacement detection system based on autocorrelation.
Since autocorrelation methods have lower sampling rate requirements, a
modied autocorrelation approach has been proposed by Rabben et al. [72] to
estimate on complex demodulated RF data both the mean Doppler frequency
and the RF centre frequency from an observation window.
e method was implemented by building a custom-written, MATLAB®-
based application for analysis of vessel distensibility from ultrasound RF
M-Mode data [5] (see Chapter 6).
Moreover, in the course of my own PhD work, other PhD students were
performing cardiovascular studies in dierent mouse models. To support
their work, a number of dedicated soware tools were developed to enable
haemodynamic analysis in these animals and to derive arterial properties to
feed into computational models.
As it is complicated to measure pressure in longitudinal studies in mice,
analyses were based on measurements of diameter distension waveforms
and ow velocity in the aorta and carotid arteries. To enable this work, the
application was further adapted to obtain the aortic distensibility from data
measured using a high-frequency small animal imaging ultrasound system
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(Vevo 2100, VisualSonics, Toronto, Canada), reconstructing the complete
M-Mode image (see gure 3.7A) from RF data so the user can select a specic
zone to process.is zone is plotted as a reference for the user to perform
the manual wall segmentation (see gure 3.7B). A complete segmentation
process is shown in gure 3.7, including diameter distension curves and the
synchronized ECG signal.e method has been used by Trachet et al. [15]
and De Wilde et al. [73].
Figure 3.7: Adapted segmentation method for calculating arterial diameter dis-
tension curves in mice using an (ultrasound) RF based method. A) Original
ultrasound image of the aorta of a mouse. B) Manual segmentation of the aortic lu-
men. C) Derived diameter distension curves. D) Synchronized ECG signal. Images
were acquired with a high-frequency ultrasound device (Vevo 2100, VisualSonics,
Toronto, Canada) using a linear array probe (MS 550D, frequency 22 − 55MHz).
3.3.2 Signal alignment using a correlation method
To resolve automatically the time lag between diameter and ow velocity
waveforms, a correlation method was adapted [74], dening a correlation
factor (R) as:
R(s) = σDU(s)
σDσU(s) (3.45)
Where s is the shi, σD and σU are the standard deviations of the carotid
distension and shied blood ow velocity signals, respectively, and σDU(s)
is the covariance.
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e standard deviations were dened as:
σD = ¿ÁÁÀ 1N N∑i=1(Di − D¯)2 (3.46)
σU(s) = ¿ÁÁÀ 1N N∑i=1(Ui−s − U¯)2 (3.47)
where Di and Ui represent diameter and blood ow velocity of sample
number i, and D¯ and U¯ mean diameter and blood ow velocity over the N
samples between minimum diameter and maximum blood ow velocity.
e covariance, σDU(s), is calculated as:
σDU(s) = 1N N∑i=1[(Di − D¯)2(Ui−s − U¯)2] (3.48)
e shi corresponding to the highest correlation factor is regarded as
the correct delay (see gure 3.8A).
3.3.3 Wave speed determination
Feng et al. [75] proposed an approach to determine wave speed based on
diameter and ow velocity measurements (rather than on pressure and ow
velocity). Wave speed can be expressed as:
c2 = 1
ρDs
(3.49)
Where ρ is the density of the uid and Ds is the distensibility of the wall
(gure 3.8B), which is related to the change in pressure (dP) and diameter
(dD) through the mathematical expression:
Ds = 2 dDDdP (3.50)
Replacing equation (3.50) in equation (3.49):
dP = ρc2 2dD
D
(3.51)
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Figure 3.8: Processing and analysis of diameter distension and ow velocity
curves. A) Signal alignment using the correlation method. B) Diameter distensibil-
ity calculation with Ds = systolic diameter and Dd = diastolic diameter. C) LnDU
loop in which the slope of the loop’s linear portion indicates the value of the local
pulse wave velocity (PWVWH). Wave separation of D) diameter distension and E)
ow velocity curves. Adapted from [5].
e change in diameter (dD) is the response to travelingwaves (backward
and forward).en, changes in velocity (dU) as forward acceleration (dP > 0;
dU > 0) or backward deceleration (dP > 0; dU < 0) produce an increase in
diameter (dD > 0) while forward deceleration (dP < 0; dU < 0) or backward
acceleration (dP < 0; dU > 0) generate a decrease in diameter (dD < 0).
Changes in pressure and diameter can be considered as the linear sum-
mation of the eects in forward and backward directions.is concept can
be expressed as:
dP+ + dP− = 2ρc2D (dD+ + dD−) (3.52)
e water-hammer equation relates the changes in pressure with the
changes in velocity:
dP± = ±ρcdU± (3.53)
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And combining equations (3.52) and (3.53):
c = D
2
(dU+ + dU−)(dD+ + dD−) (3.54)
If it is assumed that dDD = d lnD, then wave speed in terms of velocity
(U) and diameter (D) is:
c = ± 1
2
dU±
dlnD± (3.55)
e linear relationship described by this equation between U and lnD
for unidirectional waves is evident plotting lnD against U , as gure 3.8C
demonstrates.is plot delivers a lnDU loop with a linear portion during
early systole, which is considered a reection-less phase. e slope of the
linear portion of the loop is equal to 12 c.
3.3.4 Wave separation
To perform the separation of waves, Feng et al. [75] adapted the water-
hammer equation to relate changes of diameter (D) and blood ow velocity
(U), and assumed that dU is additive in forward (+) and backward (-) direc-
tions, so dU = dU+ + dU−, then dD and dU in forward (+) and backward
(-) directions can be derived as:
dD± = 12(dD ± D2PWVWH dU) (3.56)
dU± = 12(dU ± 2PWVWHD dD) (3.57)
D andU waveforms in forward (+) and backward (-) directions can then
be obtained by summing the instantaneous changes in D and U in each
direction, respectively:
D± = T∑
t=0 dD± + D(0) (3.58)
U± = T∑
t=0 dU± +U(0) (3.59)
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where T is the total cycle time. D(0) and U(0) are the integration con-
stants and can be taken arbitrarily as zero.
In gure 3.8D and E, a wave separation example for diameter distension
and ow velocity curves are shown.
3.3.5 Reection magnitude
Since reections can modify the total pressure wave due to constructive
or destructive interference of the waves, the net-eect of the reections is
important. Making use of the adapted water-hammer equation, the eect
could be applicable to diameter distension waves. Once all forward and
backward harmonics are calculated, then they can be added to construct one
global forward (D+) and backward (D−) waveform. It is then straightforward
to quantify the magnitude of wave reections as the ratio of the amplitude of
D− and D+ [40]:
RM = max(D−) −min(D−)
max(D+) −min(D+) = ∣D−∣∣D+∣ (3.60)
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Cardiac Function
e heart is central to the cardiovascular system and, consequently, its per-
formance, dened as cardiac function, is crucial to maintain proper blood
supply to tissues and organs at adequate lling pressures. Competent adapta-
tion mechanisms under dierent demands, such as exercise, extreme temper-
atures or even during respiration, should be in place to guarantee a proper
cardiac function. However, disease processes or pathological adjustments
triggered by an unusual stress to the system can lead to cardiac dysfunction
and, ultimately, to heart failure (HF). Several factors inuence cardiac func-
tion and, thus, a thorough assessment is pivotal to identify subjects at risk, to
evaluate treatment selection and to follow-up patient evolution. Particularly,
intraventricular pressure gradients (IVPGs) and dierences (IVPDs) have
raised interest as relevant physics based metrics of cardiac function responsi-
ble not only for ecient lling of the ventricles but also for ecient ejection
of blood during systole.us, even if small in magnitude, IVPDs are essential
to the proper functioning of the cardiovascular system and their estimation
should be considered in the clinical evaluation of cardiac function.
Non-invasive evaluation of cardiac function is performed, largely, by
echocardiography or MRI, which are standard methods in cardiovascular
assessment due to their appealing attributes. erefore, the estimation of
IVPDs can be achieved by both imaging techniques, but there is a lack of
comparable results to examine and compare the most suitable approach.
Since non-invasive in vivo measurements miss a ground truth to contrast
the estimated IVPDs and invasive measurements are not practical in the
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clinical setting, an appealing approach to validate multidimensional ow
estimates is the use of computational uid dynamics (CFD) models with a
full knowledge of true haemodynamics. In this chapter, the application of
such models supports the implementation of a tting method to estimate
IVPDs noninvasively. Further evaluation of the feasibility of the method in
dierent sample populations is presented to identify dierential patterns of
cardiac function in subjects without HF and in patients with distinct HF
subtypes.
e chapter starts with a review on the non-invasive assessment of IVPGs
and IVPDs, and their potential role in characterisation of patients with HF.
is section sets the theoretical framework for the entire chapter and it is
adapted from a paper published in Current heart failure reports and titled
”MRI assessment of diastolic and systolic intraventricular pressure gradients
in heart failure”, vol. 13, no. 1, pp. 37-46, 2016 [13]. e second part of the
chapter deals with the assessment of methodologies to calculate IVPDs in
computational models and patients, in which an echocardiographic and an
MRI approach are evaluated with the use of a CFD model of the le ventricle
(LV).is section is based on the paper titled ”Assessment of methodologies
to calculate intraventricular pressure dierences in computational models and
patients” and published inMedical & biological engineering & computing, vol.
56, no. 3, pp. 469-481, 2018 [2].ese results supported the implementation
and feasibility assessment of an MRI based processing algorithm to estimate
IVPDs noninvasively in subjects without HF and with heart failure with
reduced (HFrEF) or preserved (HFpEF) ejection fraction.us, the third
section of this chapter is based on a published article inOpenHeart, vol. 6, no.
2, 2019, that presents the results of this approach under the title ”Non-invasive
Intraventricular Pressure Dierences Estimated with Cardiac MRI in Subjects
without Heart Failure and with Heart Failure with Reduced and Preserved
Ejection Fraction”[1].
4.1 Theoretical background and rationale of the assessment of
diastolic and systolic intraventricular pressure differences
in heart failure
4.1.1 Introduction
e increasing incidence and prevalence of HF worldwide [76]–[78] is re-
sponsible for a large burden of morbidity and mortality, poor quality of life,
and healthcare costs [79]–[81].
Assessment of ventricular function is key to characterise patients with HF.
Clinically, two major subtypes of HF are identied based on the LV ejection
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fraction (EF):HFrEF andHFpEF [82]–[84]. AlthoughLV systolic dysfunction
is thought to be the key pathophysiologic abnormality in HFrEF, diastolic
dysfunction is also present in this condition. Similarly, whereas diastolic
dysfunction is thought to be a key pathophysiologic abnormality in HFpEF,
systolic contractile abnormalities have also been reported in this condition.
Particularly, diastolic function of the LV encompasses a complex sequence
of interrelated events involving both the active and passive properties of the
ventricle as determinants of lling [85]. e pathophysiology of diastolic
dysfunction is not fully understood, and the comprehensive characterisation
of LV relaxation and lling dynamics and its integration into clinical practice
are desirable, particularly in patients with HFpEF [85]–[87].
Non-invasive quantitative analysis of intraventricular ow dynamics can
provide important insights into the processes driving LV ejection and lling.
Indeed, Doppler echocardiography is the most common approach for the
evaluation of diastolic function. Analysis of transmitral ow and annular
tissue velocity patterns is the basis of diastolic function assessments in clinical
practice. Notwithstanding, several confounding factors (e.g., the rate and
extent of ventricular relaxation, suction, atrial and ventricular compliance,
mitral valve inertance, and le atrial (LA) pressure)may inuence transmitral
ow velocity and, consequently, limit its accuracy to characterise LV diastolic
dysfunction [88]–[91].
While the analysis of blood ow velocities (in particular, the transmitral
ow velocities) is extensively used in the evaluation of LV function [87],
[92], [93], much less is known about underlying pressure gradients and
dierences driving diastolic and systolic intraventricular ow in HFrEF and
HFpEF. Derived pressure calcualtions can be inferred by solving the Euler
equation, a simplied version of the Navier-Stokes equations [94], [95], using
information regarding the spatiotemporal pattern of LV blood ow velocities,
which in turn can be obtained using ultrasound, e.g., colourM-mode (CMM)
recordings along a transmitral scanline, or magnetic resonance imaging
(MRI). Note that there is a dierence in terminology with ”gradient” referring
to a pressure dierence per unit length (e.g., in mmHg/cm) while pressure
dierence is the absolute dierence in pressure between two points in space
(in mmHg) [96].
e computation of IVPDs provides a physical and quantitative indicator
of LV diastolic function [94], [96] but can also be applied to systole for
interrogating pressure gradients produced by LV ejection. IVPDs calculated
from CMM or MRI data have demonstrated good agreement with invasively
measured IVPDs in in vitro experiments, animal models, and groups of
patients undergoing cardiac surgery [94], [95], [97]–[101].
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Although the presence of a pressure dierence from the base to the apex
of the LV was rst speculated by Katz et al. in the 1930s, it was not until
the 1970s that IVPDs were rst demonstrated [102]. Since then, multiple
animal and human studies have characterised IVPDs/IVPGs in health and
disease. Non-invasive methods to estimate IVPGs utilising measures of
intraventricular ow velocity have also been developed and applied [57],
[103]. is review focuses on the non-invasive assessment of IVPGs and
IVPDs, and its potential role in characterisation of patients with HF.
4.1.2 IVPGs/IVPDs: basic concepts
Key to understand the generation of pressure gradients are the principles
of uid mechanics that describe the pressure–velocity relationship of three-
dimensional (3D) ow across a cardiac chamber [56]. Such ow is governed
by the Navier–Stokes equations for an incompressible uid [56], [57] with
constant density (ρ):
∇ ⋅ v = 0
−∇P + B + µ∇2v = ρ [∂v
∂t
+ (v ⋅ ∇)v] (4.1)
where ∇ represents: i ∂∂x + j ∂∂y + k ∂∂z
where i, j, and k are orthogonal unit vectors, and v is a three-component
vector of local blood velocity, P is the local pressure, B represents body forces
(such as gravity) acting on the uid, and µ is viscosity.
is complex set of coupled dierential equations can be simplied on
the basis of the following assumptions: (1) the viscous term, µ∇2v, is very
small compared to the other terms and can be neglected [103]–[105]; and (2)
the gravitational force is balanced by hydrostatic buoyancy, and thus B = 0
[56], [57] leading to equation (4.2):
−∇P = ρ [∂v
∂t
+ (v ⋅ ∇)v] (4.2)
In this equation, ∂v∂t represents the inertial component (i.e., the change
in velocity through time at a given position), while (v ⋅ ∇)v represents the
convective component (i.e., the change in velocity through space at a given
instant). e minus sign indicates that the blood particle has a positive
acceleration when it moves from a region of higher to lower pressure.
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Further simplication can be achieved when ow across a restricted
orice is considered. In that case, the amount of bloodmoving at high velocity
is small compared with the volume of the overall column of blood in regions
proximal to the stenosis, making the ”inertial” component of the equation
negligible and the ”convective” component almost entirely responsible for
the change in velocity (and pressure) that occurs as blood moves from a
wide region to a narrow region [95]. e equation obtained aer these
assumptions is termed the simplied Bernoulli equation. Introduced by
Hatle et al. [106], this equation provides the ability to calculate transvalvular
pressure dierences from Doppler measurements of blood velocity [107]:
∆P = 4v2 (4.3)
e simplied Bernoulli equation is frequently used to estimate pressure
dierences across restricted orices to characterise the severity of valvular
stenosis [56], [95] and is one of the most commonly used applications of Dop-
pler echocardiography.is simple equation has been validated in in vitro
settings, for example simulating aortic stenosis [96], [108], and in clinical set-
tings for the assessment of several cardiac diseases, including aortic stenosis
[109], mitral stenosis [110], prosthetic valve function [111], [112], obstructive
hypertrophic cardiomyopathy, pulmonary hypertension, and intracardiac
shunts [107].
Calculating IVPDs from one-dimensional velocity information
As predicted by uid dynamics principles, and as described in mathematical
models of LV lling [104], [105], [113], the simplied Bernoulli equation is
applicable to pressure dierences across restrictive orices typical of stenotic
and regurgitant lesions, but is not accurate for ow in the absence of a ow-
limiting stenosis [105], [114]. When estimating IVPGs/IVPDs noninvasively,
this equation has important limitations [115]–[118] because inertial forces are
not negligible [108], [119]–[121], as it has been demonstrated in numerical,
animal, and clinical models [122]–[124].erefore, the assessment of inertial
forces is necessary to analyse intraventricular haemodynamics. Keeping the
inertial component intact in equation (4.2) and applying it to ow along
a streamline (with the distance along the streamline indicated by s), the
one-dimensional (1D) Euler equation is obtained:
∂P
∂s
= −ρ [∂v
∂t
+ v ∂v
∂s
] (4.4)
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e instantaneous pressure dierence between any two points along this
streamline ( ∂P∂s ), is the net result of the change in velocity with time at a given
point (inertial component ρ ∂v∂t ), and the change in velocity with space at any
given time (convective component, ρv ∂v∂s ) [57]. Pressure gradients can be
directly integrated into pressure dierences [95], [98], [101], [107], where the
integration path is typically along a presumed streamline from the LV base
to apex. Being s the spatial coordinate along the streamline, the unsteady
Bernoulli equation is obtained, allowing the non-invasive estimation of the
1D IVPD [56]:
∆PˆIV [t] = ∫ apex
base
∂P
∂s
ds (4.5)
Using this equation, both inertial and convective pressure dierences
can be calculated from a spatiotemporal velocity map acquired with either
ultrasound or magnetic resonance imaging (MRI).
Calculating IVPDs from two-dimensional velocity information
A more complete insight into cardiovascular uid dynamics can be obtained
from the two-dimensional (2D) pressure eld, relative to the pressure at some
arbitrary point. Unfortunately, a relative pressure eld cannot be computed
directly by integrating pressure gradients [125] without proper boundary
conditions. Two strategies have been employed for this problem type, either
a spatial-marching scheme to integrate the pressure gradient directly over
the domain of investigation or solving the Poisson equation for the pressure
on that domain or a subsection of it [126]. Specically, a spatial integration
method was selected in sections 4.2 and 4.3 to solve the system of equations
[58], [127]:
IVPD2D = ∫
Path
∂P
∂x
dx + ∫
Path
∂P
∂y
dy (4.6)
4.1.3 Non-invasive assessment of IVPG/IVPD: ultrasound and MRI
Invasive studies have shown the important pathophysiological information
derived from knowledge of the dynamics of ventricular ejection and lling
[56], [107]. Simultaneously recorded high-delity pressure tracings at dier-
ent sites within the LV have demonstrated the existence of regional pressure
dierences in both diastole [128]–[131] and systole (even in the absence of
outow obstruction) [97], [114], [132], [133]. e ability to measure these
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pressure dierences over time (particularly during diastole) provides unique
information and new insights about the complex interaction between LV
lling and function [56]. Unfortunately, most research on intracardiac pres-
sure gradients has been limited, due to the need of sophisticated high-delity
invasive catheterisation procedures that are dicult to perform in a clinical
setting [56], [98], [107].
As an alternative,omas andWeyman [103] proposed the analysis of
CMM echocardiograms. Flow velocity measurements with PW Doppler
rely on the principle that the Doppler shi of reected ultrasound waves,
induced by moving blood particles, is proportional to the velocity of those
particles. CMM echocardiography provides a spatiotemporal display of ve-
locity along an ultrasound scan (straight) line, which can be used to compute
pressure gradients across the line with the 1D Euler equation as described
above. is approach assumes that the CMM is measured approximately
along a streamline of ow, so that the Euler equation (equation (4.4)) can
be applied directly to the data. If the scan line is prescribed from the mitral
inow to the LV apex, diastolic IVPGs can be assessed. Greenberg et al. [56],
[57] described for the rst time the methodology to noninvasively estimate
the instantaneous pressure dierence across the mitral valve throughout the
diastolic lling period, including the contribution of the inertial forces of
equation (4.4), in an animal model using CMM echocardiography.is ap-
proach was subsequently applied to humans using intraoperative techniques
[117], quantifying the relative contribution of convective and inertial forces to
the pressure dierences across nonrestrictive mitral valves, and validating the
non-invasive method to calculate IVPDs using CMM echocardiography, in
order to improve the understanding of the complex phenomena underlying
LV diastolic lling [98].
A similar approach can be used to compute systolic IVPGs, when the
interrogation line is prescribed from the LV apex to the LV outow during
ejection. Bermejo et al. [107] presented a detailed description of the pro-
cessing of standard Doppler CMM echocardiographic images to measure
pressure dierences during ejection in the absence of outow obstruction. In-
tracardiac pressure gradient maps and local pressure dierences of LV inow
and ejection closely resembled tracings obtained invasively with pressure
probes.
Several studies have further validated this approach in various conditions.
Yotti et al. [134] compared their non-invasive estimation of IVPG with inva-
sive measurements, reporting high correlation and agreement. Additionally,
Rovner et al. [99], [135] validated the non-invasive measurement of diastolic
IVPG in hypertrophic cardiomyopathy and in HF patients.erefore, the
approach to derive regional pressure dierences within the ventricle has
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proven to be a viable tool for the assessment of ventricular diastolic and
systolic function, which may provide novel insights into the non-invasive
characterisation of ventricular function [95].
Important technical details for measuring IVPGs with CMM include
adequate gain and aliasing velocity settings, and a proper scan line orien-
tation, which should be aligned to the direction of blood ow and should
”pass” through the ”core” of the blood ow column. Precise prescription
of the interrogation line avoids underestimation of ow velocities (due to
imperfect alignment with the direction of blood ow) and allows to cap-
ture the most relevant spatiotemporal information of the intraventricular
ow eld. Interestingly, Greenberg et al. [56], [57] demonstrated that a very
precise alignment of the scan line is not required: the error in calculating
IVPGs was small (mean squared error < 0.26mmHg) even if the scan line
was misaligned to up to 20° and even if it was displaced from the centerline
to more than halfway to the edge of the mitral valve.
Despite the fact that Doppler ultrasound velocity imaging is the most
widely used technique for non-invasive estimation of IVPGs/IVPDs, the
method has some important limitations. Moreover, the quality of the ori-
ginal CMM data is dependent on anatomic windows, and the method has
sensitivity to motion in a single direction, parallel to the beam path [58].
ese issues give rise to potential errors in the estimated pressure dierences
attributable to insucient sampling of the blood velocity eld [136]–[139].
Whenever spatial or temporal derivatives are applied to discretely sampled
data, noise is bound to increase in the process. Although the subsequent
spatial integration will smooth out the noise to some degree, it is essential to
obtain a complete CMMmap before processing [95].
Phase contrast magnetic resonance imaging (PC-MRI) is an alternative
technique to assess intraventricular ow velocity [140]–[147] and to calculate
pressure gradients and relative pressure dierences across vessel or valve
stenoses [142], [144], or in more general ow regimes.is technique relies
on the fact that when two opposing magnetic gradient pulses are applied
to static nuclei aligned in a magnetic eld, the eects of the two pulses on
their nuclear spin cancel each other out. However, when a particle moves in
the time between the pulses, a shi in the phase of the nuclear spins within
the moving particle is accumulated, which is proportional to the velocity of
movement along the gradient’s direction. With PC-MRI, velocity maps along
any given anatomical plane can be generated. When the gradient direction is
applied exactly perpendicular to the anatomic plane (”through-plane” velocity
encoding), ow can be measured along the LV (or blood vessel) cross section.
For the assessment of IVPGs, "in-plane" interrogation of a single long axis
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LV slice can be used.is technique has been validated using high-delity
pressure catheters in a pulsatile ow phantom and in a canine model [58].
With in-plane PC-MRI data, a 2Dmap of ow velocities is obtained by the
application of a velocity encoding in one direction: from right to le or from
top to bottom of the specic anatomic plane.ese two velocity encoding
schemes can be applied in the same acquisition, or in separate acquisitions
(rst from right to le, and then from top to bottom, with subsequent o-line
reconstruction of the 2D velocity eld).
Finally, the acquisition of 4D PC-MRI images is now possible, allowing
for measurements of velocity vectors in three spatial dimensions, with un-
restricted image orientation for estimating pressure gradients in vivo [100],
[127], [141], [147]–[149]. Although this method is less popular than other
MRI techniques due to its extended imaging times [150], advances in gradient
hardware continues to improve acquisition for 4DMRI data, which may lead
to a more widespread use [127].
Among other parameters, PC-MRI sequences require a user-dened
velocity encoding sensitivity (VENC), which should be as low as possible to
minimize noise during the acquisition, yet higher than peak ow velocity
in the region of interest to avoid aliasing. Although the VENC should be
tailored to individual measurements, a good starting point for the assessment
of IVPGs in the absence of mitral stenosis or signicant mitral annular
calcication is 130cm/s in most cases.is value must be raised in patients
with increased LV inow velocities, particularly in those with advanced
diastolic dysfunction and elevated lling pressures, whom oen exhibit peak
ow velocities above this threshold.
Some limitations of PC-MRI include phase-oset errors caused by in-
homogeneities of the magnetic eld environment (short-term eddy currents)
[151], which can be recognized as apparent velocities within stationary tissues
that tend to increase with distance from the center of the image, being typ-
ically stable over all frames of a retrospectively gated cine acquisition [152].
Correction for phase-oset may be performed using PC-MRI data acquired
from a stationary phantom [153], or alternatively, using information from
stationary tissue located in the imaging plane [154]. Other potential prob-
lems of PC-MRI include signal loss due to turbulent ow, or partial volume
averaging due to limited spatial resolution. e slice thickness should be
optimized to avoid partial volume averaging while preserving a good signal
to noise ratio.
We proposed an approach, further developed in sections 4.2 and 4.3,
to perform interrogations of intraventricular ow using in-plane PC-MRI
of the 3-chamber view (”LVOT” view), in two separate single breath hold
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Figure 4.1: In-plane phase contrast MRI interrogations of intraventricular ow
velocities in a 3-chamber view of the heart during diastole and systole. For each
cardiac stage, panels show A) Magnitude data; B) Phase data. In the magnitude
data, cardiac chambers are identied as LV: le ventricle; LA: le atrium; Ao: aorta.
Figure adapted from [13].
acquisitions (each with a single-direction velocity encoding, right to le and
anterior to posterior). A slice thickness of 5.5mm is used, while maximizing
temporal resolution to acquire at least 30 points throughout the cardiac cycle,
with a typical VENC of 130cm/s.is acquisition can be easily added to a
standard < 1 hour scanning protocol, without compromising the eciency of
the scan. An example of in-plane PC-MRI measurement of intraventricular
ow is shown in gure 4.1, whereas the le panels of gure 4.2 show the
o-line processing proposed by us [1], [2] of in-plane 2D PC-MRI data to
assess IVPDs (between the base and the apex of the LV). Briey, aer the
sequence is displayed, two points are placed inside the image: at the mitral
annulus (P1) and at the LV apex (P2). A total velocity is calculated from both
velocity components to project it onto the reference line delimited by P1 and
P2, through a complete cardiac cycle, creating a pseudo-ultrasound CMM
map (gure 4.2).is velocity information is then used to solve equation (4.4)
and obtain the total pressure dierence between P1 and P2 (see gure 4.2),
together with its inertial and convective components.
An analogous approach using CMM echocardiography is also shown in
gure 4.2 (right panels). An automated data analysis algorithm, described in
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detail elsewhere [59], [60], is used. From original CMM images, the velocity
colour scale region and a single beat region of interest (ROI) are selected,
and then, the E-wave, A-wave, and the vertical position of the mitral plane
are located for orientation of the algorithm.e grayscale values from the
CMM image background are removed, thus leaving only the velocity colour
scale image to which a dealiasing technique is applied to create a point-by-
point velocity reconstruction of the ROI. Finally, the total pressure dierence
(gure 4.2) and its inertial and convectional components are calculated. For
further details see sections 4.2 and 4.3.
Figure 4.2: Examples of (A) cardiacMRI and (B) colourM-mode (CMM) record-
ings obtained from a patient with heart failure with preserved ejection fraction
(HFpEF). Base-to-apex pressure dierences calculated from available velocity infor-
mation with each modality are shown. Processing of cardiac MRI and echocardio-
graphic CMM data involves the selection of a ROI by the user and the prescription
of an anatomic streamline.e spatiotemporal velocity prole along the streamline,
represented in colour in (2), is used to compute IVPGs.ese data are then used to
compute base-to-apex IVPDs (3). Single-point ow velocity curves extracted from
the data at the mitral annular level (4) are also shown. Figure adapted from [13].
A related approach for the assessment of diastolic function using intra-
ventricular spatiotemporal ow velocity maps (such as those obtained with
CMM echocardiography) is the evaluation of LV inow propagation velocity
(Vp). Normal LV intracavitary lling is dominated by an early wave followed
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by an atrial-induced lling wave. In the normal ventricle, the early lling
wave propagates rapidly toward the apex, which is driven by a pressure gradi-
ent between the LV base and the apex. is gradient represents a suction
force and has been attributed to LV restoring forces and relaxation [85]. In
order to relate intraventricular ow patterns to LV myocardial function in a
quantitative manner, the slope method [155], [156] was proposed for measur-
ing mitral to apical ow propagation from a spatiotemporal map of blood
ow velocities along a scan line from the mitral annulus to the LV apex [85],
[157]. Vp of the inow jet traveling toward the apex during early diastole is
measured as the slope of a linear approximation of an isovelocity contour
during early lling [59]. However, limitations of the method have hampered
its use, and other approaches have been proposed to expand the assessment
of diastolic function [85], [157]. For instance, Stewart et al. [59] suggested
that a single slope does not accurately represent the Vp for normal subjects or
patients with diastolic dysfunction. Instead, they showed that intraventricu-
lar early diastolic Vp is characterised by a steep ”initial” slope, indicating
rapid ow Vp at the base, which abruptly changes to a ”terminal”, less steep
Vp, distal to an inection point, located along the LV cavity. In general, the
assessment of IVPGs represents a more detailed approach to the assessment
of intraventricular spatiotemporal velocity proles.
IVPGs: physiologic determinants and clinical studies
Diastolic IVPGs are related to the complex interaction between LA pressure
and suction forces generated by active LV relaxation and recoil [158], [159],
whereas ejection-phase IVPGs from the apex to the outow tract are deter-
mined by the interaction between the force generated by LV contraction and
the properties of the arterial tree. It should be noted, however, that systolic
and diastolic IVPGs are interrelated via the eects of myocardial function
and various mechanisms of systolic-diastolic coupling.
e acute eects of changes in cardiac contractility and diastolic function
have been studied in multiple animal models. As early as the 1980s, regional
pressure dierences in the LV, both during diastole and systole, were shown
by Falsetti et al. [160], using invasive measurements through high delity
transducers. Pressure dierences were amplied with beta-adrenergic ag-
onists and reduced by beta-adrenergic blockers. Courtois et al. [130], using
invasive measurements in a canine model, found diastolic IVPGs to corre-
late signicantly with EF and demonstrated that coronary occlusion led to
a decrease in the peak diastolic base-to-apex LV pressure dierence. Steine
et al. [161] conducted a similar experiment in adult dogs and demonstrated
a signicant decrease in peak diastolic mitral to apical pressure dierence
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aer coronary microembolization. In their study, this pressure dierence
correlated with both the time constant of LV isovolumic relaxation (τ) and
stroke volume. In addition, an increase in contractility and a decrease in the
rate of relaxation induced by isoprenaline infusion were also associated with
a decrease in the peak early diastolic LV pressure dierence in this model
[162]. Firstenberg et al. [163] conrmed the association of early diastolic
IVPDs with indices of systolic function using both invasive (high-delity
conductance catheterisation) and non-invasive (CMM echocardiography)
measurement techniques and found them to increase with inotropic stimula-
tion. Yotti et al. [134] studied the ejection IVPDs from apex to the outow
tract in minipigs using CMM echocardiography and established their corre-
lation with invasively measured indices of systolic function, including peak
systolic LV elastance, preload recruitable stroke work, and peak of the rst
derivative of pressure corrected for the end diastolic volume, during states of
varied contractility and induced acute myocardial ischemia.
Although highly informative, most of the previously mentioned studies
were conducted in anesthetized, open-chest animal experiments, precluding
a precise assessment of the normal human physiology. Firstenberg et al. [164]
performed an invasive studied of IVPDs in humans undergoing coronary
surgical revascularization and found that not only peak diastolic gradients
increased aer revascularization, but this change also correlated with an
improvement in the EF and τ, linking these gradients to both systolic and
diastolic function.
Myocardial relaxation, LV elastic recoil, and LV lling are dependent
on the time-varying systolic load and the deformation of cardiac muscle
during contraction [159], [165]. us, ejection-phase and diastolic IVPGs
are intrinsically linked. A particularly interesting index of systolic–diastolic
coupling that can be assessed with the analysis of IVPGs is the late systolic
reversal of the ejection-phase apex-to-outow tract IVPD, which occurs as
systolic ow decelerates and the heart relaxes, such that pressure is lower in
the apex than in the outow tract.e magnitude of this reversal jet has been
shown to correlate with τ over a variety of lusotropic states in animal studies
[166]. Smiseth et al. [167] showed in human subjects, using CMM echocar-
diography, that the apex-to-outow pressure dierences correlated strongly
with τ, independent of changes in LV loading conditions. ese ndings
are consistent with those of Yoshida et al. [168], who assessed the ”inertia
force” of late systolic aortic ow among patients with suspected coronary
artery disease referred for cardiac catheterisation. In this study, inertia force
was computed from the relation between LV pressure and its rst derivative
(LVP/dPdT). Patients with reduced EF had absent late systolic ”inertia force.”
In addition, Vp was lower among patients with reduced EF or those with
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preserved EF who had no ”inertia force”, compared to those with preserved
EF who had a measurable ”inertia force”.e authors suggested that the force
generated by late systolic blood inertia unloads themyocardium in late systole,
promoting a smaller end-systolic volume and a greater deposition of elastic
forces in the myocardium, leading to increased elastic recoil (and diastolic
suction) during early diastole. However, the eect of inertial unloading on
LV end-systolic volume is likely to be very small. It appears more likely that
late systolic unloading may have favourable eects on calcium cycling and
on various maladaptive pathways, since a large body of evidence now links
increased late systolic load to the development of LV hypertrophy, brosis,
systolic and diastolic dysfunction, the risk of new-onset HF, and the risk of
HF readmission among patients with established HF [165], [169]–[177].
Various studies have assessed IVPGs in experimental models of HF and
in humans with established HF. Guerra et al. [178] assessed IVPDs in a
doxorubicin-induced dilated cardiomyopathy adult rabbit model.rough
continuous invasive measurement of IVPDs, they demonstrated that the
physiological early diastolic base-to-apex and late diastolic apex-to-base
pressure dierences, as well as systolic biphasic IVPDs, were abolished in
rabbits with HF. Rovner et al. [135] studied the relationship between IVPDs
and peak oxygen consumption (peak VO2, a measure of aerobic capacity) in
patients with HFrEF.ey found that, compared to normal controls, subjects
with HFrEF had a decreased ability to augment their IVPDs during exercise,
suggesting a diminished ability to generate ventricular suction.is inability
to increase IVPDs correlated well with peak VO2. Yotti et al. [101] studied
the response to stress in cardiomyopathy patients using a dierent technique.
ey estimated diastolic IVPDs in patients with dilated cardiomyopathy and
healthy controls at baseline and during dobutamine infusions using CMM
echocardiography.ey found that, while dobutamine increased diastolic
IVPDs by 44% in healthy controls, IVPDs showed only a 23% increase in
patients with HF, indicating a decreased capacity to recruit a larger suction
force with stress. In contrast to the observation in the study by Rovner
et al. [135], they also found baseline IVPGs to be lower in the HF group.
Ohara et al. [179], who studied IVPDs in patients undergoing dobutamine-
stress echocardiography, reported a similar nding.ey demonstrated that
subjects with diastolic dysfunction had a decreased ability to augment their
IVPDs in response to dobutamine.
As noted by Gillebert and De Buyzere [158], an insucient adrenergic
augmentation of diastolic IVPDs may play a role in exercise intolerance
in patients with HFpEF, although further studies are needed to test this
hypothesis. It is worth noting that, while IVPD augmentation during exercise
and adrenergic stimulation may be informative to characterise subjects with
102
4.1. Background and rationale of IVPD estimation
HFpEF, the inability to demonstrate variations in IVPDs at baseline has
generated an interest in other parameters, such as Vs, which is a combination
of the Vp parameter and the length of the inection point where Vp abruptly
decelerates [59], [180].
Iwano et al. [181] showed that the reduction in IVPDs in patients with
HFrEF or HFpEF was driven by a reduced gradient in the apical region, while
the basal IVPD was preserved, presumably by an increase in LA pressure.
A previous study [10] compared MRI-derived IVPDs among 23 subjects
without HF, 13 subjects with HFrEF and 14 subjects with HFpEF. HFpEF was
associated with greater amplitude of the reversal of the base-to-apex IVPD
during early lling compared to controls and patients with HFrEF.ese data
may indicate that HFrEF and HFpEF are associated with distinct patterns of
IVPD abnormalities during early diastolic lling, supporting fundamental
dierences in the nature of diastolic dysfunction in these two conditions.
ese studies, however, are limited by the small sample sizes. Further studies
are required to better elucidate the distinction in IVPDs/IVPGs between
patients without HF, patients with HFrEF and patients with HFpEF, and the
mechanisms behind these dierences.
4.1.4 Conclusions
IVPGs provide important insights about ventricular physiology. Overall,
methodologies to estimate IVPGs has been underutilised, which may be due
to the theoretical complexity of the derivation of IVPGs. A wider availability
of automated analysis tools will facilitate the increased use and investigation
of IVPGs in HF. Similarly, the continued improvement in MRI pulse se-
quences and hardware to characterise intraventricular ow elds with great
detail using novel techniques (such as 4D owMRI), may provide additional
precision and insights regarding the non-invasive assessment of IVPGs. It
remains to be determined whether the assessment of ventricular function by
IVPG measurements provides incremental clinically useful information to
standard non-invasive assessments. Nevertheless, the assessment of IVPGs
represents an informative clinical research tool.
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4.2 Assessment of methodologies to calculate intraventricular
pressure differences in computational models and patients
4.2.1 Introduction
Section 4.1 introduced basic concepts and the rationale for the estimation
of IVPGs/IVPDs, including their impact in cardiovascular function, related
physiological determinants and uid dynamic principles, and relevant non-
invasive assessment methods. Particularly, MRI and ultrasound based meth-
ods were identied as common approaches to estimate IVPGs/IVPDs.
However, it remains unclear how MRI and ultrasound-derived IVPDs
compare in vivo, as simultaneous assessments are technically impossible and
validation studies require the use of invasive procedures, which are dicult in
the MRI suite [99]. Furthermore, the impact of including multidimensional
velocity information on the computation of IVPDs is undened. Computa-
tional modelling has been used previously to simulate cardiac ow of the
heart and the aorta [57], [182]–[186] but has not been used for analysing the
accuracy of IVPD determination, which is becomingmore relevant in clinical
research to complement the understanding, the analysis, and the diagnosis
of diastolic dysfunction noninvasively [60], [95], [101], [158].
erefore, the primary aims of this study are (1) to compare IVPDs
deduced from synthetic CMM and 1D and 2D phase contrast MRI data from
a CFD model of a relaxing and lling LV, and (2) to assess the feasibility of
these methods in a small cohort of patients with HFpEF, who are known to
have underlying diastolic dysfunction.
4.2.2 Methods
Previously established, uid dynamic theory is resumed to describe the IVPD
calculations.ereaer, the CFD model is described together with how the
simulated velocity data was processed. Finally, the clinical component of the
study is introduced.
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Calculating IVPDs from 1D velocity information
From equation equation (4.5), the non-invasive estimation of the 1D IVPD is
obtained as:
IVPD1D = ∫ apex
base
∂P
∂s
ds (4.7)
IVPD1D = ρ∫ Sapex
Sbase
∂v
∂t
ds + 1
2
ρ (v2apex − v2base) (4.8)
Calculating IVPDs from 2D velocity information
To evaluate equation (4.6) for a given path of integration, the selected path is
broken up into linear segments, each of which has a vector length dened by
dx Ð→ ∆xi and dy Ð→ ∆yi , and the total pressure drop, across all segments,
is calculated as the sum using [58]:
IVPD2D =∑
i
⎡⎢⎢⎢⎢⎣(∂P∂x )i ∆xi + (∂P∂y )i ∆yi
⎤⎥⎥⎥⎥⎦ (4.9)
In gure 4.3, a detailed graphical description of the method is presented.
4.2.2.1 Computational uid dynamics model of the le ventricle
e LV was modeled as a prolate spheroid [62] with a xed mitral inlet
and aortic outlet, contracting and expanding at a heart rate of 60bpm with
an EF of 60% (gure 4.4, table 4.1). e computational mesh contained
180,000 tetrahedral cells, and the 3D Navier-Stokes equations were solved
using ANSYS® Fluent®. During this CFD simulation, the mesh was adapted
mathematically [62] according to a volumetric boundary condition, with the
intraventricular blood volume varying between 170ml at end-diastole and
69ml at end-systole.e systolic and diastolic periods were clearly dened
by mitral and aortic ows: the mitral inow presented a specic pattern with
two characteristic peaks during diastole (E- and A-waves), and the aortic
outow showed a unique peak during systole (see gure 4.4).e blood was
modeled as an incompressible Newtonian uid with a viscosity of 3.5mPa ⋅ s
and a density of 1060kg/m3.
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Figure 4.3: Graphical description of the implemented method for calculating
IVPDs from 2D data. Top) Reference points (P1–P2) were selected by the user
inside the CFD model.e calculation of the pressure gradients was performed for
all the points inside each frame. Middle)rough interpolation, values of the line
determined by the reference points were obtained, together with ∆x and ∆y. Bottom)
e equation (4.9) is applied to calculate the IVPD curves. Figure adapted from [2].
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Figure 4.4: CFDmodel. On the top le of the gure, the structure of the model is
shown, indicating its general geometrical parameters and the location of the valves.
On the right, the model is shown during systole, early lling (E wave), and late lling
(A wave).e bottom panel demonstrates changes in volume (gray solid line), mitral
ow velocity (dotted line), and aortic ow velocity (dashed line). Figure adapted
from [2].
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A dedicated graphical user interface was developed in MATLAB® (e
MathWorks, Natick, Massachusetts) for processing the model data. Once
the velocity and the pressure information was displayed at frame 1 (i.e., end-
diastole, gure 4.5), two points were placed inside the model: P1 at the LV
base and P2 at a distance of ∼ 4cm near to the LV apex, making sure it was
always inside the LV boundary during the complete cycle.e pressure dier-
ence between these points was calculated, applying the previously described
approaches.e pressure curve IVPDCFD was calculated directly from the
CFD model data as the pressure dierence between points P1 and P2 and
used as a reference (gure 4.5). To assess the impact of the virtual scan line
denition, IVPDs were calculated using three dierent placements of P1 and
P2, with two of them deliberately deviated from the main direction of ow. In
gure 4.5, all three congurations are shown: line A represents a well aligned
scan line while lines B and C represent a small and an extreme deviation
from the main ow direction, respectively.
Table 4.1: CFD model haemodynamic parameters.
Parameter Value
Mitral valve short axis [cm] 1.1
Mitral valve long axis [cm] 1.7
Mitral valve area [cm2] 5.9
Aortic valve diameter [cm] 2.3
Aortic valve area [cm2] 4.2
Signal period [s] 1
Systolic period [s] 0.345
Temporal resolution [ms] 5
HR [bpm] 60
EF (%) 60
Maximum volume [ml] 170.6
Minimum volume [ml] 69.09
Outow peak [cm/s] 120
E-wave inow peak [cm/s] 75.31
A-wave inow peak [cm/s] 30.07
4.2.2.2 IVPD curve characterisation
e diastolic period of the IVPD waveforms, both in silico (gure 4.5) and
in vivo (gure 4.6, bottom), is typically characterised by (i) a large forward
positive peak associated with the early lling wave, (ii) a negative peak as-
sociated with the deceleration of the early lling, and (iii) a second positive
peak associated with the late lling wave due to atrial systole. To facilitate the
identication of these three pressure peaks, we dened them as (i) E-wave, (ii)
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reversal, and (iii) A-wave peaks, and they were established as the parameters
to be extracted and compared for each applied method.
One-dimensional IVPD calculation
e CFD velocity information was projected along a scan line prescribed
manually and corresponding with the inow streamline, between P1 and
P2. By this way, the velocity component in the direction of the beam was
computed. ereaer, this information was used as an input to calculate
IVPDs using two dierent approaches:
• IVPD1DMRI determination: equation (4.4) was solved with this veloc-
ity information to obtain the pressure dierence between P1 and P2
(IVPD1DMRI).
• IVPDCMM determination: to mimic the velocity estimate as would be
obtained from ultrasound, data were colour-coded and a synthetic
pseudo-ultrasound CMM (gure 4.5) image was generated. Using
a MATLAB® application [59], [60], a pressure dierence curve
(IVPDCMM) was calculated from this pseudo-CMM image. Limits of
colour coding for this pseudo-image were chosen to represent the
range between maximum and minimum velocities in the CFD eld.
Two-dimensional IVPD calculation (pseudo 2D phase-contrast imaging)
To mimic IVPD based on 2D phase-contrast MRI imaging, both the x and y
velocity components were used to obtain temporal and spatial gradients in
order to calculate the pressure gradient elds.en, interpolated values along
the line delimited by P1 and P2 were used to solve equation (4.9), applying
the direct integration method previously described (see gure 4.3).
To study the impact of the lower temporal resolution (as is the case in
MRI phase-contrast imaging), data were downsampled to 70 frames for one
cardiac cycle, going from a time step of 5 to 14.3ms for the CFD model to
compare computed IVPDs with the ground truth.
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Figure 4.5: General description of the CFD model display and processing inter-
face to illustrate the strategy implemented and the general results. On the top
of the gure, the model is displayed in two dierent plots, showing velocity and
pressure data.e gure shows the early mitral inow or E-wave in frame 108 (0.54s)
out of 200. Two points are placed by the user (P1 at the LV base and P2 towards the
LV apex) to dene a reference line for producing a pseudo-colour M-mode image
to show velocity information between those two locations over time. is image
becomes the input for the IVPD1D and IVPDCMM calculation using 1D velocity
information to determine pressure dierences between P1 and P2 during a complete
cardiac cycle. At the bottom of the gure, pressure curves derived from the CFD
model for dierent reference point (P1–P2) placements are shown to demonstrate the
impact of these alterations on the outcome for all applied methodologies: IVPDCFD
(black solid line) curve was extracted directly from the model pressure data and
used as reference; IVPD1D (solid light gray line), IVPDCMM (dashed gray line),
and IVPD2D (dotted dark gray line). Black circle marks in curves obtained from
a properly aligned scan line (line A) are connected through gray vertical lines to
the time axis to indicate the timing of extracted parameters presented in table 4.2.
Figure adapted from [2].
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4.2.2.3 In vivo application: MRI- and ultrasound-based IVPD calculation
and comparison
Sample population
We studied a clinical sample of patients withHFpEF, recruited at the Corporal
Michael J. Crescenz Veterans Aairs (VA) Medical Center.
We included adult patients with HFpEF who met the following criteria:
(1) symptomatic HF with current New York Heart Association (NYHA) class
II–IV symptoms; (2) LV ejection fraction (LVEF) > 50%; (3) at least one of the
following within 1 year prior to consent: hospitalization for decompensated
HF, acute treatment for HF with intravenous diuretics or haemoltration,
chronic treatment with a loop diuretic for control ofHF symptoms, or chronic
diastolic dysfunction evidenced by LA enlargement (LA volume > 34ml/m2)
or Doppler signs of increased LA pressure as dened by the American Society
of Echocardiography [85]; and (4) stable medical therapy. Key exclusion cri-
teria were as follows: (1) clinically signicant valve disease (more than mild
aortic ormitral stenosis ormore thanmoderate aortic ormitral regurgitation);
(2) atrial brillation or utter; (3) signicant ischemia seen on stress testing
within the past year that was not revascularized; (4) other clinically important
causes of dyspnea such as lung disease; (5) hypertrophic, inltrative, or in-
ammatory cardiomyopathy; (6) pericardial disease; (7) primary pulmonary
arteriopathy; and (8) severe renal dysfunction (estimated glomerular ltra-
tion rate < 30ml/min/1.73m2) or liver disease. We included patients who had
phase-contrast MRI measurements and CMMmeasurements within 1 week.
Informed consent was obtained from all subjects, and the study was approved
by the Corporal Michael J. Crescenz VAMedical Center Institutional Review
Board.
Cardiac MRI
We measured intraventricular ow using in-plane phase-contrast MRI from
a 1.5T Magnetom Avanto or Espree system (Siemens Medical Solutions). A
phase-contrast gradient echo pulse sequence with in-plane velocity encoding
was applied using retrospective gating, in a plane corresponding to the three-
chamber view (”LV outow tract view”) in which both the mitral inow and
the LV outow are well visualised. Maximal velocity encoding was usually
set at 150cm/s but adjusted during the examination to avoid aliased velocity
measurements. Other typical acquisition parameters included the following:
a slice thickness of 5.5mm, a repetition time of 35.15ms, and a ip angle of
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10○. View sharing was used, and 70 frames were acquired per cardiac cycle.
We performed two consecutive acquisitions, each with in-plane velocity
encoding in one direction. Both acquisitions were merged o-line to obtain
the in-plane 2D velocity maps.
A MATLAB® application was created to open and process phase-contrast
MRI data (gure 4.6, le). Aer the images were loaded and displayed, two
points were placed inside the image: one at the mitral annulus (P1) and
another one at the LV apex (P2). Two methods were used to calculate the
IVPD:
1. A rst approach based on the calculation of a total velocity from both
velocity components to project it onto the reference line delimited by P1
and P2, through a complete cardiac cycle (gure 4.6, middle le).is
velocity information was then used to solve equation (4.4) and obtain
the total pressure dierence between P1 and P2 (IVPD1DMRI ; gure 4.6,
bottom le, black solid line). A colour-coded image, analogous to an
ultrasound CMM, was also produced and displayed in the soware
interface but was not used directly in the computation of IVPDs.
2. e second method used the 2D velocity information available to
perform a direct integration for a linear segment delimited by P1 and P2,
calculating the pressure gradients to solve equation (4.9) (IVPD2DMRI ;
gure 4.6, bottom le, gray dashed line).
Doppler echocardiography
Doppler transthoracic echocardiography was performed at rest with the
patient in supine position using a Vivid E9 device (GE Healthcare, Horten,
Norway), equipped with a cardiac probe. A CMM image was acquired,
prescribing a scan line that coincides with the main diastolic intraventricular
ow stream as previously described [85].
We used an automated data analysis algorithm, developed in MATLAB®
and described in detail in previous publications [59], [60], to process the
CMM data (gure 4.6, right). From the original CMM images, the velocity
colour-scale region and a single beat region of interest (ROI) were selected
(gure 4.6, top right), and then the E-wave, A-wave, and the vertical position
of themitral planewere located for orientation of the algorithm.e grayscale
values from the CMM image background were removed, thus leaving only
the velocity colour-scale image to which a de-aliasing technique was applied
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to create a point-by-point velocity reconstruction of the ROI (gure 4.6,
middle right). Finally, the IVPD was calculated (gure 4.6, bottom right),
allowing the extraction of parameters to be compared with cardiac MRI
post-processing results.e following parameters were considered: E-wave,
reversal, and A-wave peak pressures.
Figure 4.6: Cardiac MRI (le) and CMM (right) based methods to estimate
IVPDs. Top) a ROI selection by the user inside an original recording example
(from the same patient). Middle) processing results used to calculate and extract all
parameters. Bottom) IVPD derived from the application of imaging velocity data to
solve equation (4.2); le) solid black line: IVPD1D ; gray dashed line: IVPD2D , right)
solid black line: IVPDCMM . Figure adapted from [2].
4.2.2.4 Statistical analysis
Continuous variables are described as mean ± standard deviation. To as-
sess the performance of the methods for determining IVPDs, the root of
the mean square error (RMSE) was used as the estimator of the dierence
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between the IVPD curve obtained directly from the CFDmodel pressure data
(IVPDCFD) and IVPD curves calculated from the CFD velocity data with the
described approaches (IVPD1DMRI , IVPD2DMRI , and IVPDCMM). For the
in vivo application, selected parameters (E-wave, reversal, and A-wave pres-
sure peaks) were calculated from cardiac MRI and ultrasound imaging and
compared with each other. Scatter plots were constructed, and correlation
(Pearson and Spearman) coecients were computed. Regression analysis
and Bland-Altman plots were also used to compare results among the various
applied methods. Signicance level (α) was set at 0.05.
4.2.3 Results
4.2.3.1 CFD model processing results
e pressure curve from the model (IVPDCFD) is shown in gure 4.5 (black
line), and selected parameters are summarized in table 4.2.e E-wave peak,
coinciding with the absolute maximum IVPD (1.392mmHg), is followed by
the reversal of the IVPD, which was the absolute minimum (−1.618mmHg),
and the A-wave peak (0.8847mmHg).
e impact of the scan line alignment on the calculated pressure curves
is shown in gure 4.5 and table 4.3, using the IVPDCFD curve as a ref-
erence. e most accurate results were obtained for scan line A and the
IVPD2DMRI method (2D RSME = 0.0798mmHg), while IVPD1DMRI and
IVPDCMM delivered inferior results (1D RSME = 0.2550mmHg; CMM =
0.2633mmHg). A moderate misalignment of the scan line (line B) increased
the error for all techniques although IVPD2DMRI demonstrated the best per-
formance (1D RMSE = 0.5016mmHg; 2D RMSE = 0.1444mmHg, CMM =
0.5215mmHg).e same was true for an extreme misalignment (line C; 1D
RMSE = 0.6222mmHg; 2D RMSE = 0.1782mmHg; CMM = 0.6853mmHg).
All approaches underestimated the E-wave and the A-wave peak values,
whereas reversal peak pressure was overestimated when compared with
IVPDCFD peak values (table 4.2). In general, IVPDCMM peaks presented,
in almost all cases, the highest values (in magnitude).
To assess the impact of temporal resolution, a scan line with a good
correspondence with the inow streamline was imposed (gure 4.5, line A).
ere were small eects of reducing the frame rate with slightly lower peak
pressures in undersampled data (table 4.2).
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4.2.3.2 In vivo processing results: calculation of pressure curves from a
HFpEF population
In gure 4.7 and gure 4.8, the Bland-Altman and scatter plots contrasting
selected parameters (E-wave, reversal, and A-wave peaks) obtained from all
three approaches are shown. Figure 4.7 refers to the comparison betweenMRI-
derived methods (IVPD1DMRI vs. IVPD2DMRI) while gure 4.8 compares
both MRI methods against the CMM approach [IVPDCMM vs. IVPD1DMRI
(black circles) and IVPDCMM vs. IVPD2DMRI (gray triangles)].
e lowest and the highest parameter average values were ob-
tained from the IVPD1DMRI (E-wave 1.368 ± 0.695mmHg, reversal−1.262 ± 0.812mmHg, and A-wave 1.130 ± 0.475mmHg) and the IVPDCMM
(E-wave 3.041 ± 1.197mmHg, reversal −2.541 ± 1.507mmHg, and A-wave
2.287 ± 0.926mmHg) curves, respectively (table 4.4). ere was a high
correlation between IVPD1DMRI and IVPD2DMRI parameters (gure 4.7;
Pearson R for E-wave = 0.88, reversal = 0.94, and A-wave = 0.77).
IVPDCMM parameters showed acceptable correlations with 1D MRI data
(gure 4.8; Pearson R for E-wave = 0.78 and reversal = 0.79), except for
the A-wave peak pressure (Pearson R = 0.17). e correlation between
CMM data and 2D data was lower, even if it was similar for all three peaks
(gure 4.8; Pearson R for E-wave = 0.55, reversal = 0.68, and A-wave = 0.47).
Table 4.2: Extracted parameters frompressure curves obtained using the CFDmodel
and its downsampled version to assess the impact of reduced temporal resolution. A
properly aligned scan line was imposed for this analysis (see line A in gure 4.5).
Temporal resolution Parameter
E-wave peak pressure [mmHg] Reversal peak pressure [mmHg] A-wave peak pressure [mmHg]
Original Downsampled Original Downsampled Original Downsampled
IVPDCFD 1.392 −1.618 0.8847
IVPD1D 1.236 1.204 −1.626 −1.675 0.7014 0.7181
IVPD2D 1.221 1.219 −1.644 −1.702 0.8304 0.8849
IVPDCMM 1.36 1.249 −1.791 −1.742 0.7729 0.7472
Table 4.3: Root mean square error (RMSE) quantifying the dierence between
the reference IVPD directly obtained from the CFD model and the IVPD curves
retrieved by applying three methods using three dierent scan line positions [illus-
trated in gure 4.5, from the well-aligned line (line A) to the erroneously aligned
line (line C)]. Additionally, the range of maximal positive and negative dierences
(∆ range) is included to complement the analysis.
RMSEmodel [mmHg]
Line A ∆ range Line B ∆ range Line C ∆ range
IVPD1D 0.2550 [−0.6429, 0.4979] 0.5016 [−1.7336, 0.2647] 0.6222 [−2.2093, 1.2858]
IVPD2D 0.0798 [−0.2300, 0.3194] 0.1444 [−0.3772, 0.2446] 0.1782 [−0.6104, 0.2615]
IVPDCMM 0.2633 [−0.6629, 0.5215] 0.5215 [−1.8525, 0.2692] 0.6853 [−2.4533, 1.3529]
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Figure 4.7: Bland-Altman plots and scatter plots comparing the impact of using
1D and 2D MRI-based estimates on the calculation of IVPD parameters. Figure
adapted from [2].
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Figure 4.8: Bland-Altman plots and scatter plots comparing the impact of using
MRI-based estimates against CMM ow velocity information in the calculation of
IVPD parameters [IVPDCMM vs. IVPD1DMRI (black circles), and IVPDCMM vs.
IVPD2DMRI (gray triangles)]. Figure adapted from [2].
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Table 4.4: Parameters extracted from IVPD curves in a HFpEF patient population.
Parameter
E-wave peak pressure [mmHg] Reversal peak pressure [mmHg] A-wave peak pressure [mmHg]
IVPD1D 1.368 ± 0.695 −1.262 ± 0.812 1.130 ± 0.475
IVPD2D 1.747 ± 0.890 −1.369 ± 0.892 1.484 ± 0.478
IVPDCMM 3.041 ± 1.197 −2.541 ± 1.507 2.287 ± 0.926
Values are presented as mean ± Std(n = 13).
4.2.4 Discussion
4.2.4.1 CFD model data
e CFD model data, generated using a 3D LV model and based on the full
Navier-Stokes equations, indicate that IVPDs can be fairly well estimated,
making use of the Euler equations. As anticipated, the best results were
obtained when using the 2D velocity information in the computations (i.e.,
equation (4.9)), with the estimated pressure gradient fairly predicted through-
out the complete cardiac cycle, irrespective of the accurate alignment with
the ow (gure 4.5).e 1D methods perform reasonably well for the prop-
erly aligned scan line and capture the peak values (E- and A-waves and ow
reversal) well.
In clinical practice, most IVPD data have been collected using CMM
imaging. e ultrasound-based method has successfully been validated
against invasive data [98], [101], and itwas shown that scan linemisalignments
up to 20○ result only in small variations in IVPDs (< 0.26mmHg) [57]. To
emphasize, the presence of vortices, which are formed at the leaet tips,
grows throughout diastole, explaining why results in early diastole tend to be
somewhat better than in atrial lling [57].
Additional research on the impact of scan line misalignment indicated
that an angle misalignment of ±35○ (in any spatial direction) was associated
with an error of −0.2 to −0.6mmHg (95% condence limits of agreement),
whereas a ±0.5cm coaxial displacement from the centerline (representing
a 50% uncertainty of the LVOT diameter size) induced an error of 0.3 to−0.7mmHg [134]. However, misalignment errors related to the 1D simpli-
cation could be higher in ventricles with geometrical variations such as
localized septal hypertrophy [101], [134].
In our CFD model study, we generated synthetic CMM images directly
from the CFD data, meaning that we simply colour-coded the velocity com-
ponent in the scan line direction. As such, data are free of any measuring
noise and do not account for any operator-dependent ultrasound settings on
the machine.ese synthetic images were then further processed using ded-
icated soware developed by Stewart et al. [59]. Misalignment deteriorated
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the result of the 1D CMMmethod, although for the tested cases, the estimate
of the early lling peak pressure gradient remained acceptable (which was not
the case for the ow reversal and A-wave). We speculate that the fact that the
1D method deteriorated most in mid- and late diastole is because of the com-
plexity of the ow eld during that phase, with complex multidimensional
vortex ow.
e 1D limitation, inherent to the CMM technique, can be overcome
when multidimensional ow velocities are available, as is the case for echo
PIV [187], [188] and MRI [58]. In the CFD study, we extracted 2D ow
velocities in an assumed imaging plane and processed the data in two ways:
(i) a 1D approach which is basically an MRI equivalent of a CMM and (ii)
direct integration which makes use of the 2D velocity information.e 1D
method (IVPD1DMRI) yielded virtually identical results as the CMM (due to
the way the CMM image was generated).e 2DMRImethod (IVPD2DMRI)
provided the most consistent data, even for the most extreme misalignment
case (although it is advisable to dene the scan line as much as possible
aligned with the ow).
Other important factors aecting the computation of IVPDs are the
temporal, spatial, and velocity resolutions of the imaging techniques as they
determine the accuracy of the partial derivative terms in the Euler equation
[57]. Rojo-Alvarez et al. [189] assessed the inuence of temporal, spatial, and
velocity resolutions of the ultrasound scanner, on cardiovascular parameters
derived from velocity images, and found that, for the ideal image model they
used, temporal resolution turned out to be the most critical parameter for
the accuracy of the results.e impact of temporal resolution on calculated
pressure dierences derived fromMRI has also been addressed to identify
minimum requirements to capture components of motion of blood velocities
and accelerations in the heart, reducing temporal resolution data sets from
higher temporal resolution experiments [58].
In our CFD study, reducing the temporal resolution from 200 to 70Hz
had albeit little impact and changed the values of the three most relevant
peaks by not more than 8%.
We can thus conclude from the CFD model data that the 2D direct inte-
gration method provides the most accurate IVPDs (in the tested settings)
but the accuracy of the 1D methods, particularly to estimate the early lling
peak pressure dierence, is still acceptable for reasonably aligned scan lines.
119
4. Cardiac Function
4.2.4.2 In vivo data
e main purpose of the in vivo analysis was to (i) demonstrate the feasibility
of the MRI-based methods in a HFpEF patient population and (ii) relate the
in vivo ndings to the theoretical CFD results. As illustrated in gure 4.6 for
a representative case, derived IVPDs from both modalities showed similar
patterns with distinct peaks typical of the diastolic period and associated
with the early and late lling waves (E-wave, reversal, and A-wave pressure
peaks).
Comparing rst the 1D and 2DMRI-basedmethods (gure 4.7), we found
the 1Dmethod to underestimate the magnitude of both the positive wave and
negative peaks (though by less than 0.4mmHg on average), with correlation
coecients between 0.7 and 0.9. While dierences were smaller for the
synthetic CFD model data, these results are in line with the model ndings.
As these methods are based on the same measured MRI velocities, these data
demonstrate the impact of reducing the available velocity information.
e main rationale for calculating IVPD1DMRI from the MRI data was
to have a direct equivalent for comparison against IVPDCMM data and to
have an intermediate point of comparison for the CMM and MRI-based ap-
proaches. As can be observed fromgure 4.8, themagnitude of all IVPDCMM
peaks is substantially higher than that for IVPD1DMRI , with mean dierences
in the order of 1 to 1.5mmHg. While correlation coecients are relatively
high for the E-wave and the deceleration peaks (close to 0.8), there is virtually
no correlation for the A-wave magnitude.
When incorporating the 2D velocity information in the IVPD estimate
and comparing IVPD2DMRI with IVPDCMM , the correlation deteriorates for
the E-wave and ow reversal pressure dierence.is is not unexpected, as
we are now comparing a 1D technique with a 2D technique. Again, pressure
gradients are substantially higher (about 1mmHg on average) when derived
from CMM images. Several factors may contribute to this dierence. First,
it is impossible to have identical integration paths (points P1 and P2) in
ultrasound and MRI. In MRI, the integration path is based on a 2D image
that is processed o-line; with ultrasound, the integration path is dened
by the operator aligning the ultrasound beam from the apex to the base.
Also, the integration path is not necessarily the same due to the dierence in
the access window for example, being longer with ultrasound in our study
(MRI = 5.10 ± 1.02cm, CMM = 7.57 ± 0.62cm). is would lead to larger
instantaneous pressure dierences. Second, there are intrinsic dierences in
the physical principles underlying the velocity estimation by the MRI and
ultrasound imaging techniques.ird, dierent soware is used to process
the data. Fourth, images are not acquired simultaneously (within a time
frame of a week) and with the patient in (slightly) dierent positions.
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It is clear from the above that straightforward and direct comparison of
the dierent methods is extremely hard in an in vivo setting, which was the
main rationale for setting up the CFDmodel simulations. Taken together, our
data indicate that (i) IVPDs based on 2D velocity information (as acquired
byMRI) are more accurate than IVPDs derived from 1Dmethods and (ii) the
correlation between IVPDs estimated from CMM and MRI-based methods
is relatively poor.
In this study, we mainly focused on technical aspects related to the com-
putation of IVPDs from ow velocity data acquired from colour Doppler
ultrasound or 2D phase-contrast MRI and demonstrated (via the computer
model study) that the accuracy of the calculation is signicantly enhanced
when accounting for the multidirectionality of the ow velocity vectors.is
is particularly true for the pressure dierence in mid- to late diastole, when
diastolic vortex formation generates complex intraventricular ow patterns
in an enlarged cavity. From a clinical perspective, most diagnostic infor-
mation is probably to be gained from the peaks related to the early lling
wave, where the ability of the ventricle to forcefully relax, “suck in” the blood,
and generate large IVPDs links to the active relaxation properties of the
myocardium. Nonetheless, larger studies would be needed to make stronger
statements on the clinical utility of pressure-related parameters that can be
derived from velocity data. Such studies should ideally be based on 2D (or
3D) MRI ow velocity data to allow assessing the added value of analysing
pressure dierences in mid- to late diastole.
4.2.5 Limitations of the study
Our study has some intrinsic limitations. First, the CFDmodel is idealized in
terms of anatomy and physiology and we did not study the performance of
the methods over a wide range of LV sizes and EFs. Nonetheless, the model
is representative for the patients studied, i.e., patients with preserved systolic
function and EF (> 50%). We did run simulations in a model with an EF of
49%, with virtually identical conclusions regarding the comparison of the
dierent methods (data not shown). Second, MRI and CMM images were
obtained in dierent moments, in some cases within a week, and therefore,
baseline conditions were certainly dierent, making a direct comparison of
the results dicult.
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4.2.6 Conclusions
In conclusion, our modelling data indicate that methods incorporating 2D
velocity information, as can be acquired via phase-contrast MRI, provide
more accurate estimates of IVPDs. At the same time, this study also pinpoints
diculties in validating these new measures against CMM-based data, the
presumed gold standard method. More research is warranted, and in vivo
validation of MRI-based methods is ideally based on invasive recordings of
IVPDs.
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4.3 Noninvasive Intraventricular Pressure Differences
Estimated with CardiacMRI in Subjects withoutHeart
Failure and withHeart Failure with Reduced and Preserved
Ejection Fraction
4.3.1 Introduction
Section 4.1 described two major HF subtypes, HFrEF and HFpEF, whose
dierences may impact clinical outcomes. us, characterisation of these
subtypes is relevant to have a better understanding of the nature of physiologic
abnormalities in HF patients, both for diastolic and systolic function.
Although echocardiography is the standardmethod for assessing diastolic
function, it has intrinsic limitations. In contrast, cardiac MRI can measure
2D or 3D velocity vectors in a plane or volume, with more accurate and
reproducible measurements [190]. Moreover, MRI is increasingly utilised
for the evaluation of cardiac function [58], [101], [191] and represents an
alternative to better assess the intraventricular ow and, through it, linked
by mathematical expressions, the IVPDs, as results in section 4.2 suggest.
erefore, the aim of this study is to demonstrate the feasibility of an
MRI-based method to characterise IVPDs throughout diastole and systole.
4.3.2 Methods
We prospectively enrolled a sample of patients at the Corporal Michael J.
Crescenz VAMedical Center.e protocol was approved by the Philadelphia
VA Medical Center Institutional Review Board, and all subjects provided
written informed consent.
HFrEF was dened as a symptomatic HF in the presence of a LVEF <
50%. HFpEF was dened as the presence of all of the following: 1) NYHA
class II-IV symptoms consistent with HF; 2) LVEF > 50%; 3) mitral inow
early diastolic (E-wave) to annular tissue velocity (e’) ratio > 14, [84] or at
least 2 of the following: (a) an average mitral E/e’ ratio > 8; (b) treatment with
a loop diuretic for control of HF symptoms; (c) LA volume index > 34mL/m2
of body surface area (BSA); (d) NT-pro B-type natriuretic peptide level >
200pg/mL; (e) LV mass index > 149g/m2 in men and 122g/m2 in women
(measured by cardiac MRI) [92]. No-HF subjects had an LVEF > 50%, no
signicant valvular disease, and no symptoms and signs consistent with HF
[93].
Key exclusion criteria were: 1) claustrophobia; 2) presence of metallic ob-
jects or implanted medical devices in body; 3) more than mild aortic stenosis;
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4) atrial brillation; 5) conditions that would make the study measurements
less accurate or unreliable (i.e., arrhythmia aecting cardiac gating, inability
to perform an adequate breath hold for cardiac MRI acquisitions); 6) known
inltrative or hypertrophic cardiomyopathy, or extracardiac amyloidosis or
sarcoidosis [93].
4.3.2.1 Doppler echocardiography
Doppler transthoracic echocardiography was performed at rest with the
patient in supine position using a Vivid E9 device (GE Healthcare, Horten,
Norway), equipped with a cardiac probe.
4.3.2.2 2D Phase Contrast imaging acquisition and processing
Intraventricular ow velocities were measured with phase-contrast MRI,
using a 1.5T MRI scanner (Avanto system, Siemens Healthcare, Erlangen,
Germany). A phase contrast gradient echo pulse sequence with in-plane
velocity encoding was applied using retrospective gating in a plane corres-
ponding to the 3-chamber view (“LV outow tract view”) in which both the
mitral inow and the LV outow are well visualised. We performed two
consecutive breath-held acquisitions, each with in-plane velocity encoding
in 1 direction. Both acquisitions were merged o-line to obtain the in-plane
2D-velocity maps. Images were obtained with the following imaging para-
meters: TE = 2.7ms, TR = 4.8ms, temporal resolution = 39.8ms, bandwidth =
450Hz/pixel , eld-of-view = 360x360mm2, matrix = 152 − 192x256, spatial
resolution = 1.88x1.88mm2, slice thickness = 6mm, ip angle = 20○. Max-
imal velocity encoding was usually set at 130cm/s but adjusted during the
examination to avoid aliased velocity measurements.
4.3.2.3 Image processing and computation of IVPDs
AMATLAB® (MathWorks, Natick, MA) custom-designed graphic user in-
terface was programmed to process all phase-contrast MRI sequences.e
pressure dierence between two points in a plane (the scanning plane) can
be calculated from the 2D planar velocity information as [58]:
IVPD =∑
i
⎡⎢⎢⎢⎢⎣(∂P∂x )i ∆xi + (∂P∂y )i ∆yi
⎤⎥⎥⎥⎥⎦ (4.10)
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with pressure derivatives linked through the Euler equation to the 2D-
velocity information:
∂P
∂x , y
= −ρ [∂vx ,y
∂t
+ vx ∂vx ,y∂x + vy ∂vx ,y∂y ] (4.11)
with v the 2D-component vector (vx , vy) of local blood velocity and ρ,
blood density (1060kg/m3).
For the assessment of diastolic IVPDs, 2-4 reference points were placed
inside the LV along the inow direction at themitral annulus (Point 1, P1) and
the LV apex (Point 2, P2) (gure 4.9A and gure 4.9B). For the assessment of
systolic IVPDs, 2-4 reference points were placed along the outow direction,
from the LV apex (P1) to the aortic annulus (P2) (gure 4.9E and gure 4.9F).
To note, points were: 1) placed using the frame with the best anatomical
view of the structures, and 2) stationary through the whole cardiac cycle. A
pseudo-CMM image was calculated projecting velocity components within
the path delimited by the reference points and displayed for processing visual
guidance (gure 4.9C and gure 4.9G).
Available velocity components were used to calculate pressure gradient
elds and dierences.en, interpolated values along the line delimited by
P1 and P2 were used to solve equation (4.10), applying a direct integration
method [58] to obtain the IVPD curves (gure 4.9D and gure 4.9H).
4.3.2.4 Statistical analysis
Descriptive data are presented as mean ± standard deviation (SD) or mean
(95% Condence Interval, CI) for continuous variables or counts (%) for cat-
egorical variables. Dierences between groups were determined by one-way
ANOVA and adjusted for potential confounders (ANCOVA). Physiologic
indices were expressed as absolute values as well as absolute dierences
between measurements (with 95%CIs). A P-value < 0.05 was considered
statistically signicant. We presented a model with unadjusted data, and
three adjusted models: Model 1) adjusted for clinical data (age, sex, African
American ethnicity, BMI, Coronary Artery Disease, eGFR and beta-blocker,
ACE-Inhibitor/ARB, loop diuretic, and spironolactone use); Model 2) Model
1 additionally adjusted for echo parameters (mitral E-wave velocity, E-wave
deceleration time, mitral annular e’ septal); Model 3): Model 2 addition-
ally adjusted for MRI data (LV mass index and EDVI). Statistical analyses
were performed using MATLAB® statistics and machine learning toolbox
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Figure 4.9: Graphical description of the phase-contrast MRI sequence pro-
cessing to assess diastolic function (le column) and systolic function (right
column). A) and E) Original magnitude images and B) and F) calculated velocity
vectors images, showing the reference points selection, located at: Le) the mitral
annulus (P1) and LV apex (P2); and Right) LV apex (P1) and aortic annulus (P2). C)
and G) the pseudo CMM image, calculated from the 2D velocity vectors, was used as
quality reference of the IVPD curves. Calculated IVPD curves (solid black line): D)
during diastole, showing the (i) E-wave (E-IVPD), (ii) reversal E-wave (ER-IVPD)
and (iii) A-wave (A-IVPD) pressure peaks, and H) during systole, showing the (i)
S-wave (S-IVPD) and (ii) reversal S-wave (SR-IVPD) pressure peaks. C-D and G-H
are aligned in time, respectively. Important to remark, the colour scale in B, C, F and
G is a visual guidance for the user during the processing, and the linear (2 points) or
the curvilinear (4 points) approximations could be selected by the user for diastolic
and/or systolic analysis. Figure adapted from [1].
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(MATLAB® 2016b, the Mathworks; Natwick, MA) and SPSS for Mac v22
(SPSS Inc., Chicago, IL).
4.3.2.5 Reproducibility and repeatability assessment
To test the method’s reproducibility (measurements performed by two dif-
ferent operators at least one year apart) and repeatability (measurements
performed by the same operator at least one week apart), 10 cases (included
in the study) were assessed, calculating the Pearson r-value squared (r2), the
sum of squared error (SSE) and the reproducibility coecient (RPC).
4.3.2.6 Echocardiographic/MRI correlation assessment
To evaluate the potential added value of the proposed technique, correlation
coecients were calculated between selectedMRI parameters and established
Doppler-echocardiographic indices of diastolic function.
4.3.3 Results
General characteristics of the study population are shown in table 4.5.e
mean age of participants with HFrEF, HFpEF and without HF was 65.9, 62.9
and 61.8 years, respectively.e HFrEF group demonstrated a high preva-
lence of hypertension, diabetes, coronary artery disease and pronounced LA
enlargement. Consistent with the HFpEF phenotype, subjects in this group
were obese and had a high prevalence of hypertension and diabetes. Most
subjects withHFrEF andHFpEFwere receiving beta blockers, ACE inhibitors
or ARBs, and loop diuretics.e study sample was composed predominantly
of males, with a high proportion of African-Americans, particularly in the
HFrEF group.
In all three groups (No-HF, HFrEF and HFpEF), subjects exhibited, in
general, consistent IVPD patterns described previously using CMM echocar-
diography [98], [101], [134], [162] or cardiacMRI [58], [148], [192] (gure 4.9D
and gure 4.9H).e diastolic period of the calculated IVPD waveforms was
typically characterised by (i) a large early diastolic forward positive dierence
(E-IVPD) during ventricular relaxation, associated with early diastolic rapid
lling; (ii) an early diastolic negative peak associated with the deceleration
of the early lling (ER-IVPD); (iii) a second, late diastolic, positive peak
(A-IVPD) associated with atrial contraction (see gure 4.9D).e systolic
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Table 4.5: General characteristics of study subjects.
Variable
No-HF
(n = 159)
HFrEF
(n = 47)
HFpEF
(n = 32) P-value
Age [years] 61.8 ± 11.5 65.9 ± 10.7 62.9 ± 8.6 0.09
Male 145(91) 46(98) 28(88) 0.18
Race
African-American 72(45) 31(66) 16(50) 0.04†
Caucasian 74(47) 15(32) 15(47) 0.20
BMI [kg/m2] 29.5(25.7, 33.1) 27.9(24.2, 32.9) 35(29.3, 41.7) 0.0007§‡
Heart rate [bpm] 68.9 ± 13 69 ± 11.9 67.4 ± 11.9 0.84
Ejection duration [ms] 319 ± 30 311 ± 47 325 ± 33 0.27
Current smoker 43(28) 15(33) 8(25) 0.73
Hypertension 118(75) 41(89) 29(91) 0.03
Diabetes 64(41) 27(59) 18(56) 0.04†
Coronary artery disease 47(30) 24(51) 11(34) 0.03†
Drug therapy
Beta blocker 74(47) 43(91) 24(75) < 0.0001†§
ACE-inhibitor/ARB 80(51) 37(79) 26(81) < 0.0001†§
Calcium-channel blocker 41(26) 12(26) 13(41) 0.23
Spironolactone 3(2) 6(13) 4(13) 0.002†§
Statin 103(65) 36(77) 21(66) 0.33
Aspirin 84(53) 37(79) 19(59) 0.007†
iazide 34(22) 11(23) 5(16) 0.74
Loop diuretics 2(1) 35(74) 23(72) < 0.0001†§
eGFR (mL/min/1.73m2)* 86(65, 99.8) 74(56.5, 92.3) 84(63, 99) 0.056†
Le ventricular ejection fraction [%] 59.6(52.2, 65.6) 36.6(23.7, 42.5) 61.4(58, 70.3) < 0.0001†‡
LA Volume Index [mL/m2] 30.7(23.8, 39.5) 46.1(35.7, 65.3) 36.6(26.4, 49.9) < 0.0001†
LV EDVi [mL/m2] 69.9(58.4, 82.4) 102.7(85.8, 141.4) 69.1(56.7, 79.5) < 0.0001†‡
LV mass index BSA [g/m2] 64.5(56.9, 76.5) 88.6(77.9, 107.1) 72(59.3, 83.2) < 0.0001†‡
Mitral E-wave velocity [cm/s] 69.5(58.1, 85.5) 74.3(54.7, 93.6) 69.6(60.5, 92.7) 0.54
Mitral E-wave deceleration time [ms] 210(170, 240) 180(140, 220) 220(170, 270) 0.06
Mitral A-wave velocity [cm/s] 74.6 ± 21.7 62.3 ± 22.3 74.7 ± 19.6 0.008†
Mitral annular e’, septal [cm/s] 7.58(5.9, 9.65) 5.61(4.12, 7.9) 6.77(5.24, 8.19) 0.0007†
Values are mean ± SD or mean(95%CI), or counts(percentages). *eGFR was calculated using the
Modication of Diet in Renal Disease (MDRD) Study equation. † P < 0.05 for No-HF vs. HFrEF. ‡ P <
0.05 for HFrEF vs. HFpEF. § P < 0.05 for No-HF vs. HFpEF. eGFR = estimated glomerular ltration
rate; ACE = Angiotensin convertase enzyme; ARB = Angiotensin receptor blocker.
period was characterised by a typical biphasic conguration with (i) a large
forward positive peak (S-IVPD) associated with ventricular systole (rapid
ejection) followed by (ii) a negative peak (SR-IVPD) associated with ow de-
celeration (slow ejection phase) (see gure 4.9H). Selected IVPD parameters
are shown and compared in table 4.6, and gure 4.10 and gure 4.11.
4.3.3.1 Diastolic IVPDs
Unadjusted comparisons demonstrated no signicant dierences in E-IVPD
(No-HF = 0.76; HFrEF = 0.83; HFpEF = 0.83mmHg; P = 0.63) and A-
IVPD (No-HF = 0.93; HFrEF = 0.72; HFpEF = 0.92mmHg; P = 0.07)
between the groups (table 4.6 and gure 4.10). In contrast, ER-IVPD was
signicantly dierent between the groups (ANOVA P = 0.01), consistent
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Figure 4.10: Comparison of IVPDs between groups for the unadjusted model.
Computed parameters from diastole (le) and systole (right) are shown. Error bars
represent 95% Condence Intervals. Figure adapted from [1].
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Figure 4.11: Selected IVPD parameters (ER and SR – wave pressure peaks) with
statistically signicant dierences between groups for adjusted models: Top)
AdjustedModel 1. Middle) AdjustedModel 2. Bottom) AdjustedModel 3. Computed
parameters from diastole (le) and systole (right) are shown. Error bars represent
95% Condence Intervals. Figure adapted from [1].
130
4.3. In vivo assessment of MRI-based IVPDs estimation
with a more pronounced reversal of the early diastolic IVPD in HFpEF
(−1.30mmHg) compared to the No-HF group (−0.78mmHg) and the HFrEF
group (−0.75mmHg). Aer adjustment for age, sex, African American eth-
nicity, BMI, coronary artery disease, eGFR and medication use (adjusted
model 1), these dierences in ER-IVPDs persisted (No-HF = −0.76; HFrEF
= −0.85; HFpEF = −1.35mmHg; P = 0.02). Similarly, these dierences were
present aer further adjustment for Doppler-echocardiographic parameters
(adjusted model 2: No-HF = −0.68; HFrEF = −0.99; HFpEF = −1.48mmHg;
P = 0.009) and LV structure (adjusted model 3: No-HF = −0.72; HFrEF =−0.87; HFpEF = −1.52mmHg; P = 0.006) (see gure 4.11).
4.3.3.2 Systolic IVPDs
In unadjusted analyses (table 4.6 and gure 4.10), there were signicant
dierences between groups in S-IVPD (No-HF = 1.7; HFrEF = 1.41; HFpEF =
1.99mmHg; P = 0.01) and SR-IVPD (No-HF = −1.15; HFrEF = −0.90; HFpEF
= −1.37mmHg; P = 0.04), withmore pronounced IVPDs in the HFpEF group
compared to the HFrEF group. Between-group dierences in SR-IVPD were
also present aer adjustment for general clinical characteristics and Doppler-
echocardiographic parameters (adjusted model 2; table 4.6 and gure 4.11),
but no signicant dierences in systolic IVPDs were found between the
groups aer further adjustment for LV structure (adjusted model 3; table 4.6
and gure 4.11).
4.3.3.3 Reproducibility and repeatability assessment
Higher reproducibility was demonstrated for diastolic E-IVPD and ER-IVPD
parameters (r2 ≥ 0.70; SSE ≤ 0.58; RPC ≤ 0.55) in comparison with A-
IVPD (r2 = 0.56; SSE = 0.98; RPC = 0.65) and systolic parameters (S-IVPD:
r2 = 0.04; SSE = 5.3; RPC = 1.6; SR-IVPD: r2 = 0.47; SSE = 1.3; RPC = 0.76).
is trend was maintained for the repeatability assessment, albeit altogether
higher indexes were found in this case (diastolic parameters: r2 ≥ 0.92; SSE≤ 0.21; RPC ≤ 0.32; systolic parameters: r2 ≥ 0.71; SSE ≤ 1.6; RPC ≤ 0.87).
4.3.3.4 Echocardiographic/MRI correlation assessment
ere were only weak correlations between standard Doppler-
echocardiographic parameters and IVPD parameters (R < 0.20 for
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Table 4.6: Comparisons of diastolic and systolic intraventricular pressure dierence
parameters between the groups.
Variable
No-HF
(n = 159)
HFrEF
(n = 47)
HFpEF
(n = 32) P-value
Unadjusted Model
E-IVPD [mmHg] 0.76(0.68, 0.84) 0.83(0.67, 0.98) 0.83(0.64, 1.02) 0.63
ER-IVPD [mmHg] −0.78(−0.93,−0.63) −0.75(−1.02,−0.47) −1.30(−1.60,−0.99) 0.01§‡
A-IVPD [mmHg] 0.93(0.85, 1.02) 0.72(0.56, 0.88) 0.92(0.73, 1.11) 0.07
S-IVPD [mmHg] 1.7(1.56, 1.84) 1.41(1.16, 1.65) 1.99(1.65, 2.34) 0.01‡
SR-IVPD [mmHg] −1.15(−1.28,−1.02) −0.90(−1.17,−0.64) −1.37(−1.64,−1.10) 0.04‡
Adjusted Model 1
E-IVPD [mmHg] 0.75(0.65, 0.85) 0.86(0.64, 1.08) 0.85(0.61, 1.08) 0.70
ER-IVPD [mmHg] −0.76(−0.95,−0.56) −0.85(−1.23,−0.47) −1.35(−1.72,−0.97) 0.02§
A-IVPD [mmHg] 0.94(0.83, 1.05) 0.71(0.49, 0.92) 0.94(0.70, 1.17) 0.15
S-IVPD [mmHg] 1.7(1.52, 1.89) 1.49(1.14, 1.84) 1.89(1.47, 2.3) 0.16
SR-IVPD [mmHg] −1.15(−1.32,−0.98) −0.94(−1.30,−0.58) −1.34(−1.67,−1) 0.14
Adjusted Model 2
E-IVPD [mmHg] 0.84(0.71, 0.97) 0.93(0.67, 1.19) 0.79(0.54, 1.04) 0.62
ER-IVPD [mmHg] −0.68(−0.92,−0.45) −0.99(−1.41,−0.56) −1.48(−1.87,−1.08) 0.009§
A-IVPD [mmHg] 0.97(0.84, 1.11) 0.75(0.50, 1.00) 0.97(0.72, 1.22) 0.27
S-IVPD [mmHg] 1.72(1.49, 1.96) 1.46(1.03, 1.89) 1.86(1.39, 2.33) 0.25
SR-IVPD [mmHg] −1.17(−1.34,−0.99) −0.83(−1.21,−0.46) −1.32(−1.64,−1.01) 0.04‡
Adjusted Model 3
E-IVPD [mmHg] 0.85(0.72, 0.99) 0.91(0.63, 1.20) 0.79(0.54, 1.05) 0.76
ER-IVPD [mmHg] −0.72(−0.96,−0.49) −0.87(−1.34,−0.40) −1.52(−1.92,−1.13) 0.006§‡
A-IVPD [mmHg] 0.98(0.85, 1.12) 0.73(0.46, 1.00) 0.99(0.73, 1.24) 0.24
S-IVPD [mmHg] 1.74(1.5, 1.98) 1.47(1.01, 1.92) 1.86(1.37, 2.34) 0.34
SR-IVPD [mmHg] −1.17(−1.35,−0.99) −0.86(−1.25,−0.47) −1.31(−1.64,−0.99) 0.11
Data are presented as mean (95%CI). † P < 0.05 for No-HF vs. HFrEF. ‡ P < 0.05 for HFrEF vs. HFpEF.
§ P < 0.05 for No-HF vs. HFpEF.
Unadjusted Model; Adjusted Model 1: adjusted for clinical data (age, sex, African American ethnicity,
BMI, Coronary Artery Disease, eGFR and Beta Blocker, ACE-Inhibitor, ARB, loop diuretic, and
spironolactone use); Adjusted Model 2: Model 1 additionally adjusted for echo parameters (Mitral
E-wave velocity, E-wave deceleration time, Mitral annular e’ septal); Adjusted Model 3: Model 2
additionally adjusted for MRI data (LV mass index and EDVI).
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all, except for the correlation between ER-IVPD and peak A-wave
velocity (R = −0.30)). Correlation coecients between standard Doppler-
echocardiographic indices of diastolic function and IVPD parameters are
presented in gure 4.12.
Figure 4.12: Correlation coecients between echocardiographic and MRI-
based IVPDs parameters, showing the correlation between IVPD (MRI-based)
parameters: E-wave pressure peak (E-IVPD), E-wave reversal pressure peak (ER-
IVPD), A-wave pressure peak (A-IVPD), S-wave pressure peak (S-IVPD) and S-wave
reversal pressure peak (SR-IVPD); and echocardiographic parameters: peak E and
A-wave velocities by Doppler (E and A-Vel), deceleration time (Dec-time), e’ velocity
(lateral (e’-lat) and septal (e’-sep)) and E/e’. Figure adapted from [1].
4.3.4 Discussion
We compared diastolic and systolic IVPDs between subjects with HFrEF,
HFpEF or No-HF. We found physiologically expected patterns of IVPD in
all 3 groups, with signicant dierences in diastolic IVPDs. Specically, sub-
jects with HFpEF exhibited more pronounced reversal peak of early diastolic
IVPDs, which was independent of clinical parameters, echocardiographic
parameters of LV lling, and LV structure assessed by MRI. Subjects with
HFrEF demonstrated a non-signicant trend of increasing E-IVPD and
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decreasing A-, S- and SR-IVPD. Our ndings suggest distinct patterns of
diastolic and systolic IVPDs and dierences in the nature of both diastolic
and systolic dysfunction between HF subtypes. IVPD parameters demon-
strated only weak correlations with standard Doppler-echocardiographic
parameters.
Previous studies have shown that, despite being small in magnitude,
IVPDs have a signicant role in ecient lling and emptying of the LV and
could be used to characterise cardiac performance [57], [193]. However, the as-
sessment and interpretation of IVPGs and IVPDs in clinical practice remains
complicated by its dependency on a large number of factors and interac-
tions [84], [194]. Furthermore, ow occurs in multiple and rapidly changing
directions, forming complex vortex patterns [84], [193].e complexity of
intraventricular ow and technical limitations of ultrasound imaging, the
standard method in cardiovascular assessment, make it dicult to relate
intraventricular ow patterns and derived IVPDs to LV myocardial function
in a quantitative manner [84], [193], [194].
e increasing availability of cardiovascular MRI has made it an advanta-
geous alternative from a technical point of view due to its high image quality,
reproducibility, repeatability, plane of view exibility, sucient spatial and
temporal resolution and reduced operator dependency. Furthermore, MRI-
based IVPD calculations allow for a more exible denition and alignment
of the operator’s “scan line”, which could be relevant when the blood ow
exhibits a curved trajectory [134]. Additionally, 2D-velocity information from
phase contrast MRI improves the accuracy of IVPDs even if the temporal
resolution, a critical parameter to calculate IVPDs [189], is lower in compar-
ison with ultrasound. In fact,ompson et al. [58] reported that a minimum
temporal resolution of 44ms may avoid signicant underestimation of the
local acceleration contribution to the total intracardiac pressure dierences.
Previously, making use of computational uid dynamics simulations, we as-
sessed the impact of temporal resolution in IVPD calculations, showing that
the temporal resolution of phase contrast MRI is, at least in theory, sucient
to resolve IVPDs. Furthermore, we also showed that IVPDs estimated by a
1D method as colour-Doppler ultrasound are larger in magnitude than when
the 2D velocity information was used, but the estimates based on 2D velocity
information are more accurate, especially in extreme scan line misalignments
[2], which could be particularly sensible aer mid- and late diastole due to
formation of vortices [57], [162]. We speculate that this explains, at least
partly, some of the dierence between values reported here and in other
studies [56], [98], [101], [134].
ere were no signicant dierences in E- and A-IVPD between the
groups.is may be a consequence of early lling pseudonormalization due
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to greater lling pressures. Additionally, in HFpEF patients, pronounced
diastolic abnormalities can oen be elicited only during physiologic perturba-
tions, such as exercise or dobutamine infusions [135], [158], [179], as subjects
with HFpEF exhaust their reserve to preserve the diastolic suction force at
rest, limiting their ability for adaptation to stress [135], [179]. Nonetheless,
our results demonstrate that HFpEF is associated with a greater magnitude
of the ER-IVPD. Although, the slope of mitral inow deceleration tempor-
ally coincides with ER-IVPD, it is interesting to note that we did not nd
signicant dierences in the deceleration time between the groups, and that
ER-IVPD was not strongly related to the deceleration time.erefore, our
data suggests that ER-IVPD may be a more sensitive marker of diastolic
function in HFpEF.
We also examined systolic IVPDs. A typical biphasic IVPD pattern was
observed in systole, with a positive peak immediately followed by a negative
one. HFrEF individuals exhibited lower values, whereas the HFpEF group
presented an overall higher total magnitude of S-IVPD and SR-IVPD, suggest-
ing dierences in systolic ow dynamics between groups.ese dierences
could be related to the unsteady nature of ejective ow, abnormalities in
chamber geometry, and/or the sequence of regional contraction [193].
Our reproducibility and repeatability assessments suggest a general ad-
equate inter and intra-operator variability for early diastolic IVPDparameters.
Reproducibility and repeatability were lower for A-IVPD, probably due to a
more complex ow aermid- and late diastole [57], [162]. Systolic parameters
evidenced a need to rene the standardisation of the method, particularly
for S-IVPD.e overall correlation between IVPD parameters and echocar-
diographic indexes was weak or non-existent. In fact, previous publications
have pointed out a weak correlation between Doppler echocardiographic
estimates of LV lling pressure with invasive lling pressure measurements
and the necessity to include further analysis of non-invasive measures [195],
[196]. In contrast, echocardiographic [101], [134] and MRI [58] based IVPD
parameters have shown good agreement against invasive intraventricular
measurements, adding potentially relevant information for cardiovascular
assessments.
e reported data should be interpreted considering the strengths and
limitations of the study. Strengths of this study are the inclusion of patients
with HFrEF and HFpEF, and the assessment of IVPDs with phase-contrast
MRI, which overcomes a number of assumptions made with CMM echocar-
diography and allows for a more consistent interrogation of intraventricular
ow. Our study also has limitations. We did not perform invasive catheter-
based measures of distensibility which would have been unfeasible in the
absence of a clinical indication for LV catheterisation. From a technical
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point of view, the MRI acquisition requires relative long breath-holds (∼ 20s)
and has limited temporal and through plane spatial resolution, while the
processing could be aected by the image alignment and assumptions made
about the nature of ow from the 3 chambers view. Upon computation of the
IVPDs, viscous forces are neglected and it is assumed that inow and outow
is laminar [56], [134], [135]. On average, our HFpEF subjects did not have
marked LA enlargement, suggesting the presence of mild HFpEF.is may
have led to underestimations of true underlying dierences. Our population
was a clinical sample referred for a cardiac MRI study, which may not fully
represent population-based trends. Moreover, complementary myocardial
mechanic studies could be included to improve the analysis [197].
4.3.5 Conclusions
In conclusion, we demonstrated the feasibility to assess IVPDs throughout
the cardiac cycle using phase-contrast MRI and compared IVPDs between
subjects without HF and subjects with HFrEF and HFpEF. Our ndings
suggest distinct patterns of diastolic IVPDs in HFpEF, implying dierences in
the nature of diastolic dysfunction between theHF subtypes. Further research
is warranted to exploit MRI analysis thoroughly to assess the signicance of
these novel indices regarding risk stratication and response to therapy.
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Vascular Function
As cardiac function (see Chapter 4), vascular function is a key factor for the
appropriate operation of the cardiovascular system and, therefore, vascular
assessment is becoming a fundamental step in clinical practice. Several mech-
anisms, including metabolic, neural, myogenic and humoral/endothelial,
regulate vascular function and peripheral blood ow, concerning complex in-
teractions determined partly by environmental conditions.e endothelium,
for example, inuences vascular tone by releasing vasoactive molecules, such
as nitric oxide (NO). Concretely, NO acts on smooth muscle cells producing
a dilatation of blood vessels and, thus, increasing blood supply and reducing
blood pressure (BP). In fact, the major eect of the use of NO therapeutics
(nitrate [NO−3 ] or nitrite [NO−2 ]) in the cardiovascular system is the relax-
ation of smooth muscle in veins, larger arterioles and arteries through an
endothelial pathway, termed the nitrate–nitrite–NO pathway.us, it has
been hypothesized that the use of nitrates has a positive eect in the treatment
of cardiovascular dysfunction, even if there is still a gap between research
and epidemiological evidence, particularly related to the use of nitrates for
the treatment of patients with heart failure with preserved ejection fraction
(HFpEF). As it was stated in Chapter 1, although the morbidity and mortal-
ity rates are comparable in patients with heart failure and reduced ejection
fraction (HFrEF) and in patients with HFpEF, the recognition, evaluation,
and treatment of the later remains a challenge.
is chapter entails a research study on non-invasive assessment of arte-
rial properties, the interaction between the cardiac pump and the peripheral
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circulation and the impact on them by the employment of organic and inor-
ganic nitrates in a HFpEF sample population.e rst section introduces the
evaluation of vascular function through classical haemodynamic assessment
in time and frequency (Fourier transform) domains, including the analysis
of pressure-ow waveforms, wave separation and wave intensity.is study
was published in the European journal of heart failure under the title ”Eects
of organic and inorganic nitrate on aortic and carotid haemodynamics in heart
failure with preserved ejection fraction”, vol. 19, no. 11, pp. 1507-1515, 2017 [4].
e second section of the chapter describes the implementation of a novel
analysis proposed by Mynard et al. [70] to evaluate wave power transmission
into the cerebrovascular circulation, a research based on the article titled
”Eect of organic and inorganic nitrates on cerebrovascular pulsatile power trans-
mission in patients with heart failure and preserved ejection fraction” published
in Physiological measurement, vol. 39, no. 4, pp. 044001, 2018 [3].
5.1 Effects of organic and inorganic nitrate on aortic and
carotid haemodynamics in heart failure with preserved
ejection fraction
5.1.1 Introduction
Heart failure (HF) aects around 2% of thewestern population and is themost
common cause of hospitalisation in adults >65 years of age. Approximately
half of patients withHFhave a preserved le ventricular (LV) ejection fraction
(HFpEF) [33]. Multiple eective pharmacological therapies that result in
substantial clinical benet in HF with reduced ejection fraction are available.
In contrast, there are currently no proven eective pharmacological therapies
to improve outcomes in HFpEF.
Pulsatile arterial load exerts important eects on LV function and re-
modelling. In particular, wave reections originating at the periphery and
conducted back to the heart, have been shown to cause LV diastolic dysfunc-
tion, hypertrophy and brosis in experimental models, a concept supported
by an increasing body of human studies [165], [172]–[175], [177]. Acute ad-
ministration of organic nitrates has been shown to reduce wave reections
arriving at the central aorta in hypertensive or healthy subjects in some, but
not all studies [198]–[204].e eects of organic nitrates on pulsatile arterial
haemodynamics have not been well characterised in HFpEF. In recent trials
in patients with HFpEF [205]–[207], organic nitrates have not only been
poorly tolerated but have also been linked to important side eects such as
hypotension and headaches, suggesting adverse eects on the cerebrovascular
territory.
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In contrast to the unfavourable eects of organic nitrates in HFpEF, re-
cent randomized controlled trials have demonstrated that inorganic nitrate,
administered as a single dose [208] or aer one week of sustained adminis-
tration [209], improves exercise capacity in patients with HFpEF. Inorganic
nitrate undergoes a two-step reduction to NO via the nitrate–nitrite–NO
pathway [210], [211].e conversion of nitrite to NO occurs in conditions
of hypoxia and acidosis, but a recent report indicates that it also occurs via
paradoxical normoxic activation in conduit arteries [212], indicating poten-
tial eects on pulsatile arterial haemodynamic function and arterial wave
reections. Furthermore, in contrast to the frequent occurrence of headache
with organic nitrate, the administration of inorganic nitrate has not been
associated with headaches or other side eects in two recent trials in this
population [208], [209].
We aimed to assess the eect of organic and inorganic nitrate in HFpEF
on (i) wave reections arriving at the central aorta, and (ii) carotid arterial
haemodynamics (i.e. to characterise cerebrovascular eects).
5.1.2 Methods
We performed two sub-studies. In the rst sub-study (sub-study 1), we
assessed aortic and carotid haemodynamics at baseline and aer the adminis-
tration of 0.4mg of sublingual nitroglycerin (NTG). In the second sub-study
(sub-study 2), we analysed aortic and carotid pressure–ow data from our
previous randomized controlled trial of inorganic nitrate administration in
HFpEF [208]. Protocols were approved by the University of Pennsylvania and
Philadelphia VA Medical Center Institutional Review Boards, as appropriate.
All subjects provided written informed consent.
5.1.2.1 Study population
For sub-study 1, we included subjects with HFpEF who met the following
criteria: (i) symptomatic HF with a LV ejection fraction > 50%; (ii) at least
one of the following within one year prior to consent: hospitalisation for
decompensated HF, acute treatment for HF with intravenous diuretics or
haemoltration, chronic treatment with a loop diuretic for control of HF
symptoms, or chronic diastolic dysfunction evidenced by le atrial (LA)
enlargement (LA volume index > 34mL/m2), or Doppler signs of increased
le atrial pressure, as dened by the European Society of Cardiovascular Ima-
ging/American Society of Echocardiography [84]; (iii) stable medical therapy.
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Key exclusion criteria were: (i) clinically signicant valve disease (more than
mild aortic/mitral stenosis or more than moderate aortic/mitral regurgita-
tion); (ii) atrial brillation/utter; (iii) current nitrate therapy; (iv) signicant
ischaemia on stress testingwithin the past year thatwas not revascularized; (v)
other clinically important causes of dyspnoea; (vi) hypertrophic, inltrative,
or inammatory cardiomyopathy; (vii) pericardial disease; (viii) primary pul-
monary arteriopathy; (ix) BP< 110/40mmHg or > 180/100mmHg; (x) resting
heart rate (HR) > 100bpm; (xi) LV ejection fraction < 50% in the past; (xii)
adverse reactions to organic nitrates or phosphodiesterase inhibitor use; (xiii)
severe renal dysfunction (glomerular ltration rate < 30mL/min/1.73m2),
or liver disease. In sub-study 2, we utilized very similar inclusion/exclusion
criteria, as previously described [208].
5.1.2.2 Study protocol
Sub-study 1
Twenty-six subjects participated in this sub-study. Aer > 10 minutes of rest
in the supine position, BP was taken in the right arm with a validated oscil-
lometric device (Omron HEM-705CP, Omron Corporation, Kyoto, Japan).
Carotid pressure (gure 5.1) was recorded via applanation tonometry, using a
SphygmoCor-CPV System (AtCor Medical, Itasca, IL, USA) equipped with a
high-delity Millar tonometer (Millar Instruments, Houston, TX, USA). Aor-
tic pressure waveforms are only obtainable through invasive measurements,
which is not applicable in clinical practice.erefore, derived measurements
should be used instead and, previously, it has been demonstrated that carotid
pressure waveforms represent reasonable surrogates of the aortic pressure
waveform [213], [214].
Pulsed-wave Doppler measurements of ow velocities in the LV outow
tract (gure 5.1) were performed using a GE-e9 ultrasound machine (GE
Healthcare, Faireld, CT, USA), with the Doppler sample immediately prox-
imal to the aortic valve leaets within the centerline of the LV outow tract.
We computed LV outow tract cross-sectional area from its radius (r) mea-
sured in the parasternal long-axis view (area = pir2). Carotid diameters and
blood velocities were also acquired, using a vascular linear probe. Carotid
ow was computed as ow velocity multiplied by lumen cross-sectional area
(area = pir2). Aer baseline measurements were obtained, a single dose
(0.4mg) of NTG was administered sublingually, and measurements were
repeated starting 2 minutes aer administration. Comparisons were made
between the measurements obtained pre- vs. post-NTG administration.
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Sub-study 2
Seventeen subjects participated in a randomized, double-blind, cross-over
study of a single dose of inorganic nitrate given as concentrated nitrate-rich
beetroot (BR) juice (NO−3 , BEET-IT Sport, James White Drinks Ltd, Ipswich,
UK) containing 12.9mmoL NO−3 in 140mL, vs. an otherwise identical nitrate-
depleted placebo (PB) juice (James White Drinks, Ltd, Ipswich, UK).e
interventions were separated by a wash-out period of at least 5 days. We
measured aortic and carotid haemodynamics using identical methods as in
sub-study 1, ∼ 2.5h aer juice ingestion. Comparisons were made between
measurements obtained aer administration of BR vs. PB juice. One subject
was excluded from these analyses due to lack of carotid ow data during one
of the study visits.
Figure 5.1: Example of pressure–ow analyses. Tonometric pressure data are
shown at the top (le), along with the signal-averaged pressure waveform (top
right, red). Doppler ow interrogations were performed, as shown at the middle
position for the carotid (le) and LV outow (right) locations. Tracing and signal
averaging of ow waveforms (bottom blue curves) was subsequently performed.
e carotid pressure waveform is used for both carotid pressure–ow analyses and
aortic pressure–ow analyses, since the carotid pressure is a good surrogate of the
aortic pressure waveform [213], [214]. Figure adapted from [4].
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5.1.3 Pressure–ow analyses
A custom-designed soware was built in MATLAB® (e Mathworks, Natick,
MA, USA) [63], [64] to process o-line central arterial tonometry recordings
and Doppler ow velocity les. A representative example of pressure–ow
data processing is shown in gure 5.1 and gure 5.2. Signal averaging was
performed rst, followed by the time alignment of both signals as previously
described [63], [215]. Time alignment of pressure and blood ow curves was
performed to maximize: (i) the rapid systolic upstroke of pressure and ow;
(ii) concordance of the pressure dicrotic notch and cessation of ow in the
LV outow tract, or the ow dicrotic notch in the carotid; (iii) linearity of
the early systolic pressure–ow relationship.
We computed aortic input impedance (gure 5.2), which characterises
the ratio of pulsatile pressure over ow in each harmonic of HR. In this
analysis, the fundamental frequency, or 1st harmonic, is the HR, and higher
harmonics are multiples of that frequency. Proximal aortic characteristic
impedance (Zc) was computed in the frequency domain. Each pressure and
ow harmonic was separated into forward and backward components using
wave separation analysis [216], [217]. We assessed the reection coecient
in the rst three harmonics.ese are the relevant harmonics for assessing
wave reections because: (i) they contain the vast majority of the pulsatile
energy in pressure and ow signals; (ii) at higher frequencies, reections
cancel out at random, and the input impedance spectrum hovers around
aortic root characteristic impedance, mimicking a reection-free system.
As the reection coecient is derived from the ratio of two sine waves, it
is a complex number with an amplitude and phase-angle, which can corres-
pond to dierent degrees of destructive or constructive interference between
forward and backward waves. erefore, the net eect of reections was
expressed as the real part of the reection coecient, which becomes in-
creasingly positive as pressure from wave reections increases (constructive
interference), and negative when destructive interference leads to a net de-
crease in pressure by wave reections at a given harmonic [218].
We also reconstructed the forward and backward pressure waves in the
time domain.e sum of forward and backward pressure harmonics yields
the forward and backward waves, respectively (gure 5.2).e time of onset
of the reected wave was dened as the time at which the reected wave starts
adding to mean pressure. We computed the Buckberg index (also known
as the sub-endocardial viability ratio), as the ratio of diastolic/systolic pres-
sure–time integrals (i.e. areas under the pressure curve).is index provides
an assessment of the eect of pulsatile haemodynamics onmyocardial oxygen
demand (systolic load) vs. supply (perfusion pressure) [215].
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Figure 5.2: Carotid (le panels) and aortic (right panels) pressure–ow pairs
are processed via mathematical analyses in the frequency domain. Top) Time
alignment result of pressure waveform (red dashed lines) and blood ow velocity
(blue dotted line) curves. Middle)e input impedance spectrum, which consists of
modulus (red) and phase (green) is obtained. Characteristic impedance (Zc, dashed
line inmodulus plot) is computed based on the averagemodulus of higher harmonics
of the input impedance modulus. Zc is a local vascular property of the aortic root or
carotid artery, which governs the local pressure–ow relation in the absence of wave
reections. Once Zc is known, the modulus and phase of the reection coecient
in the frequency domain (at each harmonic) can be computed (not shown), along
with the net contribution of reections to pressure at each harmonic (i.e. the real
part of the reection coecient). Reection coecients in the frequency domain
are derived purely from the input impedance spectrum and thus depend purely on
arterial load. e rst three harmonics contain the vast majority of the pulsatile
energy and are the relevant harmonics. Bottom)We also performed wave separation
in the time domain.is approach yields forward (green dashed line) and backward
(red dotted line) waves reconstructed in the time domain. At the aorta, forward
and backward wave amplitude and morphology in the time domain are not purely
dependent on arterial load, but depend also on re-reections in the heart and the
LV contraction pattern. Figure adapted from [4].
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We also performed analyses of carotid pressure–ow relations. Haemo-
dynamic analysis commonly assumes a parabolic or at ow velocity prole
to convert velocity measured in a sample volume into a volumetric ow. How-
ever, this simplication may be inadequate for the carotid artery, as the ow
velocity prole is neither of both. We therefore implemented a conversion
accounting for the Womersley number (a well-established dimensionless
uid-dynamics parameter for oscillatory ow), as previously described by
Ponzini et al.[68].
In our laboratory, repeated measurements of all indices from aortic and
carotid pressure–ow analyses yielded coecients of variation of 17% or less.
5.1.3.1 Statistical analysis
Descriptive data are presented as mean ± standard deviation (SD) for continu-
ous variables, or counts (%) for categorical variables. Comparisons between
pre- and post-NTG values for sub-study 1, and between values corresponding
to BR vs. PB juice administration for sub-study 2, were performed using
paired Student’s t-test. Physiologic indices were expressed as absolute values
at each time point, as well as absolute dierences between measurements
(with 95% condence intervals). Positive dierences represent an increase in
the values associated with organic/inorganic nitrate administration, whereas
negative dierences represent a decrease in such values. A two-tailed P value
of < 0.05 was considered statistically signicant. Statistical analyses were
performed using SPSS v-15 for Mac-OS and SPSS v-21 for Windows (SPSS
Inc., Chicago, IL, USA).
5.1.4 Results
General characteristics of the study populations for sub-studies 1 and 2 are
shown in table 5.1.e characteristics of study subjects in both sub-studies
were very similar. In both sub-studies, subjects were obese, with a high
prevalence of hypertension and diabetes, as well as LA enlargement and a
high mitral E/e’ ratio. Both study samples were composed predominantly of
males, with a high proportion of African-Americans. All subjects in both
sub-studies had New York Heart Association class II–III symptoms.
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Table 5.1: General characteristics of study subjects.
Variable
NTG study
(sub-study 1) (n=26)
Beetroot study
(sub-study 2) (n=16) P-value
Age, years [median (IQR)] 60(56 − 65) 65(62.5 − 70.5) 0.10
Male sex 20(76.9) 14(87.5) 0.68
Race
African-American 16 (61.5) 14 (87.5)
Caucasian 9 (34.6) 2 (12.5)
BMI [kg/m2] 36.5(6.5) 34.4(3.5) 0.24
Obesity (BMI >30kg/m2) 22(84.6) 15(93.8) 0.63
Current smoker 4(15.4) 1(6.3) 0.63
Hypertension 24(92.3) 16(100) 0.52
Diabetes 17(65.4) 11(68.8) 0.82
Coronary artery disease 8(30.8) 3(18.8) 0.49
Chronic kidney disease (eGFR <60mL/min/1.73m2) 9(34.6) 5(31.3) 0.82
Drug therapy
Beta-blocker 14(53.9) 10(62.5) 0.58
ACE-inhibitor/ARB 18(69.2) 10(62.5) 0.65
Calcium-channel blocker 14(53.9) 7(43.8) 0.53
Mineralocorticoid receptor antagonist 0(0) 1(6.3) 0.38
Statin 15(57.7) 9(56.3) 0.93
Aspirin 17(65.4) 14(87.5) 0.16
iazide 14(53.9) 4(25.0) 0.07
Loop diuretic 13(50.0) 6(37.5) 0.43
Laboratory data
eGFR* [mL/min/1.73m2] [median (IQR)] 74.1(53.5 − 95.4) 65.5(52.4 − 89.5) 0.95
Echocardiography
LV ejection fraction [%] [median (IQR)] 57.4(55.0 − 65.5) 62.4(57.5 − 69.8) 0.30
Le atrial volume index [mL/m2] 30.3(10.9) 35.7(10.9) 0.13
Mitral E-wave velocity [cm/s] 81.8(24.9) 71.7(16.4) 0.16
Mitral A-wave velocity [cm/s] 79.2(24.6) 73.3(24.2) 0.45
Mitral septal tissue Doppler velocity [cm/s] 6.6(2.2) 6.5(1.7) 0.88
Mitral E/e’ ratio [median (IQR)] 12.8(11.0 − 14.4) 11.4(9.2 − 13.3) 0.17
TAPSE [cm] [median (IQR)] 2.3(2.1 − 2.6) 2.6(2.1 − 2.8) 0.44
TAPSE <1.6cm 0(0) 0(0)
Tricuspid regurgitant jet peak gradient† [mmHg] 31.8(3.7) 27.9(8.9) 0.054
LV end-diastolic diameter [cm] 4.8(0.6) 4.5(0.6) 0.12
LV mass [g] [median (IQR)] 243.7(214.1 − 318.3) 236.6(183.2 − 275.2) 0.62
LV mass indexed to height [g/m1.7] [median (IQR)] 96.9(71.7 − 114.1) 91.6(70.7 − 102.8) 0.39
LV mass indexed to BSA [g/m2] 109(23.5) 106.3(37.6) 0.77
Relative wall thickness [cm] [median (IQR)] 0.52(0.47 − 0.58) 0.59(0.54 − 0.66) 0.041
NT-proBNP [pg/mL] [median (IQR)] 250.5(90.5 − 510.6) 148.0(61.7 − 272.5) 0.16
Ejection duration [ms] 318(28) 330(35) 0.22
Values are expressed as mean±standard deviation, or number (%), unless otherwise specied.
ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; BMI: body mass index; BSA:
body surface area; eGFR: estimated glomerular ltration rate; IQR: interquartile range; LV: le
ventricular; NT-proBNP: N-terminal pro-brain natriuretic peptide; TAPSE: tricuspid annular plane
systolic excursion.
*eGFR was calculated using the modication of diet in renal disease (MDRD) study equation.
†Could be assessed reliably from the tricuspid regurgitation envelope in only nine subjects in
sub-study 1 and in seven subjects in sub-study 2.
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Table 5.2: Aortic and carotid pulsatile haemodynamics before (pre) and aer (post)
administration of sublingual nitroglycerin (NTG).
Variable Pre-NTG Post-NTG P-value
Central systolic blood pressure [mmHg] 133.6(27.6) 120.5(29.8) 0.011
Central pulse pressure [mmHg] 59.5(23.6) 50(19.4) 0.06
Central mean arterial pressure [mmHg] 96.8(17) 90.5(20.4) 0.019
Central diastolic blood pressure [mmHg] 74(15.4) 70.5(15.3) 0.18
Aortic pressure–ow relations
Aortic characteristic impedance [dynes ⋅ s/cm5] 172(69) 174(119) 0.93
Reection coecient, 1st harmonic 0.093(26) 0.002(26) 0.017
Reection coecient, 2nd harmonic −0.071(26) −0.117(26) 0.16
Reection coecient, 3rd harmonic −0.012(26) 0.058(26) 0.054
Forward wave amplitude [mmHg]* 52.6(20.2) 47.6(16.6) 0.26
Backward wave amplitude [mmHg]* 19.1(9.1) 16.9(7.5) 0.21
Backward/forward wave amplitude* 0.36(0.07) 0.35(0.08) 0.33
Time to reected wave onset [ms] 78(30) 89(44) 0.22
Buckberg index [%] 130(33) 129(33) 0.81
Carotid pressure–ow relations
Carotid characteristic impedance [dynes ⋅ s/cm5] 3440(2757) 1923(1277) 0.002
Carotid cross-sectional area [cm2] 0.38(0.09) 0.43(0.1) < 0.0001
Carotid bed vascular resistance [dynes ⋅ s/cm5] 19580(13402) 13078(8974) 0.001
*Computed in the time domain.
Figure 5.3: Changes in key pulsatile haemodynamic indices in the aorta (right)
and the carotid artery (le), in sub-study 1 (sublingual nitroglycerin (NTG),
solid blue bars) and sub-study 2 (inorganic nitrate, solid red bars). Mean
changes±standard errors are shown. Figure adapted from [4].
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Sub-study 1: eects of sublingual nitroglycerin on aortic and carotid
haemodynamics
Key haemodynamic parameters measured before and aer the administra-
tion of NTG are shown in table 5.2 and gure 5.3. NTG reduced central
systolic and mean pressure. NTG did not have any signicant eect on the
amplitude of forward or backward waves, the ratio of backward/forward wave
amplitudes, or the time to reected wave onset. NTG tended to delay the
peak of the reected wave, but did not improve the Buckberg index. NTG
did not signicantly reduce aortic root characteristic impedance.
e eect of NTG on the real part of the reection coecient in the
rst three harmonics is shown in table 5.2 and gure 5.3. NTG reduced the
reection coecient of the 1st harmonic, but did not reduce it in the 2nd
harmonic and actually tended to increase the reection coecient of the 3rd
harmonic.
Despite these inconsistent eects on systemic wave reections, NTG
markedly reduced carotid artery Zc, increased carotid cross-sectional area
and reduced carotid bed vascular resistance.
Sub-study 2: eects of inorganic nitrate on aortic and carotid haemodynamics
Key comparisons of haemodynamic parameters obtained aer administra-
tion of BR vs. PB juice are shown in table 5.3 and gure 5.3. Inorganic nitrate
did not signicantly reduce central systolic or mean pressure. Similar to
NTG, inorganic nitrate did not have any signicant eect on the amplitude
of forward or backward waves or the ratio of backward/forwards wave amp-
litudes, and did not reduce aortic root characteristic impedance. However, it
signicantly delayed the systolic onset of the reected wave, moved its peak
well into diastole, and tended to improve the Buckberg index.
Both table 5.3 and gure 5.3 show the eect of inorganic nitrate on the
real part of the reection coecient in harmonics 1–3. Inorganic nitrate
signicantly reduced the reection coecient of the 1st and 2nd harmonics,
and tended to reduce the reection coecient of the 3rd harmonic. In contrast
to NTG, inorganic nitrate did not reduce carotid artery Zc, carotid cross-
sectional area, or carotid bed vascular resistance.
147
5. Vascular Function
Table 5.3: Aortic and carotid pulsatile haemodynamics aer administration of
12.9mmoL of inorganic nitrate (BR) vs. placebo juice (PB).
Variable PB BR P-value
Central systolic blood pressure [mmHg] 130(20.8) 126.6(24.2) 0.50
Central pulse pressure [mmHg] 55.3(16.7) 51(18) 0.34
Central diastolic blood pressure [mmHg] 74.7(12.6) 75.6(9.8) 0.70
Central mean arterial pressure [mmHg] 97.6(14.8) 96.4(15.2) 0.70
Aortic pressure–ow relations
Aortic characteristic impedance, [dynes ⋅ s/cm5] 163(74) 185(64) 0.20
Reection coecient, 1st harmonic 0.119(0.15) −0.001(0.21) 0.032
Reection coecient, 2nd harmonic −0.03(0.13) −0.144(0.15) 0.012
Reection coecient, 3rd harmonic 0.046(0.16) −0.042(0.16) 0.091
Forward wave amplitude [mmHg]* 47.2(13.8) 47.1(14.1) 0.98
Backward wave amplitude [mmHg]* 16.8(6) 18.8(7.9) 0.30
Backward/forward wave amplitude* 0.35(0.05) 0.39(0.08) 0.08
Time to reected wave onset [ms] 64(30) 93(30) 0.016
Buckberg index [%] 128(29) 141(25) 0.053
Carotid pressure–ow relations
Carotid characteristic impedance [dynes ⋅ s/cm5] 3013(1867) 2928(1279) 0.80
Carotid cross-sectional area [cm2] 0.37(0.08) 0.40(0.12) 0.15
Carotid bed vascular resistance [dynes ⋅ s/cm5] 19391(13557) 16624(6800) 0.38
*Computed in the time domain.
5.1.5 Discussion
We assessed the eects of organic and inorganic nitrate on aortic and carotid
pulsatile haemodynamics in HFpEF. We demonstrated that organic nitrate
substantially reduced BP, but reduced arterial wave reections inconsistently
across the rst three harmonics of the pressure–ow relation (in which most
of the pulsatile energy is contained). NTG did not signicantly improve the
Buckberg index and produced profound vasodilatation in the carotid territory,
with a reduction in cerebrovascular resistance and carotid characteristic
impedance. In contrast, inorganic nitrate produced consistent reductions in
wave reections across the rst three harmonics, with a delay in the reected
wave and a trend for improvement in the Buckberg index, without signicant
cerebrovascular dilatation.ese haemodynamic dierences likely underlie
the dierential clinical eects of organic vs. inorganic nitrate observed in
recent clinical trials.
While both organic and inorganic nitrate/nitrite ultimately act by in-
creasing NO bioavailability, biochemical dierences exist between the two
classes of drugs that lead to important dierences in their action. Inorganic
nitrate is reduced to nitrite and NO via the nitrate–nitrite–NO pathway [210],
[211], which involves the reduction of nitrate to nitrite upon ingestion and
when nitrate is subsequently excreted by the salivary glands (enterosalivary
circulation) [219]. Subsequent reduction of nitrite to NO occurs via: (i) a
hypoxia/acidosis-dependent mechanism (which enhances reductions in mi-
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crovascular resistance during exercise) [208], and (ii) a ‘paradoxic’ normoxia-
dependent mechanism operating in muscular conduit arteries [212], which
explains the eect on arterial wave reections [208], [212].ere also appears
to be non-enzymatic nitrite reduction to NO in the acid gastric medium
[220]. In contrast, organic nitrates require activation in the cytochrome-P450
system, leading to tonic NO release [37]. Alternative activation via mitochon-
drial aldehyde dehydrogenase for NTG and other organic nitrates also occurs
[37].
Headache is a common side eect of organic nitrates, and can limit com-
pliance with these medications. Hypotension can be seen, and may result
in syncope [205], [210]. In contrast, inorganic nitrate has been well toler-
ated in HFpEF, with no limiting side eects, as reported in two recent trials
[208], [209]. No signicant hypotension and, in particular, no vasoactive
symptoms (such as headache) were reported.ese side eect dierences
are consistent with the haemodynamic eects observed in our study. e
profound carotid bed vasodilatation seen in response to NTG, but not inor-
ganic nitrate, is likely due to dierences in the activation of these compounds.
e high mitochondrial content of neurons may facilitate the activation of
NTG by mitochondrial aldehyde dehydrogenase in the brain, thus reducing
microvascular resistance in the cerebrovascular bed. In contrast, inorganic
nitrite (produced via reduction in inorganic nitrate) is reduced to NO in the
microvasculature, but this conversion occurs preferentially in conditions of
hypoxia/acidosis [210], [211]. Such conditions are not present in the brain, a
highly aerobic organ which demonstrates relatively preserved microvascular
oxygenation [221] due to its low resistance and high arterial ow.erefore,
conditions of hypoxia and acidosis are not present in the cerebral microvas-
culature, explaining the lack of signicant eects of inorganic nitrate in our
study.
Wave reections originate at sites of impedance mismatch throughout
the arterial tree and return to the heart during ejection, increasing pulsatile
load and aecting the LV loading sequence (early vs. late systolic load)
[217], [222]. Wave reections and late systolic load have been shown to cause
diastolic dysfunction and myocardial remodelling in animal models [173],
[175]. Human studies demonstrated a relationship between increased wave
reections/late systolic load and worse longitudinal LV function [165], LV
hypertrophy [174], and a higher risk of incident new-onset HF [177] and
readmission aer an episode of established acute decompensated HF [172].
In our study, both NTG and inorganic nitrate reduced wave reections.
However, inorganic nitrate produced numerically greater and more consis-
tent reductions in the real part of the reection coecient across the rst
three harmonics, which contain most of the pulsatile energy. In contrast,
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NTG reduced the real component of the reection coecient only in the
1st harmonic, without an eect in the 2nd harmonic, and an increase in the
3rd harmonic. e real part of the reection coecient characterises the
net eect of wave reections on the pressure–ow relation in the aorta at a
given harmonic [218]. Inorganic nitrate, but not NTG, delayed the reected
wave and tended to improve the Buckberg index (which characterises the
eect of pulsatile haemodynamics on LV systolic load vs. diastolic perfusion
pressure).e reduction in wave reections with inorganic nitrate occurred
without reductions in systemic vascular resistance or BP.is clearly indi-
cates that the eects of inorganic nitrate on microvascular resistance/BP and
those on wave reections are not necessarily linked. Reductions in wave
reections can thus be achieved in the absence of signicant hypotension.
Although these haemodynamic eects are unexpected from the well-known
hypoxia-mediated reduction of nitrite in the microvasculature, they are con-
sistent with the recently described paradoxic normoxia-dependent activation
of inorganic nitrite in the wall of muscular conduit arteries [212], because
muscular arteries are known to modify the magnitude and phase of wave
reections returning to the proximal aorta [217].
e eects of inorganic nitrate on pulsatile load from wave reections
demonstrated in our study, along with the absence of cerebrovascular eects
and side eects, is helpful not only to interpret its demonstrated short-term
clinical eects (i.e., improvements in exercise tolerance and the absence of
side eects such as headache), butmay also have implications for its long-term
clinical eects. By virtue of reducing wave reections, which are deleterious
for the LV, inorganic nitrate may exert long-term ”disease-modifying” eects
inHFpEF, potentially reducing LV diastolic dysfunction and remodelling. We
are currently assessing the ecacy of sustained administration of inorganic
nitrate (oral potassium nitrate) in a randomized cross-over phase IIb trial
funded by the National Heart, Lung and Blood Institute (KNO3CK OUT
HFPEF trial; clinicaltrials.gov NCT02840799). A single-dose study with
inorganic nitrite yielded promising results in HFpEF [223], and a larger study
with inhaled sodium nitrite (INDIE HFPEF; clinicaltrials.gov NCT02742129)
is ongoing.
An interesting observation is the absence of signicant eects of either
NTG or inorganic nitrate on the ratio of amplitudes of backward/forward
waves, which is a commonly used index of wave reections. It should be
noted that this ratio does not account for the time-resolved shape of the
waveforms (which can be dierent despite identical amplitudes). Similarly,
this ratio does not account for the time at which the reected wave exerts
its eects on central pressure (late systole vs. diastole). Furthermore, the
amplitudes of both forward and backward waves are not purely a function
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of arterial properties, but are heavily dependent on ventricular contraction
dynamics. In addition, the ratio of backward/forward waves is confounded
by rectied reections (i.e., re-reections in the heart), which substantially
contribute to forward wave amplitude [224]. Despite the lack of change in
reection magnitude, detailed analyses in the time domain demonstrated
favourable changes (delay in the onset of the reected wave aer ejection,
and a trend towards improvement in the Buckberg index) with inorganic
nitrate, but not with NTG.
Our study should be interpreted in the context of its strengths and lim-
itations. Strengths include the careful assessment of pulsatile carotid and
aortic haemodynamics using state-of-the-art non-invasive pressure–ow ana-
lyses, rather than pressure-only approaches. Input impedance assessments
distinctly characterise arterial properties distal to the point of measurement,
whereas pressure-only approaches (such as assessments of augmentation
index) can be confounded by changes in ventricular contraction or preload.
Additional strengths of our study include the use of identical methods to
measure haemodynamics aer organic and inorganic nitrate administration,
facilitating the interpretation of dierential haemodynamic eects.
Our study also has limitations. Our study populations were relatively
small; however, the paired nature of the analyses reduced measurement
variability and enhanced detection of drug eects in each sub-study. Owing
to the characteristics of the patient population at the VA Medical Center,
where most subjects were enrolled, our study populations were composed
primarily of men. Our population was predominantly African-American.
Larger studies will be required to assess whether the haemodynamic eects
of inorganic nitrate dier by ethnicity. Enrollment in the ongoing KNO3CK
OUT HFpEF trial is stratied based on gender and ethnicity; this study is
also assessing detailed haemodynamic phenotypes and will clarify this issue.
e exclusion of patients with atrial brillation reduces generalizability of the
ndings to the important subject of patients who have atrial brillation in
the setting of HFpEF. We performed two separate sub-studies with dierent
designs. We tested the eects of NTG compared to the values before drug
administration, whereas the eects of inorganic nitrate were tested in a cross-
over blinded design.is was an acute administration study, and the chronic
eects of these drugs on the carotid and peripheral circulations could be
dierent.e patient population had relatively mild HFpEF as evidenced by
the relatively low use of loop diuretics; therefore, these results may not apply
to patients who have more severe or advanced HFpEF.
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5.1.6 Conclusions
We compared the eects of organic and inorganic nitrates on aortic and
carotid pulsatile haemodynamics in patients with HFpEF. We demonstrated
that organic nitrate administration reduced arterial wave reections less
consistently than observed with inorganic nitrate. Organic nitrate also pro-
duced profound vasodilatation in the carotid territory, with a reduction in
cerebrovascular resistance and carotid characteristic impedance, whereas in-
organic nitrate did not produce signicant cerebrovascular dilatation.ese
important haemodynamic dierences are likely related to the dierential
clinical eects of these agents documented in recent clinical trials.
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5.2 Effect of organic and inorganic nitrates on cerebrovascular
pulsatile power transmission in patients with heart failure
and preserved ejection fraction
5.2.1 Introduction
In section 5.1 [4], we found that the acute administration of organic nitrates
has a profound eect on carotid haemodynamics, with a marked reduction
in carotid bed vascular resistance and dilation of the carotid artery, which
may account for the high incidence of headaches and dizziness, respectively.
e eects of vasoactive drugs on cerebrovascular haemodynamics, however,
may be relevant beyond acute side eects such as headache. Accumulat-
ing evidence links increased penetration of pulsatile energy (power) to the
brain, with the development and/or progression of cognitive dysfunction
and dementia [225], [226], which are common comorbidities in the HFpEF
population. e brain is a high-ow, low-resistance organ, in which the
microvasculature is more directly exposed to the pulsatility that occurs in
central arteries.
Although organic nitrates reduce central pulse pressure in HFpEF [4],
the marked associated cerebrovascular vasodilatory eect, with reduction of
carotid characteristic impedance and carotid bed vascular resistance, may
actually facilitate pulsatile power penetration into the brain microvasculature,
potentially undermining the benecial eects of these drugs on central pulse
pressure.e eects of organic nitrates on power penetration to the brain
have not been previously assessed, nor have these eects been compared with
the eects of inorganic nitrates.
e aim of this study is therefore to quantify and characterise the patterns
of hydraulic power carried by waves traveling through the proximal aorta
and the carotid artery, and the eects of organic and inorganic nitrates on
these parameters among patients with HFpEF.
5.2.2 Methods
e present work is based on previous studies of organic [4] and inorganic
nitrates [208] in HFpEF, here referred to as sub-studies 1 and 2 and described
in detail in section 5.1 together with the implemented haemodynamic and sta-
tistical analyses. Protocols were approved by the University of Pennsylvania
and Philadelphia Veterans Aairs (VA) Medical Center Institutional Review
Boards, as appropriate. All subjects provided written informed consent be-
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fore enrollment. Inclusion and exclusion criteria are described in detail in
section 5.1 [4] and elsewhere [208].
5.2.2.1 Wave power analysis
Recently, Mynard et al. [70] introduced the concept of wave power as ameans
to analyse the energy carried by the incident and reected pressure and ow
waves.is technique nds its origin in wave intensity analysis but has the
major advantage of allowing for a quantitative analysis of how the energy
transmitted by the heart into the aorta is distributed over the arterial tree.
Figure 5.4 shows a graphical depiction of wave power analysis. In
Chapter 3 a more detailed description of the method is developed. Aer
digitally resampling signals to 500Hz for a more accurate time-alignment
of pressure and ow, wave power (dpi) was dened as the product of
the instantaneous changes in pressure and ow (dP ∗ dQ). Wave power
can be separated into the power carried by forward-traveling (dpi+) and
backward-traveling (dpi−) waves:
dpi± = ± 14Zc (dP ± ZcdQ)2 (5.1)
where Zc is the characteristic impedance (calculated in the frequency
domain), and total power (dpi) equals the sum of power carried by forward
(dpi+) and backward (dpi−) waves.
Wave power is a function of time and demonstrates two major positive
peaks: a forward compression wave (FCW), generated by the contraction of
the LV in early systole, and a forward expansion wave (FEW), generated as
the rate of myocardial shortening is reduced in late systole [70], [227]. We
report the area under the curve (AUC) of FCW (red area) and FEW (blue
area) at the aorta and the carotid arteries, while the green area is the backward
wave (gure 5.4B).
We also computed total hydraulic power, which is related to the rate of
energy production and expenditure in the cardiovascular system, as previ-
ously described [70]. We calculated the AUC in total hydraulic power as the
total energy transmitted from the heart to the aorta and to the carotid artery.
We also computed the peak values of the total hydraulic power curve at both
locations (gure 5.4C).
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We computed the power penetration from the aorta into the carotid
vascular circulation as an index based on total hydraulic power parameters
(peak power or energy as the AUC) as follows:
%Penetration = CarotidPowerparameterAorticPowerparameter ∗ 100 (5.2)
5.2.3 Results
General characteristic parameters obtained from both sub-study popula-
tions are shown in table 5.1 and described in section 5.1. While general
haemodynamic results are summarized in tables 5.2 and 5.3, table 5.4 contains
additional haemodynamic parameters for each sub-study.
Sub-study 1: eects of organic nitrate
Parameters obtained from wave and hydraulic power analysis before and
aer NTG intake are summarized in table 5.4. Aortic and carotid FCW
and FEW were not signicantly dierent aer NTG administration.ere
was a reduction in the total aortic hydraulic power energy (1.53J/beat to
1.35J/beat, change: 11.8% decrease, P = 0.01) and a trend towards a decrease
in peak hydraulic power (7.26W to 6.59W ; change: 9.2% decrease, P =
0.06). In contrast, there was a signicant increase in peak carotid hydraulic
power (0.39W to 0.54W ; change: +38.5% increase, P = 0.008) aer NTG
administration. In gure 5.5A, the post-NTG change in total hydraulic power
parameters is clear.e observed increase in carotid hydraulic power despite a
reduced aortic hydraulic power implies an increase in the percentage of power
transmission from the aorta into the carotid (peak total hydraulic power
penetration: 5.68% vs. 8.62%; P = 0.001; total hydraulic energy penetration:
8.69% vs. 11.63%; P = 0.01, gure 5.6A).
Sub-study 2: eects of inorganic nitrate
Table 5.4 displays the calculated wave and hydraulic power parameters for
sub-study 2. No signicant changes were found for aortic or carotid values
between PB and BR intake. Figure 5.5B shows the percent dierence in total
hydraulic power parameters at the aorta and the carotid arteries in the BR
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Figure 5.4: Graphical depiction of wave and hydraulic power analysis to illus-
trate steps and parameters extracted, including A) tonometry (red dashed line)
and ultrasound (blue dotted line) signals alignment; B) wave power analysis (dpi);
and C) total hydraulic power analysis and selected parameters: AUC (Energy, gray
area) and peak values (Power, blue diamond). At le and right panels, aortic and
carotid signals and curves are shown, respectively. Displayed signals are pre-NTG.
AUC: area under the curve; FCW: forward compression wave (red area); FEW:
forward expansion wave (blue area); green represents the backward wave. Figure
adapted from [3].
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intervention compared to the PB intervention. Lastly, gure 5.6B displays a
comparison of the percent changes in power penetration parameters between
these 2 conditions, demonstrating non-signicant dierences between these
haemodynamic parameters aer PB vs. BR intake.
Table 5.4: Aortic and carotid haemodynamics and power analysis before (Pre-) and
aer (Post-) administration of sublingual nitroglycerin (NTG) (sub-study 1) and
aer nitrate-depleted (PB) and nitrate-rich beet root juice administration (sub-study
2).
Sub-study 1 (organic nitrate) Sub-study 2 (inorganic nitrate)
Variable Pre-NTG Post-NTG P-value PB BR P-value
Haemodynamics
Cardiac output [l min−1] 5.64(1.40) 5.81(1.23) 0.32 5.40(1.42) 4.89(1.15) 0.04
Stroke volume [ml] 90.41(21.91) 89.07(21.64) 0.65 83.58(16.02) 78.71(15.05) 0.07
Heart rate [bpm] 63.23(10.82) 66.58(11.06) 0.004 65.19(12.78) 62.28(10.39) 0.09
Peak aortic blood ow [cm3 s−1] 408.61(100.90) 410.03(103.16) 0.93 371.71(64.88) 350.39(65.71) 0.20
Mean aortic blood ow [cm3 s−1] 94.01(23.31) 96.86(20.42) 0.32 90.10(23.59) 81.45(19.12) 0.04
Peak carotid blood ow [cm3 s−1] 23.92(15.35) 34.31(21.51) 0.001 21.25(11.62) 22.19(13.51) 0.74
Mean carotid blood ow [cm3 s−1] 9.80(6.73) 13.08(8.38) 0.008 9.35(5.24) 10.03(6.91) 0.60
Aortic wave power analysis
FCWAUC [mJ] 0.129(0.053) 0.117(0.050) 0.26 0.107(0.046) 0.093(0.043) 0.31
FEWAUC [mJ] 0.041(0.031) 0.032(0.023) 0.17 0.036(0.017) 0.033(0.015) 0.53
Aortic hydraulic power analysis
Power [mW] 7256(2549) 6591(2204) 0.06 6666(2165) 5845(1846) 0.20
Energy [mJ] 1531(511) 1351(428) 0.01 1429(447) 1275(418) 0.18
Carotid wave power analysis
FCWAUC [mJ] 0.007(0.006) 0.010(0.011) 0.12 0.0056(0.0040) 0.0049(0.0027) 0.40
FEWAUC [mJ] 0.0014(0.0014) 0.0018(0.0020) 0.25 0.0014(0.0009) 0.0011(0.00045) 0.13
Carotid hydraulic power analysis
Power [mW] 387(240) 536(383) 0.008 356(207) 351(195) 0.91
Energy [mJ] 127(78) 150(84) 0.12 126(76) 129(68) 0.90
PB: placebo; BR: nitrate-rich beetroot juice; AUC: area under the curve; FCW: forward compression
wave; FEW: forward expansion wave.
5.2.4 Discussion
In this study, we quantied the eect of organic and inorganic nitrates on
pulsatile power penetration to the brain in patients with HFpEF. Adminis-
tration of NTG, an organic nitrate, led to a signicant reduction of aortic
hydraulic power, an increase in power penetration to the carotid artery (due
to cerebrovascular vasodilation), and an absolute increase in carotid hydraulic
power. In contrast, inorganic nitrate administration did not induce signicant
changes in aortic and carotid wave power or percentage of power penetra-
tion. Our ndings have important implications for our understanding of the
cerebrovascular haemodynamic eects of organic and inorganic nitrates in
this population, which in turn may have implications for the adverse eect
prole of these drugs and cerebro-microvascular health.
In contrast to inorganic nitrate [210], organic nitrates result in undesir-
able side eects, such as pulsatile headache, ushing, hypotension or even
syncope [4], [201]. In particular, recent trials of organic nitrates in HFpEF
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Figure 5.5: Forest plots describing the change in percentage of selected paramet-
ers. A) Aer the administration of sublingual NTG; B) Between nitrate-depleted
(PB) and nitrate-rich (BR) beet root juice intake.
* Indicates a statistically signicant change (P < 0.05). Figure adapted from [3].
Figure 5.6: Percentage of carotid total hydraulic power penetration. A) Aer the
administration of sublingual NTG; B) Between nitrate-depleted (PB) and nitrate-
rich (BR) beet root juice intake.
* Indicates a statistically signicant change against (A) pre-NTG or (B) PB. Figure
adapted from [3].
have demonstrated poor tolerability, with a high incidence of side eects
[205], [207] and frequent discontinuation of long-term use [206].e impor-
tant incidence of headaches is possibly related to the increase on pulsatile
power penetration to the cerebrovascular territory demonstrated in our study.
However, the importance of this haemodynamic eect may extend beyond
its role in headaches. Increased penetration of pulsatile power to the brain
is progressively recognized as an important factor in the development of
cognitive dysfunction and dementia [225], [226], which are common comor-
bidities in the HFpEF population [228], [229]. Due to its high blood ow
needs, the brain vasculature is a low-resistance bed, in which the microvas-
culature is more directly exposed to the pulsatility that occurs in conduit
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vessels. erefore, the pulsatile power transmission from the aorta to the
conduit branches that feed the cerebrovascular territory is a key determinant
of pulsatile haemodynamics in the cerebrovascular microcirculation. We
demonstrate, for the rst time, that despite the reduction in BP induced by
NTG in HFpEF, the marked associated cerebrovascular vasodilatory eect
actually leads to increased (rather than decreased) hydraulic power transmis-
sion into the carotid territory. In contrast, we demonstrate that inorganic
nitrates do not increase pulsatile power penetration to the brain.
Nitrates/nitrites-related adverse events can limit compliance with these
medications and have an undesired impact on various outcomes (such as
outpatient physical activity) in HFpEF. Detailed assessments of their haemo-
dynamic eects can contribute to elucidate the mechanisms of these side
eects. Given that the incidence of headaches has been reported to be greater
with organic vs. inorganic nitrates, our study focused on the dierential
eects of these agents on brain haemodynamics. However, we acknowledge
that the relationship between our haemodynamic ndings and the incidence
of adverse events should be further investigated in future studies.
Additionally to the strengths and limitations discussed in section 5.1,
a particular strength of the research discussed in this section is the imple-
mentation of an ad hoc method to assess pulsatile power in the aorta and
carotid arteries, as recently proposed by Mynard et al. [70]. is method
quanties the distribution of wave power at junctions, is relatively insensitive
to diameter variations, and is quantitatively linked to transient changes in
hydraulic pressure power, a concept related to the rate of energy production
and expenditure in the cardiovascular system.
We note that the haemodynamic eects reported herein for inorganic ni-
trate likely do not apply to short-acting inorganic nitrite preparations. Inhaled
sodium nitrite, which is currently being studied in HFpEF, demonstrates
markedly dierent pharmacokinetic properties compared to orally admin-
istered inorganic nitrate [230].e half-life of inhaled sodium nitrite is only∼ 35 minutes [231] (in contrast to several hours for inorganic nitrate) [232]
and intermittent inhaled administration is associated with pronounced cir-
culating level uctuations, which may cause hypotensive episodes in elderly
patients with HFpEF. To our knowledge, no studies have been assessed the
cerebrovascular haemodynamic eects of sodium nitrite in HFpEF. Ongoing
trials (the KNO3CK OUT HFpEF trial with orally administered potassium
nitrate and the INDIE HFpEF trial with inhaled sodium nitrite [230]) will
help clarify the side eect proles and haemodynamic dierences between
inorganic nitrite and nitrate in this patient population.
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5.2.5 Conclusions
In conclusion, to the extent of our knowledge, this study is the rst to assess
the eects of organic and inorganic nitrates on aortic and carotid wave and
hydraulic power and energy in patients with HFpEF. Our study demonstrates
that organic nitrates increase power penetration from the aorta into the
carotid, which leads to a signicant increase in carotid pulsatile hydraulic
power, despite a reduction in aortic power. In contrast, inorganic nitrate
administration did not induce signicant changes in aortic and carotid wave
and hydraulic power or percentage of power penetration.ese haemody-
namic eects likely have implications for the pulsatile haemodynamic stress
of the microvasculature of the brain. In the short term, these haemodynamic
dierences may contribute to the dierential incidence of side eects (such
as headaches) with organic vs. inorganic nitrate therapy. In the long term,
they may have implications for cognitive decline. However, the causal link
between carotid pulsatile haemodynamics and cognitive decline, particularly
in the setting of vasodilator therapy, requires further study.
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Exploration and development
of dedicated tools for the
assessment of arterial health
(in non-routine conditions)
Previously, Chapter 4 and Chapter 5 addressed novel research based on
cardiac and vascular function assessment. In this chapter, further dedicated
tools to study the cardiovascular system are explored. Dissimilar topics, such
as autonomic regulation, protocol standardization or space exploration nd
a common ground in cardiovascular research, and can impact and expand
current knowledge.
With this perspective, the chapter starts presenting a study concerning
the inuence of the autonomic nervous system (ANS) in adjustments of
the cardiovascular function under stress conditions. Indeed, the regulatory
inuence of the ANS (see Chapter 1) is paramount for the proper functioning
of the cardiovascular system, and the understanding of these interactions
can elucidate unclear adaptation and pathological mechanisms.en, the
second section introduces a web application to support the standardization of
vascular stiness parameters and to promote their widespread use in common
clinical practice. Finally, the third section is an exploratory feasibility study
of a continuous physiological and medical monitoring system, based on
tonometry and ultrasound measurements, with potential applications in
space science.
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6.1 Carotid haemodynamics during sympathetic nervous system
stimulation via handgrip and cold pressor testing in young
healthy subjects: A feasibility study
is section is based on a study published in Artery Research under the title
”Carotid haemodynamics during sympathetic nervous system stimulation via
handgrip and cold pressor testing in young healthy subjects: A feasibility study”,
vol. 8, no. 4, pp. 178-188, 2014 [5].
6.1.1 Introduction
Common functional measurements to assess the cardiovascular system (car-
diac systolic and diastolic function or arterial stiness, for example) are
typically performed during resting conditions. However, in real life, humans
are active and there is an intrinsic variability in the cardiovascular status that
must be considered when interpreting the results of these type of tests.is
variability is related to the ANS, which regulates the visceral functions of the
body and helps to control arterial blood pressure (BP), sweating, body tem-
perature, and many other activities. One of the most striking characteristics
of the ANS is the rapidity and intensity with which it can change visceral
functions [233]. us, the nervous system, acting through the autonomic
nerve bres, can exert rapid and eective control of many, if not most, of
the internal functions of the body.e signals are transmitted to the body
through two major subdivisions termed sympathetic and parasympathetic
system [233].erefore, assessment of the ANS can provide additional infor-
mation of the cardiovascular control and general state of a subject’s health.
is assessment can be done through the use of sympathetic nervous stressors,
such as the hand grip test (HGT) or the cold pressor test (CPT).
Physical activity, for example isometric exercise as in the HGT, produces
intensity-dependent increases in arterial BP that are mediated by central
signals arising from higher brain centres (i.e., central command) and by peri-
pheral feedback from skeletal muscle (i.e., exercise pressor reex or EPR) with
further modulation provided by the arterial baroreex [234] (see gure 6.1A).
e arterial baroreex is a critical cardiovascular reex that provides a con-
tinuous buering of acute uctuations of arterial BP controlling two of the
major variables that determine it: cardiac output (CO) and systemic vascular
resistance (SVR) [235]. HGT produces simultaneous increases in BP and
heart rate (HR), which are not (totally) blunted by the arterial baroreex.is
led to the speculation that baroreexes are altered in some fashion to allow
this deviation from normal baroreex physiology to occur [236].e current
understanding of the mechanisms for baroreex resetting during exercise is
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that the feed forwardmechanism of central command is probably the primary
regulator of baroreex resetting, while the negative feedback mechanism of
the EPR is more of a modulator of resetting [237] (see gure 6.1C).
CPTs are oen performed in the clinical evaluation of autonomic dis-
orders to ensure the integrity of central vasomotor processes and their eerent
pathways.e test elicits remarkable increases in arterial pressure andmuscle
sympathetic nerve activity (MSNA) with no signicant changes in HR [238].
In most healthy human subjects, cold nociceptors in the skin conduct aerent
signals that serve to regulate MSNA [238].us, CPT is performed to asses
sympathetic neural control of the peripheral and coronary circulations in
humans [239] (see gure 6.1B). Besides, CPT is suggested to be a method
that mimics the eects of chronic pain conditions eectively because of its
unpleasantness with excellent reliability and validity. Hence, fast and ecient
evaluations of pain treatments are made possible in healthy participants,
making this technique a useful and less expensive prerequisite to clinical
studies [240].
Both described stressors have distinct neural paths and receptors [238]
(see gure 6.1) and, consequently, a dierential response to each stimulus
should be measurable selecting an adequate anatomical target and appropri-
ate parameters. We hypothesize that the functional assessment of carotid
arterial properties and haemodynamics would be a good candidate for such
investigation due to its relation with the baroreex.
e aim of this study was therefore to assess the feasibility of non-
invasively monitoring carotid haemodynamics in response to sympathetic
nervous system stressors. Ultrasound was used to assess blood ow velocity
and carotid diameter distension waveforms throughout the protocol, with
subsequent derivation of functional parameters related to the tonus of
the carotid artery (stiness - local carotid pulse wave velocity) and the
downstream vascular bed (reection magnitude).
6.1.2 Methods
6.1.2.1 Subjects
Measurements were performed on twelve young (presumably) healthy vo-
lunteers (six males, six females). Subjects were instructed to refrain from
eating and ingesting beverages containing caeine and alcohol for at least 2h
before testing. Volunteers were studied in supine position in a quiet, lightly
dimmed room (temperature 25 − 28○C).
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Figure 6.1: Distinct neural paths of stressors. A) Isometric exercise produces
intensity-dependent increases in arterial BP that are mediated by central signals
arising from higher brain centres (i.e., central command) and by peripheral feedback
from skeletal muscle (i.e., exercise pressor reex or EPR) with further modulation
provided by the arterial baroreex [234]. Classically, the central command is dened
as a feed forward mechanism involving parallel activation of motor and cardiovas-
cular centres [241]. In the EPR or the “muscle metaboreex”, neural signals arising
from stimulation of chemosensitive receptors in the contracting muscles would
activate reexively the cardiovascular control areas in the medulla [242].e arterial
baroreex is a critical cardiovascular reex that provides a continuous buering
of acute uctuations of arterial BP controlling the two variables that determine
it: CO and SVR [235]. B) Cold pressor test: in most healthy human subjects, cu-
taneous application of ice water (i.e., CPT) increases arterial BP, HR, and SVR. Cold
nociceptors in the skin conduct aerent signals by unmyelinated C-bres, and the
pathway may involve vasomotor centres that serve to regulate MSNA.us, CPT
is performed to asses sympathetic neural control of the peripheral and coronary
circulations in humans [239]. C) Baroreex stimulus-response curve during rest
and exercise (resetting).e centring point is the point at which there is an equal
depressor and pressor response to a given change in BP.e operating point is the
prestimulus BP.e threshold is the point where no further increases in HR are eli-
cited by further reductions in BP. Saturation is the point where no further decreases
in HR are elicited by further increases in BP.e relocation of the operating point
(away from the centring point and closer to the threshold of the stimulus-response
curve) with increasing exercise intensity modies the baroreex in a more optimal
condition to counter hypertensive stimuli [241]. Figure adapted from [5].
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6.1.2.2 Protocol instrumentation and setup
Measurements included continuous haemodynamic recordings using a nger
cu with an optical plethysmograph (Nexn, BMEYE B.V., Amsterdam,e
Netherlands) that provided systolic blood pressure (SBP), diastolic blood
pressure (DBP), the BP waveform and HR. Ultrasound measurements of the
carotid artery were done at discrete moments during the protocol (Vivid7,
GE-Vingmed Ultrasound AS, Horten, Norway) and consisted of: 1) diameter
distension measurements using a “wall tracking” application [72] and 2)
pulsed-wave (PW) Doppler measurements.
Figure 6.2 shows the general setup during the protocol. Analogue outputs
of the Nexn monitor were connected to an external acquisition device (SC-
2345, National instruments, Austin, Texas, United States), which sent the sig-
nals to a PC. During measurements, a holder was used to x the ultrasound
probe on the carotid artery (volunteer’s dominant hand side). In gure 6.2A,
the setup for the HGT is shown.e hand grip device (Precision dynamo-
meter G200, Biometrics Ltd, Newport, United Kingdom) was connected to
the external PC to provide a visual feedback to the volunteer during the test.
In gure 6.2B, the CPT setup is shown. During the test, the subject immersed
the dominant hand in cold water for about 3 min.
Figure 6.2: General protocol setup. (1) Nexn monitor (Nexn, BMEYE B.V.,
Amsterdam,e Netherlands), (2) National instruments acquisition device (SC-
2345, National instruments, Austin (Texas), United States), (3) External PC, (4) Finger
cu, (5) Ultrasound device (Vivid7, GE-Vingmed Ultrasound AS, Horten, Norway),
(6) Ultrasound probe. Le) HGT: (7) Hand grip device (Precision dynamometer
G200, Biometrics Ltd, Newport, United Kingdom). Right) CPT: (7) Cold water.
Figure adapted from [5].
6.1.2.3 Protocol implementation
Before the start of the protocol, basic anthropometric measurements were
performed while a general explanation of the procedures was given to each
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Table 6.1: Overview of the implemented protocol.
Step Action
MVC Determination of Maximal Voluntary Contraction
Rest 20 min (minimum)
HGT30% Baseline 30% MVC (120s) Recovery
Rest 10 min (minimum)
HGT40% Baseline 40% MVC (90s) Recovery
Rest 10 min (minimum)
CPT Baseline CPT (180s) Recovery
HGT30% : hand grip test performed at 30% of the MVC; HGT40% : hand grip test performed at 40% of
the MVC; CPT: cold pressor test.
volunteer.en, the subject was asked to lay down and to perform three brief
maximal voluntary contractions (MVCs) with her/his dominant hand using
the hand grip device.e highest value obtained was selected as the reference
value and dened as the MVC. Following, to achieve a haemodynamic steady
state in each volunteer, there was an initial resting period of at least 20minutes
in supine position.
Hand grip test (isometric exercise)
e rst test performed was an HGT at 30% of the MVC (HGT30%) followed
by a resting period. Taking into account the time limitations and values used
in literature [238], [243]–[245], it was decided that a resting time period of 10
minutes in between tests was adequate. Next, a second HGT was carried out
at 40% of the MVC (HGT40%).
For both tests, ultrasound measurements were obtained at baseline, dur-
ing the test and upon recovery.e time span of the test period was 2minutes
for HGT30% and 90s for HGT40%, during which time subjects were provided
with visual feedback of their contraction force production. In all cases, ultra-
sound measurements were performed only aer one minute of the onset of
test and recovery periods.
Cold pressor test
With a resting period in between HGT40% and CPT of at least 10 minutes,
and aer baseline measurements were performed, the subjects immersed
their dominant hand into a cold water bath (0−5○C) up to the wrist for a
period of ∼ 3 minutes. Two ultrasound measurements were performed, one
during the rst half of the test (between the onset and 90s) and the second
during the nal part of the test (between 90s and the end). is second
measurement was eventually used to perform the analysis of results. is
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test was performed as fast as possible to avoid discomfort of the volunteers,
therefore the timing diered accordingly for each subject. When the test
period was over, the last ultrasound measurement was obtained aer at least
1 minute recovery.
A general summary of the protocol is presented in table 6.1.
6.1.2.4 Signal processing
All post processing was done o-line, meaning that all signals were saved,
stored and labelled for later use. Continuous haemodynamic signals
(SBP/DBP/HR/BP wave) were sampled at 200Hz and saved as ASCII les.
ese signals were divided into three established periods (baseline, test and
recovery).e test period was split as well in two parts, being expected that
the reaction to the stressors should be more prominent during the second
part (see gure 6.3), and therefore this was used for further analysis. Finally,
a mean value (and standard deviation) of each period was calculated and
used for post processing.
Mean arterial pressure (MAP) was calculated from DBP and SBP values
using the equation [246]:
MAP = 0.4 ∗ (SBP − DBP) + DBP [mmHg] (6.1)
An RF-based wall-tracking application [72] developed in MATLAB® was
used to obtain a diameter distension waveform (see gure 6.4, top le) from
which carotid distension (∆D/D) was calculated as:
△D
D
= Ds − Dd
Dd
(6.2)
where D is the outer diameter (measured between the media-adventitia
transition of far and near wall) of the carotid artery during systole (Ds) or
diastole (Dd). Results represent the mean value and standard deviation of at
least 3 cardiac cycles (see gure 6.4. Middle le: carotid diameter distension
curve - solid line).
e envelope of the blood ow velocity waveform was automatically
traced from PW Doppler mode measurements and divided in individual
cardiac cycles, providing information about the ow velocity changes in
the carotid artery. At least three cycles were obtained from each image for
deriving mean and peak blood ow velocities (see gure 6.4. Top right:
example segmentation of a PW Doppler mode image. Middle le: carotid
blood ow velocity curve - dashed line).
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Figure 6.3: Haemodynamic signal obtained with the Nexn monitor (nger
cu) during HGT40%. Derived parameters from the signal were obtained: SBP
(average from the top signal envelop), DBP (average from the bottom signal en-
velop) and BP wave. Haemodynamic parameters were calculated by the division
of the signal in three periods (baseline, test and recovery) to obtain a nal value
as the mean of each period. Using timing data, the test period was divided in two
parts. e second part was used to calculate derived parameters and to perform
comparisons against baseline data. Figure adapted from [5].
6.1.2.5 Carotid pulse wave velocity and reection magnitude
As carotid diameter distension and blood owvelocity curves are not acquired
simultaneously, they had to be aligned in time to perform further processing.
We implemented a correlation method [74] to automatically align the signals
(see gure 6.4, middle-le).
As described by Feng et al. [75], the local pulse wave velocity (PWVWH)
can be derived from the blood ow velocity curve (U) and the natural loga-
rithm of the diameter distension curve (LnD) via the well-established water
hammer equation (equation (6.3)). Plotting LnD against U (LnDU loop in
gure 6.4, middle-right), a linear portion is expected during the early part of
systole, when it is most probable that reected waves do not exist [75]. Two
points were selected (manually) from this linear portion of the LnDU loop
to determine the slope of the segment, and therefore, the local PWVWH :
PWVWH = ± 12 dU±dLnD± [ms ] (6.3)
Adapting the water hammer equation to relate changes of diameter (D)
and blood ow velocity (U), forward (D+,U+) and backward (D−,U−) wave-
forms can be obtained (see gure 6.4, bottom) from which the magnitude of
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wave reections can be derived as the ratio of the amplitude of D+ and D−
[40]:
RM = max(D−) −min(D−)
max(D+) −min(D+) = ∣D−∣∣D+∣ (6.4)
6.1.2.6 Statistical analysis
Wilcoxon signed rank tests were applied to compare baseline against test and
recovery mean values. A statistical signicant dierence was accepted at a
p-value ≤ 0.05. Data are presented as mean ± standard deviation.
6.1.3 Results
Measurements were technically feasible in all 12 subjects throughout the
complete protocol. However, for 2 subjects, ultrasound data during HGT30%
wasmissing due to storage problems (unrelated to feasibility) while data from
one volunteer was missing for HGT40% due to post processing diculties
(see table 6.2).e general features of the sample population were: mean age,
height and weight of 26 ± 2 years, 173 ± 11cm and 72 ± 13kg, respectively.
Hand grip test: haemodynamic parameters
ere was a consistent increase of BP (SBP, DBP, MAP and PP) during
both HGT’s in comparison to baseline values, as well as an increase in HR
(63.38±6.62 to 69.29±8.76bpm for HGT30%; 61.72±6.43 to 74.80±12.98bpm
for HGT40%). MAP did not fully return to baseline levels over the recovery
period, but HR did. Furthermore, blood ow velocity showed a high variab-
ility during the tests and no clear trends were observed (see gure 6.5 and
table 6.2).
Hand grip test: carotid (local) parameters
e change in carotid diameter during HGT30% was not statistically signi-
cant from baseline, in contrast to the diameter during HGT40%, which was
signicantly increased. In addition, carotid distension (∆D/D) showed a
remarkable decrease during both HGTs. During the recovery period, carotid
diameter and distension returned to baseline levels.
As gure 6.6 and table 6.2 evince, local PWVWH and RM demonstrated
a general high variability, which increased during the testing periods. No
clear trends were detectable for these parameters throughout the protocol.
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Figure 6.4: General segmentation and post processing methodologies applied
to protocol signals. Top le) Manual wall tracked segmentation results of carotid
distensibility using ultrasound images of the carotid artery (dominant hand side)
during CPT. Top right) PW-mode ultrasound signal of carotid blood ow velocity
and segmentation results: signal envelop was used as velocity curve.e velocity
curve was divided in cardiac cycles to obtain an average curve (of at least 3 cardiac
cycles) for post processing: each cycle was dened between two consecutive minimal
blood ow velocity points before the steep rise in velocity during systole. Mean blood
ow velocity was obtained as the average of the values of a velocity curve, while the
peak blood ow velocity was the maximal value of the velocity curve. Middle le)
Time alignment result of the carotid blood ow velocity (dashed line) and diameter
distension (solid line) curves using the correlationmethod [74]. Middle right) LnDU-
loop built plotting the natural logarithm of the carotid artery diameter distension
curve against the blood ow velocity curve. According to the used methodology
[75], the slope of the loop’s linear portion indicates the value of the local pulse wave
velocity (PWVWH). Bottom) Wave separation [75] results of carotid artery: le)
diameter distension and right) blood ow velocity curves, indicating the original
wave and the derived forward and backward waves. Figure adapted from [5].
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Cold pressor test: haemodynamic parameters
e highly signicant increase in BP during CPT is comparable with the one
obtained during both HGTs while the increase in HR was more modest for
CPT. MAP did not fully return to baseline values upon recovery, but HR did.
Again, velocity parameters were highly variable, and none of the observed
dierences were statistically signicant. All results are shown in gure 6.5
and table 6.2.
Cold pressor test: carotid (local) parameters
During CPT, carotid diameter increased while distension decreased, and all
parameters returned to baseline values upon recovery. PWVWH and RM
exhibited less variability than during HGT. PWVWH increased signicantly
and did not return to baseline values during recovery while RM presented
a borderline signicant increase (p = 0.054) during the test period (see
gure 6.6 and table 6.2).
6.1.4 Discussion
Compatible with previous results [234], [238], [241], [247], [248], HGT
leads to an increase in both BP (around 10mmHg for MAP) and HR (+6 −
13beats/minute). Functionally, this allows the baroreex to operate at the
prevailing BP evoked by the exercise [237] (see gure 6.1C). As illustrated
in gure 6.5, the CPT led to a similar increase in BP (+11mmHg), but this
increase was not accompanied by a similar increase in HR, as precedent re-
sults on CPT have shown [238], [239], [249], [250].is is consistent with the
notion, outlined in the introduction, that physical exercise (in this case iso-
metric exercise) somewhat “blunts” the baroreex, suppressing the reduction
in HR that one would anticipate in case of active pressure control. Moreover,
prior experimentation has veried that the arterial baroreex is reset from
rest to exercise in direct relation to the work intensity [40].is plausibly
explains the dierence in HR during HGT30% (lower exercise intensity, lower
HR) andHGT40% (higher exercise intensity, higher HR). Additionally, barore-
ex resetting has been observed at the onset of isometric exercise [251], [252].
Baroreex resetting also occurs during CPT although only about 120s aer
the onset of the cold stimulus [253].is is consistent with our data, demon-
strating that the HR was still under baroreex control when measurements
were performed (see gure 6.5 and table 6.2).
Similarly to BP trends during all tests, carotid diameter showed an in-
crease, even if it was less prominent. Due to a higher distending pressure, an
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Table 6.2: General results of selected parameters during the implemented protocol
(n = 12).
Parameter Test Baseline Test period Recovery
MAP [mmHg] HGT30% 91.00 ± 11.86 100.70 ± 13.33b 94.00 ± 12.22a
HGT40% 89.83 ± 6.85 101.03 ± 9.05b 92.49 ± 7.63a
CPT 91.03 ± 6.97 102.24 ± 8.59b 93.96 ± 7.89a
SBP [mmHg] HGT30% 119.49 ± 16.13 131.31 ± 19.71b 125.01 ± 17.32a
HGT40% 118.85 ± 8.12 131.13 ± 11.86b 123.59 ± 9.65a
CPT 119.85 ± 9.23 133.53 ± 11.66b 124.08 ± 9.80a
DBP [mmHg] HGT30% 72.01 ± 9.47 80.30 ± 9.58 b 73.32 ± 9.28
HGT40% 70.48 ± 6.64 80.97 ± 7.72b 71.75 ± 6.74
CPT 71.81 ± 6.07 81.38 ± 7.21b 73.88 ± 6.94a
PP [mmHg] HGT30% 47.48 ± 8.44 51.00 ± 11.67a 51.69 ± 9.68b
HGT40% 48.38 ± 4.95 50.16 ± 6.50a 51.84 ± 5.13b
CPT 48.04 ± 5.62 52.14 ± 7.05a 50.21 ± 4.59a
HR [bpm] HGT30% 63.38 ± 6.62 69.29 ± 8.76 a 62.82 ± 6.47
HGT40% 61.72 ± 6.43 74.80 ± 12.98b 61.10 ± 5.84
CPT 59.13 ± 5.56 64.25 ± 8.61a 59.54 ± 6.38
Ds [mm] HGT30% 7.45 ± 0.59 7.61 ± 0.71c 7.43 ± 0.60
HGT40% 7.52 ± 0.57 7.68 ± 0.65a 7.45 ± 0.56
CPT 7.52 ± 0.57 7.71 ± 0.64a 7.46 ± 0.59
∆D/D HGT30% 0.09 ± 0.02 0.07 ± 0.02b,c 0.09 ± 0.02
HGT40% 0.09 ± 0.02 0.07 ± 0.02b 0.09 ± 0.02
CPT 0.10 ± 0.02 0.08 ± 0.02 a 0.10 ± 0.02
L PWVWH [m/s] HGT30% 4.07 ± 1.56 4.23 ± 3.08 c 3.39 ± 1.51
HGT40% 3.67 ± 1.91 4.39 ± 2.73d 3.44 ± 1.70
CPT 3.17 ± 1.12 3.99 ± 1.06a,d 4.19 ± 1.64a
RM HGT30% 0.42 ± 0.08 0.43 ± 0.08c 0.39 ± 0.04
HGT40% 0.42 ± 0.06 0.42 ± 0.09d 0.39 ± 0.04
CPT 0.42 ± 0.06 0.46 ± 0.06 d 0.45 ± 0.06
M BFV [cm/s] HGT30% 23.71 ± 5.56 22.19 ± 7.04 22.79 ± 3.95
HGT40% 21.31 ± 4.13 24.18 ± 6.93a 21.89 ± 5.28
CPT 22.02 ± 5.38 23.88 ± 6.15 24.11 ± 6.27
P BFV [cm/s] HGT30% 61.56 ± 12.43 49.80 ± 12.75 a 59.08 ± 12.03
HGT40% 57.06 ± 11.41 53.75 ± 13.32 58.27 ± 15.48
CPT 57.64 ± 14.60 57.37 ± 14.98 66.83 ± 19.83a
Values are shown as mean ± standard deviation. MAP: mean arterial pressure, SBP: systolic blood
pressure, DBP: diastolic blood pressure, PP: pulse pressure, HR: heart rate, Ds : systolic diameter,
∆D/D: carotid distension, L-PWVWH : local pulse wave velocity, RM: reection magnitude, M BFV:
mean blood ow velocity, P BFV: peak blood ow velocity.
a p < 0.05.
b p < 0.001.
c Data based on a sample of 10 volunteers (n = 10).
d Data based on a sample of 11 volunteers (n = 11).
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increase in diameter of this elastic artery is slightly blunted by the increase in
muscular tone which may explain why the increase in diameter was smaller
than the increase in BP.ere was a remarkable decrease in carotid distension
during all tests although trends were dierent.is can be explained by the
increase inmuscular tone, operating BP, functional stiness, and the (inverse)
inuence of HR [247]. Previous studies showed similar outcomes during
HGT [254] and CPT [249]. During recovery, BP did not return to baseline
values, while HR, diameter and distension did (see gures 6.5 and 6.6 and
table 6.2).
In gure 6.5, additional parameters extracted from ultrasound images,
such as mean blood ow velocity and peak blood ow velocity, can be ob-
served. However, these results were aected by high variability, precluding
any further attempts to extract useful information from them.
Results for local PWVWH are presented in gure 6.6 and high variability
is clearly a major issue. e same method was used previously to assess
PWVWH during resting conditions (∼baseline) in 40 consecutive samples
from the Asklepios study [255].ey found a PWVWH of 6.00±1.93m/s [256]
while the baseline value we obtained was of 3.64 ± 1.53m/s (mean value of
the three baseline periods). As can be expected for a younger population, our
local PWVWH value was lower. In another study, a homogeneous population
of 22 healthy male volunteers was recruited from the military academy (mean
age 21.7 ± 1.4 years, range 19-24 years) to calculate the local PWVWH during
baseline (4.28 ± 1.00m/s) and CPT (5.58 ± 1.68m/s) [249]. Although the
absolute values in their study are somewhat higher both at baseline and
during CPT than the values we calculated, the relative increase of 30% is close
to the increase of 26% obtained by us.e dierences in absolute value may
be due to a dierence in methodology: they used pressure curves instead of
diameter distension curves for calculating the local PWVWH .
Finally, the RM was calculated. As values rely on local PWVWH for their
calculation, also these data showed a high variability (gure 6.6).e data
suggest a (borderline) higher RM value during CPT (p = 0.054) possibly as a
consequence of an increase in down stream resistance [257]. Note, however,
that the methodology used to calculate the local PWVWH and the RMmight
be prone to error. In a recent study, it was demonstrated that although
reection-free periods will emerge as straight sections in single point loop
methods as the LnDU-loop method, the opposite is not necessarily true: a
straight section in the loop does not necessarily mean that wave reections
are absent during that part of the cardiac cycle [258], corrupting the pulse
wave velocity estimations in general [256].
To the best of our knowledge, few previous studies presented an analysis
of the baroreex based on both HGT and CPT stressors and none included
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ultrasound measurements.is setup delivered interesting insights not only
related to the physiological phenomena but on practical issues in order to
improve the acquisition and subsequent analysis. Obviously, the proposed
protocol can be easily extended, including a dynamic exercise test and/or
head down measurements, using an alternative methodology for calculating
the local pulse wave velocity, or improving the acquisition to synchronize the
haemodynamic parameters with the ultrasound imaging for assessing the
baroreex sensitivity and for investigating baroreex resetting during CPT.
Moreover, an interesting addition to the setup would be a neck suction device
to expand the comprehension over the reset phenomena during dierent
stress stimuli.
Figure 6.5: Haemodynamic parameter results. Black circles representmean values
during a period (indicated below) of each test. A dierence from baseline is denoted
as signicant * (p < 0.05) or highly signicant ‡ (p < 0.001). Figure adapted from
[5].
6.1.5 Limitations
e sample size was enough to conduct a feasibility study but a larger sample
is necessary to draw any meaningful physiological conclusion. Additionally,
it was assumed that all volunteers were healthy subjects at the moment of the
protocol and a previous screening was not performed.
e study tests were not randomized.erefore, even if baseline values
were, in general, obtained between tests, it cannot be excluded that repetitive
application of the stressors may inuence the individual response.
During the protocol, respiratory changeswere not tracked and ultrasound
signals were not acquired continuously neither simultaneously, introducing
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Figure 6.6: Carotid local parameters results. Black circles represent mean values
during a period (indicated below) of each test. A dierence from baseline is denoted
as signicant * (p < 0.05) or highly signicant ‡ (p < 0.001). Figure adapted from
[5].
potential inaccuracies to calculate local PWVWH and RM.Ultrasound images
could be aected by movement artefacts due to the eort of the volunteers
during the tests.is problem was mitigated by the use of a holder but not
completely eliminated, causing problems especially for Doppler measure-
ments (velocity parameters).
6.1.6 Conclusions
It is feasible to monitor non-invasively the carotid haemodynamic response
to a sympathetic nervous system stimulus using carotid ultrasound, although
the variability, especially on the ow-related parameters, is high. Further
analysis showed supporting evidence of specic physiological response of
the autonomous cardiovascular system to regulate adequately each stress
stimulus, suggesting the possibility of assessment of the several subsystems
involved.
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6.2 An easy web interface for the assessment of carotid-femoral
pulse wave velocity and local arterial stiffness relative to
the reference values databases
is researchwas adapted for submission and accepted as an oral presentation
at the 25th European Meeting on Hypertension and Cardiovascular Protection,
Milan, Italy. e abstract, titled ”A simple calculator for the assessment of
measurements of carotic-femoral pulse wave velocity and local arterial stiness
relative to the reference values database”, was published in the Journal of
hypertension, vol. 33, e-Supplement 1, pp. e60, 2015 [6].
Further improvements of the application were submitted and accepted as
an oral presentation at the Artery 15 conference (Krakow, Poland) under the
title ”An easy and intuitive web interface for the assessment of measurements of
carotid-femoral pulse wave velocity and local arterial stiness relative to the ref-
erence values database”.e abstract was published in ARTERY RESEARCH,
vol. 12, pp. 43, 2015 [7].
6.2.1 Introduction
Arterial stiness is a crucial parameter for the assessment of cardiovascular
risk, and carotid to femoral pulse wave velocity (cf-PWV) has become the
gold standard measure of arterial stiness and a routine parameter in clinical
assessment of patients because it is relatively easy to calculate, its reliability
and, most importantly, because of the large evidence demonstrating its as-
sociation with incident cardiovascular disease, independently of traditional
risk factors in various populations.
Nevertheless, a wider implementation of arterial stiness assessment
has been hampered by the lack of established reference values on a large
population and the absence of standardisation of the methodology for PWV
evaluation. For instance, several methods are applied for determining the
aortic path length distance, introducing under or overestimations that could
reach the 25-30% of the real travelled aortic path length determined by MRI,
as table 6.3 indicates.us, reference values of cf-PWV and local carotid and
femoral arterial stiness, derived from the distensibility coecient (DC), have
been established [259]–[261], and standardisation of the method has been
proposed by experts [262].erefore, the aim of this project was to create
an application that allows easy assessment - for dierent methodological
approaches - of a given measured value of arterial stiness, providing the
percentile reference associated with that specic value.
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Table 6.3: Comparison of methodologies to calculate the reference distance (n =
98). Adapted from [263].
Tape measured distance Tape - MRI [Mean (SD)] Tape/MRI [%] cf-PWV cut-o value [m/s]
(CA-FA) – (SSN-CA) 2.32 (3.8) +4% 9.98
(CA-FA) – (SN-CA) -2.35 (3.8) -5% 9.12
(SSN-FA) – (SSN-CA) -5.11 (3.5) -10% 8.64
(CA-FA) 12.99 (4.2) +25% 12.00
(SN-FA) – (SN-CA) -14.77 (3.9) -29% 6.82
(CA-FA) x 0.8 0.26 (3.8) +0.4% 9.64
Body height/4+7.28 -0.5 (3.9) -1% 9.50
Body height x 0.29 -0.9 (4.0) -1.8% 9.43
Distance measured in centimetres.e reference distance is the real travelled aortic path length
determined by MRI: (AA-FA)-(AA-CA) = 50.7 (4.2). Tape measured distance refers to the distances
determined by tape measure directly on the body surface. SD: standard deviation; cf-PWV:
carotid-femoral pulse wave velocity; AA: ascending aorta; CA: carotid artery; FA: femoral artery; SN:
sternal notch; SSN: suprasternal notch.
6.2.2 Methods
Reference values of cf-PWV (11,092 individuals; age range: 15-97 years, 49.8%
men) and local carotid (22,708 individuals; age range 15-99 years; 54% men)
and femoral (5,069 individuals; age range: 15-87 years; 49.5% men) arte-
rial stiness were obtained [259]–[261]. Individuals without cardiovascular
diseases and established cardiovascular risk factors constituted a healthy sub-
population and were used to determine equations for percentiles of cf-PWV
and sex-specic percentiles of carotid and femoral DC across age [260], [261].
e nal derived equations of mean and standard deviation (SD) were:
• For cf-PWV [259]:
MeanPWV (ms ) = 4.6 − (0.1 ∗ Age) + (1.8−3 ∗ Age2)+(6.0−4 ∗ Age ∗MAP) + (2.8−2 ∗MAP) (6.5)
SDPWV (ms ) = −0.50 + (Age ∗ 0.02) + (MAP ∗ 5.10−3) (6.6)
• For local carotid artery stiness [260]:
In men:
Meancarotid(10−3kPa−1) = −12.85 + 70.85 ∗ (Age10 )−0.5 (6.7)
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SDcarotid(10−3kPa−1) = 2.51 + 15.43 ∗ (Age10 )−1 (6.8)
In women:
Meancarotid(10−3kPa−1) = 4.958 + 1.399 ∗ (Age10 )−2 +
218.2 ∗ (Age
10
)−2 ∗ ln (Age
10
) (6.9)
SDcarotid(10−3kPa−1) = −3.664 + 21.55 ∗ (Age10 )−0.5 (6.10)
• For local femoral artery stiness [261]:
In men:
Mean f emoral(10−3kPa−1) = 5.604 + 0.779 ∗ (Age10 )2
−0.411 ∗ (Age
10
)2 ∗ ln (Age
10
) (6.11)
SD f emoral(10−3kPa−1) = 2.829 + 3.677 ∗ (Age10 )−1 (6.12)
In women:
Mean f emoral(10−3kPa−1) = 9.438 + 0.163 ∗ (Age10 )3 −
0.092 ∗ (Age
10
)3 ∗ ln (Age
10
) (6.13)
SD f emoral(10−3kPa−1) = 5.984 − 0.005 ∗ (Age10 )3 (6.14)
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To calculate the arterial stiness percentile of a patient, the real stiness
value has to be compared with the expected normal stiness value. While the
expected mean and SD values are calculated using equations (6.5) to (6.14),
the Zscore is derived as:
Zscore = Parameter − ExpectedValuemeanExpectedValueSD (6.15)
Finally, the Zscore is converted into a percentile using the standard normal
distribution.
Using these equations, an application was created to provide the per-
centile reference value from routine parameters obtained in clinical practice.
Additionally, standardisation of cf-PWVmeasurements is also available in
accordance to the expert consensus document, which supports the use of
80% of the direct carotid-femoral distance [262] (see table 6.3).
Figure 6.7: Web interface for the assessment of arterial stiness parameters.
ere is an upper menu for selecting the parameter to be determined (or stand-
ardised) among: a. Carotid; b. Femoral; c. cf-PWV, or d. cf-PWV (conv.). In
the gure, the option for Carotid DC is selected and displayed. DC: distensibility
coecient; cf-PWV: carotid-femoral pulse wave velocity; conv.: conversion means
that standardisation of PWVmeasurements is performed to the 80% of the direct
carotid-femoral distance method [262].
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Figure 6.8: Calculation of carotid distensibility coecient. Data of a 60 years
old woman with a carotid artery diameter and distension of 6mm and 0.4mm,
respectively, a SBP/DBP of 120/80mmHg, and whose measurements has been done
with an ART.LAB device at 1cm proximal to the carotid bifurcation. Results show
a local arterial stiness (DC) of 25.83 ⋅ 10−3/kPa, a local PWV of 6.04m/s and
an arterial stiness percentile of 97, meaning that 97% of the healthy reference
population has a lower carotid DC.
6.2.3 Results
e tool can be found at: http://users.ugent.be/~flondono/ and
consists in an upper menu where the user selects the parameter to be de-
termined (or standardised). en, a panel is displayed according to the
selected option: a. Carotid; b. Femoral; c. cf-PWV, or d. cf-PWV (conv.).
Subsequently, the user provides a number of inputs which are used to cal-
culate the selected parameter, the percentile and, when relevant, additional
information. Figure 6.7 shows the interface of the web application.
For the calculation of carotid or femoral DC, the interface requires the age
(in years), diameter and distension (in mm), and SBP and DBP (in mmHg).
When this information is provided, three drop-down menus allow to select:
1) the anatomical location of the diameter/distension measurement: 0 to
1, 1, 1 to 2, or 2cm proximal to the ow divider of the arterial bifurcation;
2) the echo-tracking system used: ART.LAB, Wall Track system, Vivid-7 or
Carotid Studio; 3) the sex of the subject. Aer all parameters are correctly
introduced, the application calculates and presents the arterial stiness value
expressed as distensibility coecient (DC), the local PWV and the patient’s
stiness percentile. To calculate the percentile, the arterial stiness value is
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Figure 6.9: Calculation of carotid-femoral pulse wave velocity. e used infor-
mation is of a 65 years old individual with a SBP/DBP of 120/80mmHg, an arterial
path length of 70cm obtained with the full CA-FA distance method and a transit
time of 60ms. Calculations show a MAP of 96mmHg, a cf-PWV of 11.67m/s, a
cf-PWV (standard) of 9.33m/s and a percentile 3, indicating that 3% of the healthy
reference population has a lower cf-PWV. CA: carotid artery; FA: femoral artery.
rescaled to the standards of the ”reference values database”: the ART.LAB as
the device and 1cm proximal to the ow divider as the location. An example
of carotid artery stiness calculation is shown in gure 6.8, introducing the
data of a 60 years old woman with a carotid artery diameter and distension
of 6mm and 0.4mm, respectively, a SBP/DBP of 120/80mmHg, and whose
measurements has been done with an ART.LAB device at 1cm proximal to
the carotid bifurcation.e application plots the calculated parameters below
the described menu, which in this case indicates that for this subject the local
arterial stiness (DC) is 25.83 ⋅ 10−3/kPa, the local PWV is 6.04m/s and her
arterial stiness percentile is 97. is percentile indicates that 97% of the
healthy reference population has a lower carotid DC. Local femoral artery
stiness is similarly obtained.
Analogously for the calculation of the PWV, interface elds must be lled
with age (in years), SBP and DBP (in mmHg), the measured arterial path
length (in cm) and the transit time (in ms). Again, there is an additional
drop-down menu to select the distance method used to measure the arterial
path length.e options include the standard distance method being 80% of
the full carotid-femoral (CA-FA) distance, the full CA-FA distance, subtrac-
ted distance methods using the sternal (SN) or the suprasternal (SSN) notch,
and distances based on body height (see table 6.3) . Employing these data, the
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Figure 6.10: Standardisation of carotid-femoral pulse wave velocity measure-
ments. Data of a 40 years old person with a SBP/DBP of 120/80mmHg and a
cf-PWV of 9m/s obtained with the subtracted (CA-FA)-(SSN-CA) distance method.
e results are a MAP of 96mmHg, a standard cf-PWV of 8.64m/s and a percentile
of 57, indicating that 57% of the healthy reference population has a cf-PWV lower
than this subject. Standardisation means that PWVmeasurements are rescaled to
the same metric of the approach performed to the 80% of the direct carotid-femoral
distance method [262]. CA: carotid artery; FA: femoral artery; SSN: suprasternal
notch.
application calculates and displays the MAP, the measured PWV depending
on the distance method used, the standard PWV and the percentile. An ex-
ample of such calculation is shown in gure 6.9, introducing the information
of a 65 years old individual with a SBP/DBP of 120/80mmHg, an arterial path
length of 70cm obtained with the full CA-FA distance method (see table 6.3)
and a transit time of 60ms. e interface delivers a MAP of 96mmHg, a
cf-PWV of 11.67m/s, a cf-PWV (standard) of 9.33m/s and the percentile 3.
is percentile indicates that 3% of the healthy reference population has a
lower cf-PWV.
e last example concerns the standardisation of a cf-PWVmeasurement,
rescaling it to the same metric of the proposed standard method [262].e
required information for this calculation is the age (in years), SBP and DBP
(in mmHg), the cf-PWV value and the selection of the distance method
used to determine the arterial path length from a drop-down menu.en,
the application shows the MAP, the standardised cf-PWV value and the
percentile. A practical example of this function is presented in gure 6.10
using the data of a 40 years old person with a SBP/DBP of 120/80mmHg and
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a cf-PWV of 9m/s obtained with the subtracted (CA-FA)-(SSN-CA) distance
method (see table 6.3). e results are a MAP of 96mmHg, a standard cf-
PWV of 8.64m/s and a percentile of 57, indicating that 57% of the healthy
reference population has a cf-PWV lower than this subject.
6.2.4 Conclusions
An easy and intuitive interface was created to assess a given measurement of
arterial stiness relative to known reference values. Further work includes
the promotion and improvement of the application so that arterial stiness
becomes a routine parameter to assess the cardiovascular state of a subject, en-
hanced by the standardisation of the methodologies and the use of reference
values.
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6.3 Applanation tonometry and ultrasound imaging for
continuous physiological and medical monitoring to support
ESA space research
Results regarding the short arm human centrifuge (SAHC) were adapted for
submission and accepted as an oral presentation at the 25th EuropeanMeeting
on Hypertension and Cardiovascular Protection, Milan, Italy. e abstract,
titled ”Continuous monitoring of hemodynamics in the short arm human
centrifuge: a feasibility study”, was published in the Journal of hypertension,
vol. 33, e-Supplement 1, pp. e104-e105, 2015 [8].
6.3.1 Introduction
Space exploration is a challenging eld not only in terms of aeronautic engi-
neering but in many dierent domains, including medicine and biomedical
engineering. One of the most evident needs is to better understand vascu-
lar adaptation mechanisms due to microgravity and dene cardiovascular
risks for long duration ights. Additionally, it is crucial to nd an adequate
method to assess and validate the eciency of countermeasures against mi-
crogravity eects. Currently, non-invasive haemodynamic recordings at the
nger are obtained to perform cardiovascular assessment for astronauts due
to its ease of use. However, the value of these measurements is under de-
bate due to the distance of the measurement locations to the heart. us,
a system denominated continuous physiological and medical monitoring
(CPMM) is proposed to improve the non-invasive analysis of the cardiovas-
cular state in subjects submitted to microgravity conditions on ground and
in space.e term “continuous” implies repeated measurements to be able
to document changes, and not long-term permanent/continuous measure-
ments.e CPMM system consisted in a combination of pressure and ow
measurements using tonometry and ultrasound, respectively.
e aim of the study was to assess the feasibility of measurements of
the system and its characteristics, such as ease of use, robustness, and user
dependability. Furthermore, the study explored the obtainment of useful
and reliable parameters to evaluate the cardiovascular state of a subject un-
der dierent stress conditions, including physiological changes induced by
articial gravity in the SAHC (Verhaert, Kruibeke, Belgium) with the goal
of detecting and preventing potential disorders induced by weightlessness.
e project was developed under a European Space Agency (ESA) contract
(and with its support) by the Belgian company Verhaert in consortium with
the Institute for Space Medicine and Physiology (MEDES, Toulouse, France)
and Ghent University.
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6.3.2 Methods
6.3.2.1 Sample population
CPMM clinical assessments were performed on 14 healthy volunteers (7 men
and 7 women).e candidates were recruited via the MEDES internal le of
volunteers and complied with the main basic selection criteria: i.e., age 20 –
40 years, non-smokers, no overweight nor excessive thinness with body mass
index (BMI, weight kg/ (height)2 m2) between 20 and 25, active (normally t)
and free from any orthopaedic, musculoskeletal and cardiovascular disorders
(see table 6.4).e medical selection was carried out at MEDES Space Clinic.
Table 6.4: General characteristics of study subjects for the CPMM protocol imple-
mentation.
Parameter Age [y] Weight [kg] Height [cm] BMI [kg/m2] SBP [mmHg] DBP [mmHg] HR [bpm]
Min 20 51.8 161 20.0 95 48 37
Max 40 84.4 191 24.7 132 91 87
Mean 28.6 66.5 174.1 21.8 112.1 64.6 62.4
SD 6.14 9.19 8.32 1.42 11.97 11.04 13.89
SD: standard deviation; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood
pressure; HR: heart rate.
6.3.2.2 CPMM protocol
e performed protocol, summarized in gure 6.11, consisted in ve parts,
changing the posture or activity of the subject: 1) lying down (baseline);
2) in tilt position; 3) submitted to a lower body negative pressure (LBNP);
4) walking; and 5) cycling. Each evaluation session was performed by an
operator under medical supervision by a MEDES physician assisted by a
technician. BP measurements (SBP, DBP and HR) were obtained every 5
minutes by a Dinamap© Pro (GE Medical Systems) device.
6.3.2.3 Tonometry measurements
e tonometry acquisition system allows for an easy placement of the tono-
meter and reduces motion artefacts. Specically, the arterial pressure is
transferred by direct contact of a silicone rubber surface with the skin, and a
very sensitive pressure sensor is utilised to measure the pressure wave. Tono-
metry post processing includes averaging of the signal and posterior wave
shape analysis (see gure 6.12).
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Figure 6.11: CPMM scientic evaluation campaign ow chart. CPMM: continu-
ous physiological and medical monitoring.
Figure 6.12: Example of a tonometry signal obtained from the carotid artery
during the test campaign of the CPMM system. Le) Tonometry signal showing
several pressure waves during a ∼1-minute period. Middle) Averaged tonometry
signal. Right) Wave shape analysis of the pressure wave (blue line), showing the
(manually selected) inection point (cyan) and the ejection duration point (green).
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6.3.2.4 Ultrasound measurements
e ultrasound system corresponds to an acquisition unit (Telemed,
Lithuania) and a biplane transducer (Mepy, Belgium/France).e system is
compact, and the innovative linear array probe can physically be split in two,
with the probe being equipped with connectors for setting both halves of the
probe in a linear or T-junction conguration, as shown in gure 6.13.
Figure 6.13: Ultrasound linear array probe.e biplanar probe of the ultrasound
system has an innovative design that allows dierent congurations: A) linear
conguration of the probe; B) splitting of the probe in two separated segments; C)
T-junction conguration of the probe.
6.3.2.5 Ultrasound image processing
e segmentation implemented for post-processing of ultrasound images was
based on the algorithm proposed by Faita et al. [264].e semi-automatic
algorithm was developed in MATLAB® [265] and consists of 4 steps: ltering,
heuristic search, outlier removal and parameter estimation. To initiate the
processing of B-mode arterial images, the user must click on a pixel rep-
resenting the inside of the arterial lumen. All steps are performed for the
upper and lower portions of the image (in reference to the selected point)
independently.
First, the ltering operates with a sobel kernel, then with an edge detector
and, nally, with various morphological operators to pre-process the image
and to deliver a mask.is pre-processing step is performed to identify the
pixels belonging to the intima-media complex and the adventitia of the artery.
Next, the heuristic search nds a predetermined pattern for each column.
e algorithm searches for three values in comparison with a given threshold:
higher - lower - higher (in this order). Only the columns that comply with
this pattern are considered for further processing.e remaining points are
used as inputs for a cubic spline interpolation. Points located too far from
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this spline are identied as outliers and removed. Finally, the segmentation
delivers two lines indicating the intima-media layer of the analysed artery at
the upper and the lower portions of the image.
From this segmentation, dierent parameters are calculated, such as
the diameter, which is obtained using the polyline distance method [266].
Adaptations of this segmentation algorithm were implemented to obtain
arterial cross-sectional areas from B-mode images, and to process M-mode
ultrasound images to determine diameter distension curves and PWDoppler
images to dene the envelop of blood ow curves and derived parameters.
Examples of segmented ultrasound images using the implemented algorithm
are shown in gure 6.14.
6.3.2.6 SAHC measurements
All measurements were performed at MEDES facilities in 4 young (presum-
ably) healthy volunteers (3 males). In two (male) volunteers, the protocol was
divided in three periods: acceleration, steady rotation velocity and decelera-
tion, obtaining carotid PW-Mode ultrasound images during each period. For
one (female) volunteer, carotid PW-Mode ultrasound images and brachial
and radial tonometry signals were acquired at baseline and during the steady
rotation period. For one (male) volunteer, carotid and femoral PW-Mode
ultrasound images and brachial, radial and carotid tonometry signals were
acquired at baseline and during an initial and a following faster rotation
velocity. Next day, follow-up measurements of this volunteer were obtained.
e SAHC and the setup of the CPMM system are shown in gure 6.15A.
6.3.3 Results
A complete data set was recorded in all 14 volunteers. Results were analysed
to evaluate the feasibility and practical application of the CPMM system.e
last two parts of the protocol, cycling and walking, involved the movement of
the volunteer, introducing artefacts to the signals. In contrast to tonometry,
ultrasound delivered better results and proved to be a more robust technique
in extreme conditions.
6.3.3.1 Sphygmomanometer measurements
Four parameters were obtained (SBP, DBP, MAP and HR), and pulse pressure
(PP) was calculated with the formula:
PP = SBP − DBP (6.16)
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Figure 6.14: Ultrasound imaging examples obtained during the test campaign
of the CPMM system. A) B-mode image of the carotid artery and segmentation of
the cross-sectional area (le, blue line) and the diameter (right, red line). B)M-Mode
image of the carotid artery and segmentation results of the diameter distension.e
red shaded regions highlight the deep breath artefact of the signals. C) Spectral
PW Doppler images of the carotid (le) and the femoral (right) arteries, showing
the segmentation results of the envelop ow curve (green line) and the start/end
of each cardiac cycle (red points). CPMM: continuous physiological and medical
monitoring.
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Figure 6.15: CPMM test campaign in the short arm human centrifuge. A) Pho-
tos of the short arm centrifuge including preparation of the volunteer. B) Spectral
PW Doppler images of the carotid artery during acceleration (le) and decelera-
tion (right) phases of the protocol. CPMM: continuous physiological and medical
monitoring.
Values for the sample population are shown in table 6.4.
6.3.3.2 Tonometry measurements
Tonometry signals were processed to calculate parameters such as pressure
estimations, augmentation index (Aix), ejection duration (the duration of the
le ventricular systolic ejection or systolic time interval inms), among others.
A tonometry signal example is shown in gure 6.12. Tonometry signals are
calibrated using sphygmomanometer information as:
MAP = DBP + 40%PP (6.17)
With MAP, DBP and tonometry signals, SBP and PP values were calculated.
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6.3.3.3 Ultrasound measurements
In gure 6.14A, a B-Mode image of the carotid artery is displayed. At the
le, there is a zoomed region of the original image to show the segmentation
results of the cross-sectional carotid area (blue line) and, at the right, there is
a longitudinal zoom to show the segmentation of the carotid diameter (red
lines).e image is divided in two parts due to the ultrasound probe cong-
uration (T-shape), which allows to achieve a longitudinal and a transversal
view of the artery simultaneously, improving time acquisition, especially for
B-Mode images. Femoral images were also obtained and processed analo-
gously but quality was, in general, lower than for carotid results. Figure 6.7B
shows an example of an M-Mode image of a carotid artery and the corres-
pondent (derived) distension curve. Interestingly, this image exhibits an
artefact produced by deep breathing, easily recognizable to avoid its selection
when calculating a distension curve. For M-mode images, quality of carotid
segmentation results was also higher in contrast to femoral results. PW-Mode
ultrasound images of carotid (le) and femoral (right) arteries are displayed
in gure 6.14C.e envelop of blood ow curves was obtained (green line)
whereas red points indicated the start and/or the end of one cardiac cycle.
All (complete) cycles were included to calculate the blood ow mean and
peak velocities.
6.3.3.4 SAHC measurements
PW-Mode ultrasound images of the carotid artery were obtained in all 4
volunteers during dierent steps of the protocol. Femoral ultrasound imaging
revealed greater diculties related mainly to the placement of the probe aer
baseline, even if in one case results were feasible. Tonometry was, in general,
more challenging due to the intrinsic sensitivity of themethod. Overall, radial
arterial tonometry provided the best results, while brachial arterial results
were acceptable only in one occasion. Carotid tonometry was measured only
for one subject with suitable results for processing. Figure 6.15B displays
PW-Mode images obtained during the acceleration (le) and deceleration
(right) phases of the protocol.
6.3.4 Conclusions
e CPMM system provided interesting and promising results for future
applications, and remarkable qualities as it is inexpensive, practical and
exible. Acquisition and processing improvements are still necessary to
deliver optimal results. Concrete strategies for enhancing the xation system
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are primary to reduce the variability of the data and improve acquisition.
Finally, the use of the CPMM system in the SAHC was assessed successfully.
Tonometry measurements were feasible under a spin velocity limit, while
PW-Mode ultrasound images were more robust and stable. However, a
larger sample population must be included to support general conclusions.
Nevertheless, suitable signals and locations were identied for future research.
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Conclusions
roughout the history of cardiovascular research, successive milestones
have been achieved to prevent, diagnose and treat cardiovascular diseases
(CVDs). From the comprehension of the electrical signalling of the heart for
implementing electrocardiography (ECG) and the development of cardiovas-
cular surgery to the appearance of cardiovascular implantable devices and
heart transplant procedures, the fast evolution of cardiovascularmedicine has
contributed to change the role of health care in society [267]. Furthermore,
cardiac imaging, cardiovascular drugs, preventive cardiology and, more re-
cently, the concept of arterial health have also transformed diverse aspects of
health care beyond the clinical setting. Nowadays, genetics and molecular
biology, along with a period of technological development, are remodelling
cardiovascular medicine, partly due to concepts that already revolutionized
information technologies but only until now are emerging in health care
[268] with promising results to empower patients and stimulate them to
change lifestyle, and improve diagnosis and treatment. In consequence, inter-
disciplinary research is becoming a paradigm in medicine.e contribution
of this PhD is to be sought within this context, aiming to improve technical
methodologies in cardiovascular research with an interdisciplinary perspec-
tive on two areas that still face several challenges: heart failure with preserved
ejection fraction (diastolic dysfunction), which has not an eective treatment
yet, and arterial health assessment, which lacks of a widespread application
in medical practice.
Hence, Part II - Novel Cardiovascular Research presents the development
of non-invasive methodologies for the assessment of cardiovascular func-
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tion.e three specic goals established for this PhD project were developed
and structured in distinct but associated chapters. In addition to the novel
strategies and ndings described through this dissertation, the proposed
research raised several questions to be answered yet, and we consider this
PhD project as a positive starting point for further cardiovascular investi-
gation. For instance, validation remains a fundamental requirement for all
proposed studies to corroborate in more general conditions, i.e., larger and
heterogeneous populations, the discussed results and, thus, to support the
conclusions. Nevertheless, precise questions generated by each study should
be also considered.
Chapter 4 was dedicated to the assessment of cardiac function and the
accomplishment of goal 1, i.e., to develop and to validate a non-invasive
processing tool for the estimation of intraventricular pressure dierences
(IVPDs) in order to characterise patients without heart failure (HF), and
with HF and reduced (HFrEF) or preserved (HFpEF) ejection fraction, on
the basis of previous work [56]–[58], [98], [101], [127], [134]. In this chapter,
we proposed novel technical tools, including an MRI-based algorithm, to
estimate noninvasively IVPDs during diastole and systole, and a computa-
tional uid dynamics (CFD) model to assess and to validate the performance
of the proposed algorithms to estimate IVPDs. Concisely, we found that
even if intraventricular pressure gradients (IVPGs) and IVPDs provide in-
teresting insights about cardiac function, the application of non-invasive
methodologies to estimate these parameters is limited.e progress of car-
diac imaging modalities and the development of advanced methods merging
CFD and ow velocity measurements could promote the use of IVPDs in
the clinical setting as a result of greater availability, more robust validation
approaches and accurate results. Eectively, we demonstrated the feasibility
to assess IVPDs throughout the cardiac cycle using phase-contrast MRI to
identify distinct patterns in patients without HF and subjects with HFrEF
and HFpEF. Nonetheless, the proposed research on IVPD estimation raises
practical questions on how a more accurate le ventricle (LV) model over
a wide range of sizes and ejection fractions (EFs) would impact the assess-
ment of the proposed approaches or how invasive catheter-based measures
would compare with non-invasive calculations. Additionally, the impact of
technical issues about the MRI-based method should be evaluated, including
the limited temporal and through plane spatial resolution, image alignment
and assumptions made about viscous forces and the nature of ow from the
3 chambers view.
e focus of Chapter 5 was the evaluation of vascular function to sup-
port the realization of goal 2, which is to evaluate the dierential eects of
organic and inorganic nitrates in the vascular function of HFpEF patients,
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building on previously formulated haemodynamic analysis [40], [63]–[71].
We established that organic nitrate administration reduced arterial wave
reections less consistently than observed with inorganic nitrate and pro-
duced profound vasodilatation in the carotid territory, with a reduction in
cerebrovascular resistance and carotid characteristic impedance. Addition-
ally, our study also evidenced that organic nitrates increase power penetration
from the aorta into the carotid, which led to a signicant increase in carotid
pulsatile hydraulic power, despite a reduction in aortic power. In contrast,
inorganic nitrate did not produce signicant cerebrovascular dilatation nor
induce signicant changes in aortic and carotid wave and hydraulic power
or percentage of power penetration.ese haemodynamic dierences may
underlie the distinct eects on exercise capacity, adverse events, such as the
dierential incidence of headaches, and pulsatile haemodynamic stress of
the brain microvasculature in HFpEF patients. Further questions to be con-
sidered are the inuence of the design of both studies, the chronic eects
of these drugs on the carotid and peripheral circulations and the potential
association between carotid pulsatile haemodynamics and cognitive decline.
Finally, goal 3: to propose and to develop additional strategies for im-
proving cardiovascular medicine in dierent applications, was addressed in
Chapter 6. In brief, we proved the feasibility to monitor noninvasively the
carotid haemodynamic response to a sympathetic nervous system stimulus
using ultrasound measurements. Also, we developed an easy and intuitive
interface to assess a given measurement of arterial stiness relative to known
reference values. Additionally, we proposed a system to evaluate vascular
function, based on tonometry and ultrasound measurements.e system
proved to be inexpensive, practical and exible, and was assessed successfully
in the short arm human centrifuge (SAHC), although tonometry measure-
ments were feasible under a spin velocity limit, while PW-Mode ultrasound
images were more robust and stable. Notably, these proposed strategies
should be improved and further promoted to achieve a higher impact.
Beyond the specic (novel) interrogations generated by the research
presented in this dissertation, it is also stimulating to consider emerging
methodologies in the cardiovascular eld for addressing the posed challenges.
Hence, potential future work is discussed hereaer, proposing the integration
of dierent approaches to enhance and optimize cardiovascular research.
Prospective and Perspective
Part II proposed novel cardiovascular research based on traditional and state-
of-the-art analysis for the assessment of cardiovascular function. Currently,
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the prevalent digitalization of medical data oers an appealing opportunity
towards the automatization of critical and time-consuming procedures, such
as segmentation and parameter calculation from medical signals and images.
erefore, this section outlines technologies that can potentially facilitate
and, at best, improve cardiovascular research.
e wavelet transform is a relevant time–frequency analysis and coding
tool that exceeds other applications based on traditional Fourier methods for
processing biomedical signals in specic tasks, such as denoising/ltering,
compression, and extraction of scale-based features. Wavelet-based ap-
proaches are employed to a wide variety of signals, such as electromyography
(EMG), electroencephalography (EEG), clinical sounds, respiratory patterns,
blood pressure trends and DNA sequences, even if ECG processing imple-
mentations are the most common [269]–[271].erefore, ECG processing
through wavelet approaches could complement classical haemodynamic ana-
lyses, such as the ones described in Chapter 5, and assessment studies on
the autonomic nervous control of the cardiovascular function, as the one
proposed in Chapter 6, section 6.1. Moreover, most protocols include already
ECG recordings that could be processed o-line and further analysed without
adding costs or time to acquisition protocols. Data compression, image en-
hancement and reconstruction are also important wavelet applications to
improve analysis [272]–[275], which could boost a wider spread of cardiac
MRI protocols and reinforce the use of related parameters, such the ones
proposed in Chapter 4. Furthermore, DeMelis et al. [276] proposed a wavelet
method to analyse the blood pressure waveform, providing and displaying
specic features related to wave reection and aortic valve closure, which
can be an interesting addition to traditional haemodynamic assessment (see
Chapter 5) using the same measurements. In fact, pattern extraction tools
are becoming more important as inputs of machine learning algorithms for
automatic classication problems, which is currently a eld of great interest
and development. Khatami et al. [277], for instance, combine the denoising
properties of the wavelet transform to pre-process medical images with deep
belief networks to classify them.
e adoption of machine learning is ubiquitous in information tech-
nology and is reaching rapidly and strongly for medical practice. Several
reasons have driven this change towards the application of these techniques
in research and clinical care, among which are the digitalization of health
care, the advances in high-performance computing, the availability of big
data and the increasing accessibility of machine learning algorithms capable
of performing complex tasks.us, machine learning has been integrated
with more traditional approaches and standard protocols to address unsolved
issues and to optimize relevant processes, such as risk stratication, diagnosis,
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treatment and follow-up of patients. For instance, cardiovascular risk predic-
tion is based on regression models and assumes that each risk factor is related
in a linear fashion to CVD outcomes [278]. Although useful and robust, these
statistical methods oversimplify complex relationships, including non-linear
interactions, and they are limited to use a small number of predictors that
operate in the same way on everyone, and uniformly throughout their range
[279]. In contrast, machine learningmethods are conceived for solving partic-
ular challenges that are not well addressed by typical regression approaches
[279].
Furthermore, machine learning has the potential to transform medicine
by better exploiting big data for algorithmdevelopment [278]. Currently, com-
puter analysis and high-level interpretation of cardiac imaging are becoming
feasible, boosting machine learning capacity to provide a powerful platform
for integration of clinical and imaging data and for optimization of diagnosis
and prognosis [268]. Indeed, machine learning methods could impact the
prediction, prevention and proactive management of CVDs by, for example,
uncovering hidden structures in cardiology data to support the identication
of subtypes in chronic (multifactorial) complex diseases, such as HF [268],
potentially leading to novel therapeutic discoveries and personalised cardio-
vascular care [280], [281]. It is thus clear that machine learning promises
to transform medical research with more sophisticated and reproducible
conclusions drawn from comparisons against training databases. Moreover,
machine learning may represent a cost-eective risk stratication and dia-
gnostic tool and, ultimately, it may lead to the optimization of day-to-day
clinical workow [268].
In practice, several studies showed the solid performance of machine
learning algorithms at predicting CVD cases and excluding non-cases cor-
rectly [278]. Machine learning algorithms have proved to dierentiate success-
fully complex patterns of cardiac structural and functional abnormalities in
dierent cardiac pathologies [282], to classify properly LV wall motion based
on spatiotemporal proles from cardiac cine MRI [283] or even to segment
the LV in cardiac MRI [284]. In fact, large numbers of machine learning ap-
plications are becoming common topics for submissions to medical journals
[285].ereby, the incorporation of machine learning algorithms into stud-
ies proposed in Part II - Novel Cardiovascular Research corresponds to the
current evolution of medical research. Concretely, the proposed methods de-
scribed in Chapter 4 could benet greatly with machine learning approaches,
from MRI reconstruction to IVPDs analysis, improving timing and support-
ing diagnosis. For instance, a supervised machine learning algorithm for
classication of HF subtypes using IVPD extracted parameters and/or other
variables may facilitate risk stratication, diagnosis, treatment and follow-
up of patients.is proposal could be extended to echocardiographic data
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used in Chapters 5 and 6 to enhance the proposed haemodynamic analysis.
Moreover, unsupervised machine learning could be applied experimentally
to datasets presented in Part II to discover hidden patterns for improving the
analysis without additional time consuming and bias (manual) segmentation
processes.
Machine learning is an essential step towards a functional automatization
of processes, together with the construction of large databases containing
relevant and diverse cardiovascular signals and images to train ecient al-
gorithms.e next step is to overcome the shortcomings of machine learning
through the implementation of deep learning methods, which develop more
complex strategies to improve the performance in specic applications [286].
With this perspective, deep learning arises as a further milestone in the road
to improve cardiovascular medicine.
A pending task to implement successfully deep learning in cardiovascu-
lar medicine is the creation of extensive databases for training and testing.
Concretely, the analysis of cardiac function is essential in clinical cardiology
for patient management, disease diagnosis, risk assessment, and therapy
decision. Due to remarkable characteristics, cardiac MRI has become the
standard method to assess cardiac function (Chapter 2). However, in daily
practice this type of analysis is still a semi-automatic task because of the lack
of accuracy of fully automatic cardiac segmentation methods, leading to time
consuming tasks prone to intra- and inter-observer variability. Only recently,
few datasets have been proposed to gauge performances of state-of-the-art
cardiac MRI segmentation methods [287]–[290] for supporting interpreta-
tion and diagnosis of many cardiomyopathies, but there is still a gap to be
lled.
It has been demonstrated that deep learning methods can successfully
classify patient data and get highly accurate segmentation results in cardiac
MRI. In particular, convolutional neural networks (CNN) [291], [292] ev-
idenced accurate correlation scores on clinical metrics and low bias and
standard deviation on commonly used physiological measures, even if ad-
ditional limitations should be also improved [291]. Furthermore, a fully
automatic segmentation of the LV in cardiac MRI can be achieved as well us-
ing a combined deep-learning and deformable-model approach [293]. Other
eective applications of deep learning algorithms include automated cardiac
MRI volume analysis [294] and MRI reconstruction [295]. Beyond the spe-
cic aim of these implementations, practical lessons can be further extracted
regarding the development of deep learning methods. For instance, the pre-
viously stated necessity of huge amount of data to train algorithms could be
tackled by using articial data enlargement, pre-training and careful design,
so deep learning methods can be successfully employed for medical image
200
segmentation [293]. Many of these studies could become a starting point for
developing methods to process the data employed in Part II and support fur-
ther analysis. Regarding waveform analysis and/or feature extraction, using
a CNN could lead to more accurate calculations of established parameters,
extraction of novel measurements or automated classication of cases with
the advantage of using a full set of available features.
Although several challenges remain for the successful implementation
of machine and deep learning [279], [285], [296], [297], these methods will
surely change medical practice [298], [299].
Personal perspective
is PhD project evinces the current prominence and need of progress in
cardiovascular research and medicine at dierent levels to face successfully
the global CVD epidemic in an increasingly aging population. Nonetheless,
in order to deal with this challenge eectively, the implementation of inter-
disciplinary research and interdisciplinary health care is vital.e dramatic
progress in medical technologies, the new challenges posed by economic
and social costs in medicine, the necessity to rely on meaningful statistical
analysis, the importance of bioethical principles on patient care, the arrival
of new approaches for data management and, naturally, the central role of
medicine, they all demonstrate that the future of the medicine resides in
the constructive collaboration of interdisciplinary groups to successfully
delivering quality care for patients.
e manifest focus of this dissertation on (cardiovascular) interdisciplin-
ary research raises a fundamental question: which is the role of biomedical
engineering in this transforming health care scenario? Reasonably, there
are many potential responses from several viewpoints, thereby the following
(partial) answer is essentially based on the experience gained during this PhD
project. Most of the research conducted was possible as the result of joint
eorts of professionals with various academic backgrounds and expertise
elds. For instance, studies on arterial stiness were supported by collabor-
ative work of research groups of the medicine and engineering faculties of
Ghent University (see Part II), the HF investigation, described in Chapters 4
and 5, was performed in association with the arterial haemodynamics and
cardiovascular core lab of the University of Pennsylvania (Philadelphia, USA),
and the development of an integrative system of applanation tonometry and
ultrasound imaging for continuous physiological and medical monitoring
to support space research (see Chapter 6) was feasible through a consor-
tium with the company Verhaert (Kruibeke, Belgium), the Institute for Space
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Medicine and Physiology (MEDES, Toulouse, France) and the European
Space Agency (ESA).is collaborative work was not only fruitful but also
an enriching professional and personal experience in which there were also
challenges to overcome, such as nding a productive way of communication
with other professionals. Nevertheless, those challenges became great oppor-
tunities to improve ideas and to achieve more complex objectives. And it is
in this context that the role of the biomedical engineering becomes apparent
as a crucial bridge between medicine and engineering to strengthen interdis-
ciplinary research, to generate fundamental understanding of dierent elds
and to catalyse the research process.
Remarkably, the key conclusion of this PhDproject is the decisive respons-
ibility of biomedical engineering, and of health care in general, to produce a
substantial social impact from an interdisciplinary and scientic perspective.
e investment of resources must be reected in the improvement of the
quality of life of patients, family and society overall. It is critical that the
academia approaches society to generate long-term (eective) solutions for
real and relevant problems, to justify its work and eorts.
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